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Eva-Fiore Kovacovsky (*1980) Born in Bern, lives and works in Amsterdam and Berlin.
Eva-Fiore Kovacovsky examines phenomena in the world of plants, which she collects according 
to her own criteria and uses as a starting point in her artworks. Kovacovsky works with several 
different reproduction techniques and methods of photography. She abstracts, manipulates,  
arranges, and reproduces parts of plants and in this way generates artworks that deal with our 
own perception.
For her Fotogramme series shown here, Kovacovsky works with leaves that she has collected 
because of their distinctive patterns of perforations. She uses the leaves with holes eaten into 
them by beetles and caterpillars as negatives, places them in the negative carrier of a colour 
photographic enlarger, and exposes them on photographic paper. She constructs intuitive  
images by working in a playful way with different enlarging lenses, image details, multiple  
exposures, shifting of the filters in the colour mixing head, and photographic paper.
www.kovacovsky.com
Eva-Fiore Kovacovsky’s work is in public and private collections. She is represented by the 
STAMPA gallery in Basel (www.stampa-galerie.ch).
All images courtesy of Eva-Fiore Kovacovsky and STAMPA, Basel
At the request of the artist, the original titles of her works have not been translated.
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4Editorial
Thanks to donations of more than 20 million francs, 
in 2013 the Swiss Cancer Research foundation, the 
Swiss Cancer League, and the cantonal and regional 
cancer leagues invested another new record sum in 
cancer research. This is a wonderful result not only in 
quantitative terms; the funding of research and also 
the funded research projects achieved satisfying re-
sults also in terms of quality.
Research funding by the Swiss Cancer Research foun-
dation and the Swiss Cancer League was assessed 
comprehensively in 2013 by means of an independ-
ent external evaluation. As a part of the evaluation, 
more than 400 publications produced by funded re-
search projects from 1998 to 2006 were rated. The 
results showed that the researchers especially in 
basic biomedical, translational, and epidemiological 
research published many high-quality and important 
papers that achieved top ratings in a comparison 
with nine European funding institutions. 
The results of a survey of the researchers were also 
positive: The majority of the researchers rated the 
commitment of the two funding institutions to their 
own research activities as high to very high and to 
cancer research in Switzerland in general as positive 
to very positive. Nearly nine of ten survey respond-
ents stated that the grant application process from 
submission to review was transparent, fair, and of 
high-quality. And also a comprehensive analysis by a 
group of six independent, internationally renowned 
experts gave excellent marks for central aspects such 
as research promotion, quality assurance, monitor-
ing, structures, and resources.
The experts were particularly impressed by the quality 
of the work of the Scientific Committee, the group of 
17 experts who review approximately 170 to 180 ap-
plications for grants and bursaries each year accord-
ing to defined criteria and international standards. 
5Prof. Thomas Cerny, MD
President of the Swiss Cancer Research  
foundation
Prof. Jakob R. Passweg, MD
President of the Swiss Cancer League
They thus perform an extremely valuable service for 
the Swiss Cancer Research foundation and the Swiss 
Cancer League. Thanks to the work of the Scientific 
Committee, only the highest quality and most prom-
ising research projects are funded. We therefore ex-
tend sincere thanks to all members of the Scientific 
Committee and especially to Prof. Martin F. Fey, MD, 
who has served as president of the Scientific Com-
mittee since 2006 and will be stepping down at the 
end of this year. Prof. Nancy Hynes, PhD, molecular 
biologist and breast cancer specialist, has been 
elected the new president and will take office at the 
start of 2015. 
We would like to express our heartfelt thanks to all 
charitable donors for your support. Your generosity 
and loyalty make it possible for us to fund outstand-
ing cancer research aiming to continue to improve 
chances of survival and quality of life of patients 
with cancer.
Thomas Cerny Jakob R. Passweg
6and great advances in diagnosis and treatment. To-
day, more than half of persons with cancer – approx-
imately 37,000 new cancer cases are diagnosed each 
year – can be treated successfully. 
Nevertheless, each year approximately 16,000 pa-
tients die of cancer, and with some types of cancer, 
such as pancreatic cancer or brain tumours, the 
chances of successful treatment are low. Further 
advances in the fight against cancer are therefore ur-
gently needed – not only to improve survival rates 
and the quality of life of persons with cancer but also 
to be able to detect cancer as early as possible and 
to prevent cancer. And to achieve this, we continue 
to need great efforts in research.
Diverse research areas
The SCR, SCL, and the CCL support research pro-
jects across the entire broad range of cancer re-
search, grouped in four central research areas: basic, 
clinical, psychosocial, and epidemiological cancer re-
search. Basic biomedical research studies biological 
processes, how cancer cells develop, proliferate, and 
spread in the body. Clinical, laboratory-oriented 
research – also called translational research – works 
with cancer cells and tumour tissue to identify new 
biomarkers or targets, so that better diagnostic meth-
ods or more effective drugs can be developed. In 
clinical, patient-oriented research, clinical trials are 
conducted with patients with the aim to optimize 
existing treatments or to establish new, improved 
treatments. 
In 2013 the Swiss Cancer Research foundation 
(SCR), the Swiss Cancer League (SCL), and eight 
cantonal cancer leagues (CCL) gave a total of  
20.4 million francs to cancer research in Switzer-
land – which was again a new record sum. Also 
gratifying are the results of an independent exter-
nal evaluation that gave the work of the SCR and 
the SCL in research funding and also the quality 
of the funded projects excellent marks. We thank 
all of the charitable donors for their trust and 
support.
Each year, the SCR, SCL, and several CCL grant about 
20 million francs to universities, hospitals, and aca-
demic research institutions for oncological research. 
The SCR, which contributes approximately two-thirds 
of this sum, is dedicated exclusively to supporting 
cancer research. About one-third of the funds are 
contributed by the SCL and several CCL. The SCL and 
the CCL are engaged at a broad level in the fight 
against cancer; in addition to funding cancer re-
search, their priority tasks also comprise supporting 
and advising persons with cancer and their families, 
cancer prevention, and early detection of cancer.
Contrasting developments
In Switzerland and in most European countries, two 
basic tendencies have characterized cancer develop-
ments in the last 20 years: Cancer incidence is in-
creasing, but death rates are declining. The fact that 
there are more and more new cancer cases each year 
is primarily the result of demographic developments, 
since cancer is more frequent with increasing age. 
The main reasons for the welcome decline in cancer 
mortality are especially improved early detection 
Funding internationally top-level cancer research
Rolf Marti, PhD
Head of the Scientific Office, Swiss Cancer League and director of the
Swiss Cancer Research foundation 
7An experienced team
In the context of a reorganization of the SCL in 2013, 
an additional department was created out of the 
Scientific Office. The Scientific Office, which is also 
the home of the SCR head office, is responsible for 
calls for proposals and the grant application review 
process as well as financial controlling and quality 
control of the funded research projects. The Scien-
tific Committee and the Scientific Office work for 
both the SCL and the SCR. Thanks to this synergy, 
administrative expenses can be kept low and charita-
ble donations can be used efficiently. Where needed, 
the Scientific Office also provides its know-how and 
its resources to partner organizations such as the 
foundation SWISS BRIDGE or the CCL, which carry 
out their research funding more or less indepen-
dently of the SCL and the SCR. 
The new department that was formed is the Science 
& Development department. In addition to medical-
scientific support, another focus of this new depart-
ment is the development of research studies on im-
portant topics. One example is the study “Equal and 
Secured Access to Cancer Drugs for Off-Label Use”, 
which was conducted for the SCL by the independ-
ent consulting group INFRAS and presented in June 
2013. The study quantified the extent of inconsistent 
reimbursement and thus the unfair distribution of 
access to off-label drugs in oncology. It also outlined 
approaches that could be applied in order to stand-
ardize medical benefit assessment and to regulate 
the reimbursement of these treatments by the health 
insurance companies in a uniform manner nation-
wide.
Psychosocial research studies the psychological and 
social effects of cancer with the aim to improve the 
quality of life of persons with cancer and their fami-
lies. Epidemiological research examines, for example, 
the rates of cancers in the population and the factors 
that have an effect on cancer risk, such as age, gen-
der, smoking habits, amount of physical activity, 
nutrition, social environment, and environmental 
factors. Also funded are research projects in nursing 
sciences, prevention, public health, and health ser-
vices research, which analyses how effective, expe-
dient or economical medical health services are 
under everyday conditions.
Evaluation confirms quality
In 2013, an extensive external evaluation was con-
ducted to assess the efficiency and success of the 
research funding by the SCR and the SCL and the 
quality and significance of the research findings of 
the research projects funded. The results were very 
gratifying: The work of the SCR, SCL and especially 
the Scientific Committee, which peer-reviews the 
grant applications submitted, was rated very good 
overall. The SCR and the SCL fund research projects 
that are of excellent quality and produce many pub-
lications of great scientific importance – with top-
level values in an international comparison.
For the foundation board of the SCR and the board 
of the SCL, research quality was not only the top 
priority in their funding activities in the past: It con-
tinues also in the future to be the most important 
decision criterion in selecting projects for funding. A 
guarantor of quality assurance is the sound work of 
the 17 experts on the Scientific Committee, whose 
expertise covers all relevant areas in cancer research. 
The competency centre and operational hub for re-
search funding is the Scientific Office.
820.4 million francs for cancer research
In 2013 the SCR and the SCL provided 17.1 million 
francs for 80 research projects, bursaries, and re-
search organizations as well as 10 national and inter-
national projects and organizations (Figure 1). If we 
add their contributions to scientific conferences and 
workshops, which were not included in that figure, 
the total increases to 17.2 million francs. As in previ-
ous years, 80 % of the funds came from the SCR and 
20 % from the SCL. In addition to this, the CCL sup-
ported a total of 53 research projects and institutions 
with a total of 3.1 million francs in funding. The re-
sulting overall total for the year 2013 was 20.4 mil-
lion francs for cancer research projects and activities 
– approximately the same as the total funding in 
2012 (20.2 million francs).
Distribution of cancer research spending
Although the total amount of cancer research fund-
ing by the SCR and the SCL in 2013 remained almost 
the same as in 2012, there were changes in the dis-
tribution of the spending (Table 1). Once again, in 
2013 most of the funding – 74 % – went to inde-
pendent research projects, but the amount in this 
funding area was about 1.5 million francs less than in 
2012. The amount of funding given to six Swiss re-
search organizations for basic services increased 
by 315,000 francs and was 12 % of the total amount 
of cancer funding; 7 % went to persons receiving 
bursaries, which was 55,000 francs more than in 
2012, and 1 % went to scientific conferences, meet-
ings, and workshops.
Funding contributions going to national and interna-
tional projects and organizations, which made up 6 % 
of total funding in 2013, are shown here separately in 
the overview for the first time. The SCR and the SCL 
each contributed 150,000 francs to the international 
CONCORD-2 study, which is examining global trends 
and geographic differences in survival for 10 cancers. 
The SCR provided 150,000 francs in funding to the 
European Organisation for Research and Treatment 
of Cancer (EORTC). The SCL gave 168,000 francs 
in support to selected projects and programmes to 
fight cancer in developing countries, which included 
100,000 francs to the programme Global Access to 
Figure 1
Cancer research funding by SCR, SCL and CCL (independent research projects, bursaries, programme research,  
research organizations, national and international projects and organizations) since the founding of SCR in 1990.  
Not included in these figures are funds for conferences, workshops, etc. Research funding by the CCL has been  
recorded centrally and published in this report only since 2009.
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9Pain Relief Initiative (GAPRI) of the Union for Inter-
national Cancer Control (UICC). In Switzerland 
the SCR provided 300,000 francs in co-funding for 
implementation of the National Cancer Programme 
2011–2015 (NCP II), and the SCL contributed 
100,000 francs towards operating and building cord 
blood banks.
The distribution of the funds to the cantons was sim-
ilar to the prior year: At 94 %, the majority of the 
funds went to the five universities and university 
hospitals in Basel, Bern, Geneva, Lausanne and Zu-
rich (Figure 2). The largest increase in per cent of the 
overall total in 2013 was for funds given to Zurich 
(+ 10 %). Other changes were in the funding going to 
Basel (– 6 %) and Lausanne (– 5 %), whereas funding 
going to Bern and Geneva remained almost constant 
(+ 1 %). The remaining 6 % of the funding went pri-
marily to the Canton of Ticino and the Canton of 
St. Gallen; smaller sums were given to the following 
cantons: Aargau, Freiburg, Thurgau, and Wallis.
Tough competition in the independent research 
projects area
In 2013 the level of competition for the limited fund-
ing available for grants for independent project re-
search remained unchanged, especially since even 
more grant applications were submitted than in the 
record year of 2012 and for this funding area the to-
tal funding available was less than in 2012 (Table 2). 
Of the 173 grant applications submitted, the SCR 
and the SCL funded 63 research projects for a total 
of 12.7 million francs. Relative to the number of 
grant applications submitted, this is a grant approval 
success rate of 36 %, which is at about the same level 
as in 2012 (39 %). The monetary grant success rate 
– the amount of fund granted relative to the amount 
of funds requested – was relatively low: Only 33 % 
of the requested funds could be granted (31 % in 
2012). The workload of the members of the Scien-
tific Committee was somewhat reduced, thanks to 
the addition of two committee members, from 15 
to 17: The average number of grant applications re-
viewed by each member decreased from 23 grant 
applications in 2012 to 21 applications in 2013. 
Table 1
Research funding by SCR and SCL in overview
Number of grant applications and amount applied for; number of grants and amounts granted in 2013  
(all funding areas)
Independent 
research projects
Bursaries Research 
organizations
Projects/ 
org.1
Projects/ 
org.2
Conferences, 
workshops, 
etc.
Total
SCR
Number of grants approved 50 7 6 2 1 9 75
Amount granted in kCHF 10,342 890 1,975 300 300 49 13,856
Proportion of total funding 75 % 7 % 14 % 2 % 2 % 0 % 100 %
SCL
Number of grants approved 13 3 1 6 1 23 47
Amount granted in kCHF 2,368 372 100 318 100 128 3,386
Proportion of total funding 70 % 11% 3 % 9 % 3 % 4 % 100 %
Total SCR and SCL
Number of grant applications 173 11 7 8 2 32 233
Number of grants approved 63 10 7 8 2 32 122
Amount applied for in kCHF 38,164 1,316 2,075 618 400 204 42,777
Amount granted in kCHF 12,710 1,262 2,075 618 400 177 17,242
Proportion of total funding 74 % 7 % 12 % 4 % 2 % 1 % 100 %
1 International projects and organizations  2 National projects and organizations
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Figure 2
Distribution of cancer research funding to the cantons by CRS and SCL in 2013
Canton Number 
of projects
Amount
in kCHF
Percent-
age
AG Cantonal Hospital 2 10 100 %
Total 2 10 0 %
BE SAKK / IBCSG / SPOG / SCCR 7 1,928 48 %
University / University Hospital 10 1,166 42 %
Bursaries 3 402 10 %
Total 20 3,996 24 %
BS FMI 1 3 0%
University / University Hospital 14 2,142 100%
Total 15 2,145 13%
FR HES-SO 1 34 87%
Research award 1 5 13%
Total 2 39 0%
GE University / HUG 11 1,142 84%
Bursaries 2 220 16%
Total 13 1,362 8%
SG Cantonal Hospital 6 336 100%
Total 6 336 2%
TG Research award 1 5 100%
Total 1 5 0%
TI IELSG 1 200 29%
IOSI / IRB 4 484 71%
Total 5 684 4%
VD EPFL 7 1,051 36%
University / CHUV 7 1,565 54%
Bursaries 2 277 10%
Total 16 2,893 17%
VS Research award 1 10 100%
Total 1 10 0%
ZH NICER 1 250 5%
ETHZ 2 475 9%
University / University Hospital 28 4,210 79%
Bursaries 3 362 7%
Total 34 5,297 32%
Total 115 16,777 100%
  kCHF 0 2,000 4,000 6,000
Abbreviations
BE  SAKK = Swiss Group for Clinical Cancer Research  
IBCSG = International Breast Cancer Study Group
 SPOG = Swiss Paediatric Oncology Group
 SCCR = Swiss Childhood Cancer Registry
BS  FMI = Friedrich Miescher Institute
FR HES-SO = University of Applied Sciences and Arts Western Switzerland
GE HUG = Geneva University Hospital
TI  IELSG = International Extranodal Lymphoma Study Group 
IOSI = Oncology Institute of Southern Switzerland 
IRB = Institute for Research in Biomedicine
VD EPFL = Swiss Federal Institute of Technology Lausanne
 CHUV = Lausanne University Hospital
ZH NICER = National Institute for Cancer Epidemiology and Cancer Registration
 ETHZ = Swiss Federal Institute of Technology Zurich
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Table 2
Distribution of funds by SCR and SCL for independent research projects
2012 2013 Change compared 
to prior year
Basic biomedical research
Number of grant applications 87 92 + 6 %
Amount applied for in kCHF 25,241 21,382 – 15 %
Percentage of requested funds 55 % 56 % + 1 %
Number of grants approved 31 26 – 16 %
Amount granted in kCHF 7,190 5,624 – 22 %
Percentage of granted funds 51 % 44 % – 7 %
Grant application number success rate 36 % 28 % – 8 %
Monetary grant success rate 29 % 26 % – 3 %
Clinical research
Number of grant applications 58 61 + 5 %
Amount applied for in kCHF 14,920 13,141 – 12 %
Percentage of requested funds 32 % 34 % + 2 %
Number of grants approved 20 25 + 25 %
Amount granted in kCHF 4,146 5,096 + 23 %
Percentage of granted funds 29 % 40 % + 11 %
Grant application number success rate 34 % 41 % + 7 %
Monetary grant success rate 28 % 39 % + 11 %
Psychosocial research
Number of grant applications 12 11 – 8 %
Amount applied for in kCHF 2,727 2,017 – 26 %
Percentage of requested funds 6 % 5 % – 1 %
Number of grants approved 5 6 + 20 %
Amount granted in kCHF 693 1,000 + 44 %
Percentage of granted funds 5 % 8 % + 3 %
Grant application number success rate 42 % 55 % + 13 %
Monetary grant success rate 25 % 50 % + 25 %
Epidemiological research
Number of grant applications 13 9 – 31 %
Amount applied for in kCHF 3,222 1,624 – 50 %
Percentage of requested funds 7 % 4 % – 3 %
Number of grants approved 10 6 – 40 %
Amount granted in kCHF 2,134 990 – 54 %
Percentage of granted funds 15 % 8 % – 7 %
Grant application number success rate 77 % 67 % – 10 %
Monetary grant success rate 66 % 61 % – 5 %
All projects
Number of grant applications 170 173 + 2 %
Amount applied for in kCHF 46,110 38,164 – 17 %
Number of grants approved 66 63 – 5 %
Amount granted in kCHF 14,163 12,710 – 10 %
Grant application number success rate 39 % 36 % – 3 %
Monetary grant success rate 31 % 33 % + 2 %
44 16 40
(percentage  
of funds)
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Good-quality projects that could not be funded
In the funding area of independent research projects, 
one category of grant applications is a particular 
problem – not only for the researchers but also for 
the funding institutions: “approved but not funded” 
(ABNF) projects. These are grant applications that 
the Scientific Committee deemed high quality and 
approved for funding but that the boards of the SCR 
and the SCL could not fund due to lack of monies. 
On the part of many researchers who are notified of 
the ABNF status of their projects there is frustration 
and a lack of understanding, often more so than 
when an application is rejected for funding.
Of the 173 grant applications submitted in 2013, the 
number of ABNF research projects was 28, or five re-
search projects fewer than in 2012. Of the 28, 23 
were in basic biomedical research, and five were in 
clinical research. As in 2012, in the areas of psycho-
social and epidemiological research, all projects ap-
proved for funding by the Scientific Committee were 
funded in 2013. The relatively high percentage of 
ABNF grant applications, 16 % of all grant applica-
tions submitted, is spurring the funding institutions 
on to generate even more monies for the funding of 
high-quality research projects. One way to do this 
As in previous years, the greatest competition for 
funding was in the basic biomedical research area, 
even though once again, basic biomedical research 
received the largest part (44 %) of the funds for in-
dependent project research. In this area the mone-
tary grant success rate in 2013 was lower, at 26 % 
(29 % in 2012). Clinical research, which comprises 
both clinical research with patients and also transla-
tional research projects, received 40 % of the fund-
ing, and the monetary success rate in this area in-
creased to 39 % (28 % in 2012). 
Compared to the prior year, there were also changes 
in 2013 in the funding and the success rates in the 
epidemiological and psychosocial research areas. 
However, the numbers already fluctuate in these 
areas each year due to the relatively small number of 
grant applications that are submitted and approved. 
In 2013, 8 % of the funding went to each of these 
two areas of research. In psychosocial research the 
monetary grant success rate rose to 50 % (25 % in 
2012), and in epidemiological research it fell to 61 % 
(66 % in 2012). The grant approval success rates 
were 28 % for basic biomedical research, 41 % for 
clinical research, 55 % for psychosocial research, and 
67 % for epidemiological research.
Table 3
Distribution of funds by SCR and SCL for independent research projects by research area and year, 2004 – 2013
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Basic biomedical research
Total in million CHF 6.00 4.18 5.14 6.12 4.35 4.80 7.00 7.56 7.19 5.62
Percentage of total amount 56 % 49 % 52 % 56 % 48 % 47 % 59 % 54 % 51 % 44 %
Clinical research
Total in million CHF 3.31 3.36 3.31 3.85 2.90 3.96 3.14 4.56 4.15 5.10
Percentage of total amount 31 % 40 % 34 % 35 % 32 % 39 % 26 % 32 % 29 % 40 %
Psychosocial research
Total in million CHF 1.00 0.61 0.74 1.05 0.84 0.70 0.36 0.93 0.69 1.00
Percentage of total amount 9 % 7 % 7 % 9 % 9 % 7 % 3 % 7 % 5 % 8 %
Epidemiological research
Total in million CHF 0.37 0.31 0.74 0.00 0.93 0.74 1.40 1.03 2.13 0.99
Percentage of total amount 4 % 4 % 7 % 0 % 11% 7 % 12 % 7 % 15 % 8 %
All projects
Total in million CHF 10.68 8.46 9.93 11.02 9.02 10.20 11.90 14.08 14.16 12.71
that has been a positive development in recent years 
is targeted fund raising with other foundations, 
which then contribute all or some of the costs of se-
lected research projects. Thanks to these project-
specific donations, additional research projects that 
were quality-tested by the Scientific Committee can 
be funded that are a good match for other founda-
tions with regard to the research topics and aims.
Funding for patient-centred research
In addition to the quality of the research projects – 
which is the central criterion in funding – an impor-
tant priority in the funding strategy of the SCR and 
the SCL is targeted support for patient-centred re-
search. Patient-centred research aims at continuous 
improvement of medical care and psychosocial sup-
port for persons with cancer. For example, treatment 
optimization studies in clinical research aim to find 
the optimal combination and sequence of treatment 
options. Another example is psychosocial research 
that investigates ways to improve the quality of life 
of patients and their families. Nursing research, 
health services research, and many epidemiological 
studies also aim at direct benefit to patients and their 
families.
For more than 10 years, allocation rules have been 
utilized as an instrument for the promotion of pa-
tient-centred research. Within the funding area of 
independent research projects, 60 % of the funding 
is earmarked for patient-centred research, broken 
down into 40 % for clinical research and 20 % for 
research studies in the psychosocial area, epidemiol-
Sandzeichnung, Videostill, 2012
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The SCR uses a maximum of 20 million francs of the 
yearly research funding budget for targeted support 
of five to six research organizations that for years 
have been performing central and indispensable ser-
vices for Swiss cancer research. Their basic services 
are funded based on performance agreements that 
define in a clear and binding way the objectives 
for research and the requirements with regard to 
reporting and evaluation. In addition, the condition 
is that the institutions must secure their financing 
long-term on their own and independently of these 
contributions. In 2013 the SCR supported six re-
search organizations with a total of 2 million francs. 
Another 100,000 francs were provided by the SCL 
(Table 4).
Funding by the cantonal cancer leagues
In 2013 the amount of funding given to research pro-
jects and institutions in the cantons by the cantonal 
cancer leagues remained practically unchanged: A 
total of 3.1 million francs was given to 53 research 
projects (Table 5). The by-far largest sum of 1.2 mil-
lion francs – 39 % of the total funding by the CCL 
for research – was given once again by the Geneva 
Cancer League. The Zurich Cancer League provided 
20 % of the funding, followed by the Bern Cancer 
League (14 %), the Cancer League of both cantons of 
Basel (10 %), and the Cancer League of Ticino (9 %). 
The remaining 8 % was given by the Cancer League 
of Thurgau and the cancer leagues of Eastern and 
Central Switzerland. Of the 19 cantonal cancer 
leagues in total, 11 did not fund cancer research in 
2013, since for the majority of the cantonal cancer 
leagues, funding research is not a priority task. The 
research projects and institutions supported by the 
CCL are presented from pages 44 to 63.
ogy, nursing sciences, public health, and so on. The 
remaining 40 % of the funding for independent re-
search projects goes to basic biomedical research. In 
2013, the distribution of funds for independent re-
search was 44 % for basic biomedical research and 
56 % for patient-centred research (Table 3). 
Support of research organizations
A further instrument for promoting patient-centred 
research is financial support for basic services that 
established Swiss research organizations perform for 
the benefit of clinical and epidemiological research in 
Switzerland. In clinical research, which is very costly 
in terms of time and resources, these services include 
designing study protocols, coordinating national and 
international multicentre studies, and administrative 
tasks for the study approval process with Swissmedic 
and the ethics committees. In the area of cancer ep-
idemiology, the organizations supported by the SCR 
and the SCL provide researchers with know-how and 
resources for collecting, managing, and analysing 
data in the cantonal and national cancer registries.
Table 4
Supported research organizations
Funding by SCR, according to performance agreement by research organization and year, 2009 – 2013
Amount in kCHF
2009 2010 2011 2012 2013
Swiss Group for Clinical Cancer Research (SAKK) 600 600 600 600 900*
International Breast Cancer Study Group (IBCSG) 560 560 560 560 500
National Institute for Cancer Epidemiology and Cancer Registration (NICER) – – 200 200 250
International Extranodal Lymphoma Study Group (IELSG) – – – 200 200
Swiss Paediatric Oncology Group (SPOG) 100 100 100 150 150
Swiss Childhood Cancer Registry (SCCR) – – 50 50 75
Total 1,260 1,260 1,510 1,760 2,075
* of which 100,000 francs were from the SCL
Table 5
Research funding by the cantonal cancer leagues in overview
Number of research projects and institutions supported and amount granted in 2013 in comparison with prior year 2012
Cancer league Number of 
projects and 
institutions 
supported 
2012
Number of 
projects and 
institutions 
supported 
2013
Change 
compared 
to 2012
(absolute)
Amount 
granted 
2012 
in kCHF
Amount 
granted 
2013
in kCHF
Change 
compared 
to 2012
(relative)
Aargau 1 0 – 1 60.0 0.0 –
Basel 10 10 0 280.0 300.0 + 7 %
Bern 9 9 0 490.0 438.0 – 11 %
Central Switzerland 2 1 – 1 110.0 50.0 – 55 %
Eastern Switzerland 2 1 – 1 120.0 100.0 – 17 %
Geneva 12 14 + 2 1,131.9 1,234.5 + 9 %
Grisons 1 0 – 1 5.0 0.0 –
Neuchâtel 1 0 – 1 144.0 0.0 –
Thurgau 2 3 + 1 33.0 112,0 + 239 %
Ticino 4 5 + 1 210.0 268.0 + 28 %
Zurich 9 10 + 1 551.5 642.2 + 16 %
Total 53 53 0 3,135.4 3,144.7 0 %
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The research organizations supported in 2013 in brief
Swiss Group for Clinical Cancer Research (SAKK)
SAKK is a decentralized academic research institute that has conducted clinical studies  
on cancer treatment in all larger hospitals in Switzerland since 1965. SAKK encompasses  
a wide network of about 20 Swiss research groups and a coordination centre in Bern.  
For rare cancers SAKK works together with selected collaborative groups in other countries. 
SAKK aims to improve cancer treatment, study the effectiveness and tolerability of new 
treatments (radiotherapy, chemotherapy, surgery), and establish new treatment standards. 
In 2013 nearly 1000 adult patients participated in 44 clinical studies conducted by SAKK. 
As an independent and non-profit organization, SAKK pursues no commercial interests.
International Breast Cancer Study Group (IBCSG)
Since 1977 the IBCSG has conducted academic clinical trials with the aim to support breast 
cancer research, coordinate international research activities, and improve the treatment  
of women with breast cancer. The IBCSG is a multicentre study group with a coordination 
centre located in Bern, a data management centre and a statistics centre in the United 
States, and a pathology reference laboratory in Italy that serves the entire organization.  
In Switzerland, all university clinics, numerous cantonal and other hospitals, and oncolo-
gists in private practices participate in IBCSG studies. In 2013 250 patients participated  
in seven clinical studies conducted by the IBCSG.
National Institute for Cancer Epidemiology and Cancer Registration (NICER)
NICER promotes and supports population-based cancer registration and epidemiological 
cancer research in Switzerland. As a national coordination centre, NICER harmonizes the 
work of the 20 cantonal and regional cancer registries. It compiles the cancer data col-
lected in the cantons, assures the quality of the data, and analyses the data at the national 
level. These data collected in the network are utilized to determine national statistics on 
cancer incidence, mortality, and survival rates. This work aims to make possible evidence-
based decision making both in health care policy and in clinical medicine that will benefit 
the health of the population and also individual patients with cancer.
International Extranodal Lymphoma Study Group (IELSG)
The IELSG, a multicentre study group, was created in 1998 in Ascona, and its coordination 
and data management centre is in Bellinzona. It aims to foster research in the area of ex-
tranodal lymphomas (ENL) and to coordinate international research activities. As these 
lymphomas develop from all organs and sites in the body, different treatments are required, 
and their effectiveness has to be analysed separately. To obtain a sufficient number of 
cases, multicentre studies are necessary. At present there are more than 200 international 
institutes in this network. In 2013 the IELSG coordinated nine clinical studies with more 
than 200 participants.
Swiss Paediatric Oncology Group (SPOG)
SPOG has been conducting clinical and epidemiological cancer research in paediatric  
oncology for 35 years, with the aim to improve treatment and quality of life of children  
and adolescents with cancer. The SPOG is a national, independent association located in 
Bern. Belonging to the SPOG are all paediatric oncology departments at Swiss hospitals 
and the Swiss Childhood Cancer Registry. As childhood cancer is relatively rare, research  
in childhood cancer is possible only in the framework of international collaborations. At 
present, more than 20 SPOG clinical studies are ongoing, with approximately 150 patients 
participating.
Swiss Childhood Cancer Registry (SCCR)
The SCCR is the national cancer registry for children and adolescents in Switzerland.  
Since 1976 it has collected data on all new cases of cancer in young persons up to the age 
of 20. It also documents treatments and conducts longitudinal studies on health and  
quality of life of childhood cancer survivors. In this way it contributes towards research on 
the causes of childhood cancer, improvement of cancer treatment, and prevention of late 
effects in cancer survivors. The SCCR, which is funded from several sources, is located  
at the Institute of Social and Preventive Medicine at the University of Bern and works 
closely with the SPOG. Up to now, the SCCR has collected data on 9300 children and  
adolescents with cancer.
Sandzeichnung, Videostill, 2012
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Overall, the SCR, SCL, and the CCL gave 20.4 million 
francs to cancer research in 2013, which was 1 % 
more than in 2012 (Table 6). This sum supported a 
total of 175 research projects, bursaries, research or-
ganizations, and conferences and workshops. Two-
thirds of the monies was contributed once again by 
the SCR, 17 % by the SCL, and 15 % by the CCL. The 
increase in the figures for the funding area “Other” 
was primarily for two reasons: First, in 2013 there 
were significant, one-time contributions to large in-
ternational studies (CONCORD-2), and second, for 
the first time, the figures here also include the contri-
butions to national projects and organizations, in 
particular for Oncosuisse and implementation of the 
National Strategy Against Cancer 2014–2017.
Table 6
Research funding by SCR, SCL, and CCL in overview
Number of grants approved and amount granted in 2013 and change compared to prior year 2012 
(all funding areas) 
Independent 
research projects
Bursaries Research 
organizations
Other* Total
SCR
Number of grants approved 50 – 2% 7 – 13 % 6 0 % 12 + 50 % 75 + 3 %
Amount granted in kCHF 10,342 – 6% 890 + 8 % 1,975 + 12 % 649 + 233 % 13,856 + 1 %
SCL
Number of grants approved 13 – 13% 3 + 50 % 1 – 30 + 114 % 47 + 52 %
Amount granted in kCHF 2,368 – 25% 372 + 284 % 100 – 546 + 680 % 3,386 + 2 %
CCL
Number of grants approved 53 0% – – – – – – 53 0 %
Amount granted in kCHF 3,145 0% – – – – – – 3,145 0 %
Total SCR, SCL and CCL
Number of grants approved 116 – 3% 10 + 0 % 7 + 17 % 42 + 91 % 175 + 11 %
Amount granted in kCHF 15,855 – 8% 1,262 + 37 % 2,075 + 18 % 1,195 + 351 % 20,387 + 1 %
 Change compared to 2012
*  Funding for national and international projects and  
organization, conferences, workshops etc.
68 15 17
(percentage of funds)
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Once more we extend sincere thanks to all of the 
charitable donors, whose generous and loyal support 
makes these excellent results benefitting cancer re-
search and patients possible. 
Rolf Marti, PhD
Rolf Marti has headed the  
Scientific Office and the Science 
& Development department  
since 2003. He is a member of 
the managing board of the Swiss 
Cancer League and director of 
the Swiss Cancer Research foun-
dation. As a member of the core 
group of the National Strategy 
Against Cancer 2014–2017, one of the current focuses 
of his work is implementation of the fields for action 
“Research promotion” and “Epidemiology and moni-
toring”.
 Tel. +41 31 389 91 45 
rolf.marti@swisscancer.ch 
www.swisscancer.ch/research 
www.krebsforschung.ch
20
Excellent marks for research funding
The starting point was a comprehensive self-evalua-
tion report prepared by the Research Funding Depart-
ment. The evaluation carried out by evalueSCIENCE 
had three main foci: bibliometric analysis of the scien-
tific publications, an online survey of grant applicants, 
and an evaluation by an independent group of experts 
(peers).
Bibliometrics: excellent output 
How good a research paper is and what its impact is 
within a particular field of research is mainly assessed 
based on two factors: the journals in which the paper 
is published (impact factor) and how often the paper 
is cited in other publications (citations). The more pres-
tigious the journal is and the higher the number of 
citations, the more significant the paper is. More than 
400 research projects funded by SCR/SCL in the pe-
riod from 1998 to 2006 were appraised quantitatively 
and qualitatively. 
The most important results:
–  SCR and SCL funded research projects of ex-
cellent quality. Especially projects in basic bio-
medical research, epidemiological research,  
and laboratory-oriented clinical research resulted 
in publications of great-to-very great scientific  
significance in the particular research area.  
The funding efficiency that is, the financial in-
vestment per publication was also the highest 
for these three funding areas. 
The Swiss Cancer Research foundation (SCR) and 
the Swiss Cancer League (SCL) perform excellent 
work in cancer research funding in Switzerland. 
They fund research projects of high quality produc-
ing many significant publications as output – with 
top ratings in an international comparison. These 
are the findings of an independent, externally  
conducted evaluation. At the same time, the eval-
uation identified valuable potential for improve-
ment for diverse evaluation criteria.
The board of the SCR foundation and the board of the 
SCL commissioned an extensive evaluation of their re-
search funding activities in 2012/2013. The company 
evalueSCIENCE was asked to evaluate the publica-
tions of funded research projects, the quality and ef-
ficiency of the research funding, the organs involved, 
and the governance, processes, and structures. The 
evaluation was based on the time period from 1998 
to 2012 and on international standards (method: “in-
formed peer review” following the Zurich Model, an 
evaluation method developed at the University of 
Zurich). The last evaluation of the research funding 
activities of the SCR and SCL had been conducted in 
1997.
Stéphanie Buvelot Frei, PhD
Scientific assistant in the Scientific Office, Swiss Cancer League and  
Swiss Cancer Research foundation, Bern
Kurt Bodenmüller, lic. phil. nat.
Communications manager of the Scientific Office, Swiss Cancer League and  
Swiss Cancer Research foundation, Bern
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–  In comparison, scientific output and funding effi-
ciency were lower for patient-centred research. 
This can be attributed to the fact that clinical 
studies are much more difficult and more expen-
sive, and there is also a longer lag time between 
research funding and publishable results. 
–  Less highly rated were psychosocial research  
projects, whereby it should be mentioned that the 
different research areas should not be directly 
compared to one another. Publications in this 
field of research have a lower impact factor than 
papers in basic biomedical research, for example. 
–  In a further analysis, approved research projects 
were compared to a randomly selected sample of 
grant applications not approved for funding and 
grant applications that the Scientific Committee 
deemed high quality and approved for funding 
but that could not funded due to lack of monies 
(approved but not funded, ABNF). Approved pro-
jects clearly outperformed the projects not ap-
proved for funding and somewhat outperformed 
the ABNF projects.
–  Finally, the results of the projects funded by the 
SCR and SCL were compared with publications 
put out by research projects funded by nine  
comparable funding organizations in Northern 
Europe (basis: Web of Knowledge database). The 
highest number of citations per publication was 
achieved by papers put out by projects funded  
by the SCR/SCL – which evalueSCIENCE deems  
a very favourable result. Also excellent in this 
comparison was the funding efficiency.
Survey: positive feedback 
As a part of the evaluation, 457 applicants who had 
submitted research proposals in the last five years 
were invited to take part in an online survey on the 
quality of the submission and review process. Of the 
242 researchers (53 %) that participated, 154 (64 %) 
had research proposals that were approved for fund- 
ing in the time period, 70 (29 %) had proposals that 
were not approved, and 18 (7 %) had proposals that 
were approved but could not be funded (ABNF).
The most important survey results:
–  Approximately 70 % of the applicants felt that  
the SCR and SCL are important-to-very important 
for their research activities, and over 80 % find 
the SCR and SCL positive-to-very positive for 
cancer research in Switzerland altogether.
–  The grant application review process was found 
to be transparent, fair, and qualitatively good by 
86 % of the applicants.
–  Approximately 30 % of the applicants whose  
proposals were not approved or were ABNF found 
the grant application review process to be not 
transparent and not fair. For many of the research-
ers affected, receiving an ABNF decision led to  
a greater lack of understanding and more frustra-
tion than receiving a not approved for funding 
decision. 
–  98 % of the applicants appreciated the support 
provided by the Research Funding Department in 
the context of the grant application process.
Group of experts: quality is central
The main part of the evaluation was an all-day site 
visit at the Research Funding Department by a group 
of six independent, internationally renowned experts 
(see box “Members of the group of experts”), who 
conducted five qualitative interviews with central 
actors at SCR, SCL, the Scientific Committee, appli-
cants, and partner organizations. The peers focused 
their evaluation on the following criteria: strategy, 
research support, and quality assurance as well as 
governance, structures, and resources. In their re-
port, the peers underlined the important function of 
SCR and SCL as funding organizations for cancer re-
search in Switzerland. They made particular mention 
of the excellent work of the Scientific Committee in 
reviewing grant applications. 
22
Based on the peers’ report, evaluSCIENCE worked 
out several recommendations:
–  The aim of supporting research projects of the 
best quality should remain the highest strategic 
priority. In addition, a common strategy and  
strategic guidelines should be developed for the 
research funding by the SCR, SCL, and the can-
tonal cancer leagues (CCL). 
–  The 40-40-20 rule, according to which the funds 
should be allocated to the different fields of  
research, should be re-evaluated. (Within the 
funding area of independent research projects, 
the funding is allocated as follows: 40 % for  
clinical research, 20 % for research studies in the 
psychosocial area, nursing sciences, and epidemi-
ology, and 40 % for basic biomedical research.)
–  The experts submitted a suggestion for discus-
sion: 70 % of the funds could be earmarked for 
the qualitatively best proposals within independ-
ent research projects and 30 % for specific, stra-
tegic research topics (such as funding for partici-
pation in international clinical studies, funding  
for neglected niche areas).
–  To optimize reporting by researchers (in papers,  
reviews, book chapters) it would advisable to  
develop appropriate incentives and a tougher re-
porting control. This would also improve the  
visibility of the funding organizations. 
–  Communication with grant applicants, especially 
communication of non-approval or ABNF deci-
sions), should be optimized, so as to make nega-
tive decisions better understood.
Measures implemented
The Scientific Committee, the board of the SCR foun-
dation, and the board of the SCL studied and dis-
cussed the evaluation report extensively. The mostly 
very good results affirm the organizations in their ef-
forts to support excellent research that leads to ad-
vances in treatment and in the fight against cancer 
and that helps to improve patients’ survival rates and 
quality of life. For this reason, also in the future 70 % 
to 80 % of the research funding will go to competi-
tive, independent research projects.
Based on the feedback from the grant applicants 
and the experts’ recommendations, changes have 
already been made to various terms and conditions 
of grant application submission and review pro-
cesses. Starting in 2014, the maximum amount of 
funding granted per research project has been raised 
from CHF 250,000 to CHF 375,000 and the duration 
increased from three to maximum four years. In ad-
dition, the researchers are now allowed to use more 
grant money for consumables, which gives them 
more flexibility in their budget use. Although it is still 
the case that a researcher may be the principal appli-
cant of at most one ongoing project, there is no 
longer a restriction on the number of projects as a 
co-applicant.
Further measures decided on by the Scientific Com-
mittee serve to simplify the submission of grant ap-
plications (limiting the documents to be submitted) 
and optimize the review process (two external re-
viewers per grant application). In addition, priority 
will be given to supporting research projects that are 
rated “clearly cancer-relevant”. To improve report-
ing, the grant recipients are obligated, under the 
terms of the written funding agreement, to mention 
the SCR or SCL in all publications resulting from the 
projects.
Two measures aid at improving transparency and 
communication with grant applicants: The review 
criteria and the steps in the review process are now 
described clearly and openly in the information sheet 
accompanying the application documents. Also, 
along with the letter notifying the applicant of the 
funding decision, the applicant now also receives in-
formation on their position in the ranking list of re-
viewed projects and statistical information on the 
number of applications submitted, the amount ap-
plied for, the number of grants approved, and the 
amount granted.
Research funding strategy
Implementing the experts’ recommendations re-
garding governance and structures will take some 
time. As to revising the research promotion rules and 
regulations, two goals stand in the foreground: The 
responsibilities of and cooperation between the 
board of the SCR foundation and the board of the 
SCL at the institutional level should be more clearly 
defined. In addition, research funding by the SCL 
and by the relevant CCL should be more closely co-
ordinated. A first step towards improving coopera-
tion with the CCL has already been taken: After each 
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Stéphanie Buvelot Frei has a doc-
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in the Scientific Office of the Swiss 
Cancer League and the Swiss  
Cancer Research foundation since 
2011. 
Tel. +41 31 389 93 63
stephanie.buvelot@swisscancer.ch
www.swisscancer.ch/ff-evaluation
Kurt Bodenmüller, lic. phil. nat.
Kurt Bodenmüller is a microbiolo-
gist who has worked in the field  
of science communications since 
1997. He worked for many years 
as a consultant at an international 
PR company. He has been commu-
nications manager of the Scientific 
Office of the Swiss Cancer League 
and the Swiss Cancer Research 
foundation since 2008.
Tel. +41 31 389 93 31 
kurt.bodenmueller@swisscancer.ch
www.swisscancer.ch/ff-evaluation
round of submissions the CCL are to be informed 
about all research projects in their cantons that are 
being funded by the SCR and SCL. In the longer 
term, a common research funding strategy will be 
developed that takes into consideration the specific 
characteristics of the SCR, SCL, and the CCL. Taking 
into account overarching national goals and the pri-
orities of the “National Strategy Against Cancer 
2014–2017”, the activities for funding high-quality 
and patient-centred cancer research are to be har-
monized and optimized.
Members of the group of experts
–  Prof. Denis Monard, PhD, former president of the Swiss 
Academy of Sciences (SCNAT) and former director the 
Friedrich Miescher Institute for Biomedical Research 
(FMI), president of the group of experts, Basel
–  Prof. Stanley B. Kaye, MD, head of the Drug Develop-
ment Unit and head of the Section of Medicine at the 
Royal Marsden Hospital and the Institute of Cancer 
Research, London
–  Denis Lacombe, MD, director headquarters, European 
Organization for Research and Treatment of Cancer 
(EORTC), Brussels
–  Prof. Jürg Schifferli, MD, PhD, former member of  
the National Research Council of the Swiss National  
Science Foundation (SNSF), dean of research at the 
Faculty of Medicine, University of Basel, Basel 
–  Prof. Emile Voest, MD, head of the Department of 
Medical Oncology, University Medical Center Utrecht, 
and chair of the Scientific Advisory Board of the Dutch 
Cancer Society, Amsterdam
–  Prof. Otmar D. Wiestler, MD, Dr. h. c., chairman of the 
scientific board of the German Cancer Research 
Center (DKFZ), and member of the board of German 
Cancer Aid, Bonn
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Swiss Cancer Research foundation (SCR)
In existence since 1990, the Swiss Cancer Research 
foundation generates donations that help provide 
funding for all areas of cancer research: basic, clini-
cal, epidemiological, and psychosocial research. A 
special focus is the funding of patient-centred re-
search projects that result as far as possible in direct 
patient benefit. The SCR foundation board, presided 
over by Prof. Thomas Cerny, MD, is responsible for 
distributing the funds to the researchers. The fund-
ing decisions are based on the recommendations 
made by the Scientific Committee. The Scientific 
Committee, made up of recognized experts in cancer 
research and medicine, reviews the grant applica-
tions according to clearly defined criteria. The SCR 
also supports the development and implementation 
of measures to fight cancer in Switzerland – namely, 
the National Cancer Programme 2011 – 2015.
Contact
Swiss Cancer Research 
Effingerstrasse 40
P. O. Box 7021
CH-3001 Bern
Tel. +41 31 389 91 16
info@krebsforschung.ch
www.krebsforschung.ch
Swiss Cancer League (SCL)
The Swiss Cancer League (SCL) aims for a world 
where fewer persons get cancer, fewer persons suffer 
the consequences of and die of cancer, more persons 
are cured of cancer, and persons with cancer and 
their families receive care and support in all phases of 
cancer and in dying. As the national umbrella organ-
ization with headquarters in Bern, the SCL brings to-
gether 19 cantonal and regional cancer leagues. A 
non-profit organization financed mainly through do-
nations, the SCL is Switzerland’s competence centre 
for cancer. It supports the cantonal cancer leagues 
through knowledge transfer, provision of services, 
developments, and coordination at the national level. 
It supports cancer research, provides information on 
risk factors and early detection measures, and runs 
national cancer prevention programmes. It develops 
specific continuing education courses for a variety of 
occupational groups. A number of different advice 
and support services for persons with cancer and 
their families and also the SCL brochures are devel-
oped in Bern. Responsible for strategic management 
of the SCL is the SCL board, presided over by Prof. 
Jakob R. Passweg, MD.
Contact
Swiss Cancer League
Effingerstrasse 40
P. O. Box 8219
CH-3001 Bern
Tel. +41 31 389 91 00
info@swisscancer.ch
www.swisscancer.ch
Partner organizations and committees
Kurt Bodenmüller, lic. phil. nat.
Communications manager of the Scientific Office, Swiss Cancer League
and Swiss Cancer Research foundation, Bern
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Cantonal cancer leagues (CCL)
In the 19 cantonal and regional cancer leagues, per-
sons with cancer and their family members receive 
personal and individual advice from experts on treat-
ment as well as on financial and organizational ques-
tions. The personel at the CCL often advise persons 
over a longer time period and support them in diffi-
cult situations. They provide information on legal 
and insurance issues and help with the reorgani-
zation of the clients’ social and financial situations. 
They provide contacts to other support institutions, 
such as home care organizations. If their illness 
brings persons with cancer into financial difficulties, 
they can apply for support payments. The CCL or-
ganize group meetings and courses, where persons 
with cancer can talk about their fears and experi-
ences and can learn to deal with their illness. Some 
cancer leagues offer specialized psycho-oncology 
support for children of adults with cancer. And in 
some cantons there are outpatient oncology care 
services that support persons with cancer at home. 
The CCL are at work in Switzerland and in Liechten-
stein. The services offered by the CCL vary in type 
and extent and depend strongly on the financial and 
human resources of the individual cancer league as 
well as on the services made available by other pro-
viders.
Cantonal and regional cancer leagues  
in the German-speaking part of Switzerland  
and in Liechtenstein
– Aargau Cancer League 
– Basel Cancer League 
–  Bern Cancer League
– Central Switzerland Cancer League 
– Eastern Switzerland Cancer League 
– Grisons Cancer League 
– Liechtenstein Cancer League 
– Schaffhausen Cancer League 
– Solothurn Cancer League 
– Thurgau Cancer League
– Zug Cancer League
– Zurich Cancer League 
Cantonal cancer leagues in the French-speaking 
part of Switzerland and in Ticino 
– Fribourg Cancer League 
– Geneva Cancer League
– Jura Cancer League
– Neuchâtel Cancer League
– Ticino Cancer League 
– Valais Cancer League
– Vaud Cancer League 
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President
Prof. Thomas Cerny, MD
Head physician of Oncology/ 
Haematology Clinic
Department of Internal Medicine
Cantonal Hospital St. Gallen
Past president of SCL
since 2009
Vice president
Prof. Richard Herrmann, MD
Head of Clinical Research Department
Basel University Hospital
Past president of SAKK and clinical  
research representative
since 2009
Eduard Holdener, MD
Therwil 
Independent person
since 2009
Prof. Hans Hengartner, PhD
Langnau am Albis 
Basic cancer research representative 
since 2009
Prof. Matthias Egger, MD
Member of the Board, Institute  
of Social and Preventive Medicine
University of Bern
Epidemiological research representative
since 2009
Treasurer
Gallus Mayer
Banking specialist
Head of Finance and Accounting
Notenstein Private Bank Ltd.
St. Gallen
since 2009
Erika Forster-Vannini
Former member of the  
Council of States
St. Gallen
Independent person
since 2012
Prof. Nicolas von der Weid, MD
Head of Oncology /Haematology  
Department
Co-head physician of Paediatrics
University Children’s Hospital Basel 
(UKBB)
Past president SPOG and paediatric  
research representative
since 2009
The board of the Swiss Cancer Research foundation (SCR) is made up of one representative  
each of the chairmanship of the Swiss Cancer League (SCL), the Swiss Group for Clinical Cancer 
Research (SAKK), and the Swiss Paediatric Oncology Group (SPOG); one expert each in the  
different research areas; and independent persons.
The eight members of the SCR foundation board are: 
The board of the Swiss Cancer Research foundation
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President
Prof. Jakob R. Passweg, MD
Head physician of Haematology Clinic
Basel University Hospital
since 2007
Vice president
PD Gilbert Bernard Zulian, MD
Head physician of Palliative  
Medicine Department
Hôpital de Bellerive
Geneva University Hospital
since 2009
Treasurer
Gallus Mayer 
Banking specialist
Head of Finance and Accounting
Notenstein Private Bank Ltd.
St. Gallen
since 2009
Lucienne Bigler-Perrotin
Manager
Geneva Cancer League
since 2009
Past president
Prof. Thomas Cerny, MD
Head physician of Oncology / 
Haematology
Department of Internal Medicine
Cantonal Hospital St. Gallen
since 1998
Hans Neuenschwander, MD 
Head physician of Palliative Care
Regional Hospital of Lugano
since 2010
Irène Bachmann-Mettler 
Project head, Institute of General  
Practice and Health Services Research
University of Zurich
President of Swiss Oncology  
Nursing Society
since 2003
Markus Notter, MD
Head physician of Radiotherapy  
Department
Neuchâtel Hospital
La Chaux-de-Fonds
since 2013
Prof. Daniel Betticher, MD
Head physician of Oncology  
Department
HFR Fribourg, Cantonal Hospital
since 2006
Brigitta Wössmer, PhD 
Head psychologist of Psychosomatics
Basel University Hospital
President of Swiss Society of  
Psycho-Oncology 
since 2011
Corinne Ullmann
Manager
Schaffhausen Cancer League
since 2013
The highest body of the Swiss Cancer League (SCL) is the delegates’ assembly, to which the 
 representatives of the cantonal and regional cancer leagues belong. Strategic management is the  
responsibility of the board of the SCL. The members of the board represent both different specialties 
in the fight against cancer and different parts of Switzerland. Prof. Jakob R. Passweg, MD, was 
elected president of the board in 2010, and PD Gilbert Bernard Zulian, MD, is vice president.
The 11 members of the SCL board are:
The board of the Swiss Cancer League
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The Scientific Committee is responsible for evalu-
ating the research grant applications submitted to 
the Swiss Cancer Research foundation (SCR) and 
the Swiss Cancer League (SCL) by researchers seek-
ing research funding. The committee’s peer review 
process uses strictly defined evaluation criteria (see 
box, “Criteria for high-quality cancer research”). 
The central criterion is always whether a research 
project is expected to advance our understanding 
of cancer prevention, causes, or treatment.
The 17 members of the Scientific Committee are rec-
ognized experts with outstanding achievements and 
expertise in all areas relevant to cancer research. 
Having all of the research areas represented on one 
committee prevents the formation of specialized 
subcommittees and also assures funding of research 
trends in all areas. The members serve on the com-
mittee for three years and can be re-elected twice.
The Scientific Committee
The president of the Scientific Committee is Prof. 
Martin F. Fey, MD. The committee members are rep-
resentatives of the following research areas:
– basic biomedical research: 5 members
–  patient-centred clinical cancer research:  
3 members
–  laboratory-based clinical cancer research:  
2 members
–  epidemiology and cancer prevention: 2 members
–  psychosocial and other cancer research (public 
health research): 2 members
–  translational cancer research: 2 members
Each grant application is reviewed by two members 
of the Scientific Committee. In addition, each app-
lication is reviewed by an average of three external 
peer reviewers. In the year under report, the Scien-
tific Committee reviewed 173 research grant appli-
cations, which is three more than in the previous 
Members of the Scientific Committee 2013 (left to right): Ruth Chiquet Ehrismann (as of 2013), Rolf Marti  
(head of the Scientific Office), Maria Blettner, Holger Moch, Martin Pruschy, Beat W. Schäfer, Silke Gillessen  
(as of 2013), Emanuele Zucca (as of 2013), Martin F. Fey (president), Freddy Radtke, Simone Benhamou,  
Adrian Ochsenbein, Friedrich Stiefel, Hans-Uwe Simon, Jürg Schwaller (as of 2013), Kurt Fritzsche, and Curzio 
Rüegg (as of 2013) (not pictured: Primo Schär).
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year. Once again, more than half of the grant appli-
cations submitted were in basic research. Thanks to 
the addition of two more committee members, the 
yearly reviewing workload of the individual mem-
bers could be reduced somewhat, from an average 
of 23 grant applications in 2012 to an average of 21 
applications in the reporting year. 
The Scientific Committee meets twice a year to dis-
cuss at length the grant applications reviewed by 
the committee members and external  reviewers (see 
box, “The research grant application review pro-
cess”). Based on the discussions the committee pro-
duces a ranked list of the grant applications that the 
committee recommends to the boards of the SCR 
and the SCL for grant approval. 
As the financial means are limited, it is unfortunately 
never possible to approve grants for all grant appli-
cations that the committee judges to be of good 
quality and worthy of funding. In the reporting pe-
riod 2013 there were 28 research grant applications 
that could not be approved for funding despite their 
good quality (these projects are designated “ap-
proved but not funded”, ABNF), this was five grant 
applications fewer than in the previous year (33 
ABNF projects).
Operational support for the Scientific Committee’s 
important tasks and responsibility is provided by the 
Scientific Office of the SCL and the SCR. It organizes 
the call for and the review of grant applications and 
is responsible for quality control of the funded re-
search projects.
The research grant application review process
The grant application is submitted to and recorded 
by the Scientific Office.
<
The grant application is sent for review to two mem-
bers of the Scientific Committee who are experts  
in the relevant specialist field (such as basic research 
or psycho-oncology).
<
The two Scientific Committee members recommend 
additional experts as external reviewers.
<
The Scientific Office asks the external reviewers  
to review the grant application.
<
The reviewers evaluate the grant application.  
Four to six reviews are obtained for each research 
grant application, two of which are by Scientific 
Committee members.
<
The Scientific Office collects the reviews and puts 
them in a file.
<
The research grant application is discussed in  
detail at the bi-annual meeting of the Scientific 
Committee.
<
After the meeting, the Scientific Office writes  
up detailed minutes and creates a list of all grant  
applications ranked according to the committee’s 
recommendations.
<
The ranking list is forwarded to the boards of  
the Swiss Cancer Research foundation and the  
Swiss Cancer League, which then decide which  
grant applications will be funded.
<
The Scientific Office notifies the applicant of  
the decision. The reviews are made available to  
the applicant in an anonymous form.
Criteria for high-quality cancer research 
The quality of research grant applications is evaluated 
according to the following criteria:
–  Cancer relevance: Is the proposed research project  
expected to contribute important new observations  
or knowledge on the causes, prevention, or treatment 
of cancer?
–  Originality or socio-economic significance: Is the  
proposed research project original, innovative (basic 
research projects), or of socio-economic importance 
(clinical or epidemiological projects)?
–  Choice of methodology: Have the most appropriate 
methods for the project realization been chosen?
–  Feasibility: Is the project feasible in terms of finances, 
human resources, and organization?
–  The applicant’s past accomplishments: What are the 
applicant’s (or the project group’s) previous scientific 
achievements? How good were the publications?
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Coordinated and comprehensive fight  
against cancer 
Oncosuisse, the Swiss Cancer Organization, launched 
the first National Cancer Programme 2005–2010 
(NCP I) in October 2005; it was developed on behalf 
of the Federal Office of Public Health (FOPH) and 
the Swiss Conference of the Cantonal Ministers of 
Public Health (CMPH). There were numerous obsta-
cles to be overcome with this project, such as the 
federalist structures of the Swiss health care system, 
the discrepancy between cantonal sovereignty and 
federal sovereignty, the fragmented system with its 
many actors, and uncertain financing. 
But with the NCP I, success was achieved in improv-
ing the importance of the fight against cancer on the 
national health agenda and optimizing cooperation 
among the professional associations and organiza-
tions, thus smoothing the way for a coordinated, co-
herent, and comprehensive fight against cancer in 
Switzerland. Playing a leading role here was Reto 
Obrist, director of Oncosuisse from 2002 to 2009, 
who was awarded the Cancer Prize for his outstand-
ing contribution to the development and implemen-
tation of NCP I.
www.krebsliga.ch/krebspreis
The Swiss Cancer League (SCL) awards the Cancer 
Prize to recognize extraordinary contributions to 
cancer research and the fight against cancer. In  
addition, the Research Funding Department of the 
SCL organizes the request for proposals and the 
application review process for the Swiss Bridge 
Award. The Robert Wenner Award was not given 
in 2013.
Since 1960 the Swiss Cancer League has awarded the 
Cancer Prize of 10,000 francs. It recognizes persons 
who have made excellent contributions to cancer re-
search or outstanding efforts to promote research ac-
tivities in the areas of prevention, early detection, 
and treatment of cancer. The Cancer Prize of 2013 
was awarded to Prof. Reto Obrist, MD, former head 
physician and director of the oncology department of 
the Canton of Valais.
Prizes for outstanding achievements in cancer  
research and fighting cancer
Kurt Bodenmüller, lic. phil. nat.
Communications manager of the Scientific Office, Swiss Cancer League and  
Swiss Cancer Research foundation, Bern
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Swiss Bridge Award 2013
Last year, the SWISS BRIDGE Foundation presented the 13th SWISS BRIDGE Award for Cancer 
Research with a prize of 500,000 francs. The SWISS BRIDGE Award was given in 2013 for 
“Health services research in oncology”, and four scientists were honoured for their excellent 
research in that field. The focus of the four research projects was the best possible treatment 
and care meeting the needs of patients with cancer – in view of patients’ longer-term health 
and quality of life and also from the point of view of health care economics.
The four researchers from Switzerland, Germany, and Italy shared the award as follows:
Prof. Christine Bouchardy, MD, head of the Geneva Cancer Registry, Institute for Social and  
Preventive Medicine, University of Geneva; 150,000 Swiss francs for the project: Breast cancer 
quality of care and outcome according to surgeon’s caseload
Prof. Lisa Licitra, MD, chief of Head and Neck Cancer Medical Oncology Unit, IRCCS Foun-
dation National Cancer Institute, Milan; 125,000 Swiss francs for the project: Health and  
economic outcomes of two different follow-up strategies in effectively cured advanced  
head and neck cancer
Heide Götze, PhD, Department of Medical Psychology and Medical Sociology, University  
of Leipzig; 125,000 Swiss francs for the project: Long-term consequences of cancer and its 
treatment and satisfaction with health services – predictors of physical and mental health  
in long-term survivors
PD Sibil Tschudin, MD, Department of Obstetrics and Gynaecology, Gynaecological Social 
Medicine and Psychosomatics, Basel University Hospital; 100,000 Swiss francs for the project: 
Decisional conflict of young cancer patients with regard to fertility preservation – effects  
of an online decision-aid tool
A total of 27 projects were submitted by researchers who are working at academic cancer re-
search institutes in Europe. A scientific committee of nine experts in Switzerland and four other 
countries was responsible for the peer review process. Following the evaluation, eight appli-
cants were invited to write individual, detailed project studies from which, ultimately, the four 
named winners were chosen. The Research Funding department of the SCL was responsible  
for the request for proposals and organization of the application review process.
The SWISS BRIDGE Foundation was founded in 1997 at the initiative of Thomas Hoepli,  
managing director and foundation board member, with the support of the SCL. The aim of  
the foundation is to financially support high-quality cancer research projects in Switzerland 
and other countries with the help of charitable donors and foundations. Since its founding,  
the SWISS BRIDGE Foundation has awarded more than 20 million francs for research work  
in Belgium, Brazil, Germany, England, France, Israel, Italy, Norway, Sweden, Spain, and  
Switzerland.
www.swissbridge.ch
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In July 2013 the federal government and the  
cantons approved the National Strategy Against 
Cancer 2014–2017 (NSC). The National Strategy 
was developed by Oncosuisse in collaboration 
with numerous actors and experts on behalf of the 
platform Dialog Nationale Gesundheitspolitik.  
The Swiss Cancer League (SCL) has operations  
responsibility for setting up and managing the  
implementation of the NSC. This article illustrates 
the complex implementation of the NSC objectives 
taking the example of the NSC project “health  
services research”. And it shows how these aims 
are embedded in existing national strategies and 
measures for an important field of research that in 
Switzerland is still in its infancy.
As a strategic policy platform for the fight against 
cancer in Switzerland, Oncosuisse (the Swiss Cancer 
Organization) launched the second National Cancer 
Programme for Switzerland 2011–2015 (NCP II) in 
January 2011. It was developed together with the 
Swiss cancer organizations and with the support of 
the federal government and the cantons.1 NCP II out-
lines 10 central fields with over 100 objectives and 
recommendations for improving the fight against 
cancer and making it more efficient. The main goals 
of NCP II are the following: All persons residing in 
Switzerland will have the same right to low cancer 
risk through prevention and early detection, appro-
priate diagnosis and treatment based on the latest 
findings, and psychosocial and palliative care.
The first National Strategy Against Cancer 
From the start there was consensus that for policy-
supported implementation of NCP II, it would be nec-
essary to prioritize and group the objectives, taking 
into account the limited resources, the structures as 
they developed in Switzerland, and projects already 
ongoing in the field. Under the guidance of Onco-
suisse and in a broad process involving numerous 
experts, organizations, and institutions, the (first) 
National Strategy Against Cancer 2014–2017 (NSC) 
was developed.2 In July 2013 the NSC was approved 
by Dialog Nationale Gesundheitspolitik, which is the 
joint platform of the federal government and the 
cantons that commissioned the strategy.
Over the course of 2013 and based on the NSC, 
which is broadly anchored scientifically, medically, 
and politically, further prioritization work set out 
seven fields for action and 15 prioritized projects for 
the areas of prevention, care, and research. These 
are guided by three fundamental principles: involve-
ment of all areas through coordination and coopera-
tion, person-centred care through integrated care, 
and high quality for all through equal opportunity.
National Strategy Against Cancer 2014 – 2017 
Health services research
Rolf Marti, PhD
Head of the Scientific Office, Swiss Cancer League and director of the Swiss Cancer Research foundation; 
member of the core group “Implementation of the NSC”
Kurt Bodenmüller, lic. phil. nat.
Communications manager of the Scientific Office, Swiss Cancer League and  
Swiss Cancer Research foundation, Bern
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Project organization and implementation
On behalf of the platform Dialog Nationale Gesund-
heitspolitik, Oncosuisse is responsible for setting up 
and running the complex project organization of the 
NSC and has delegated operational responsibility to 
the SCL. In a further step, the NSC core group worked 
hard to structure the diverse projects optimally so 
that the objectives of the strategy can be achieved in 
the most effective way possible. For this reason, pro-
jects that had many parallels and cross-connections 
in content and that served to reach common objec-
tives were grouped in 10 project clusters (Figure 1).
From March to July 2014 a workshop was held for 
each project cluster, where the organization of the 
individual projects was tackled together with the or-
ganizations involved in an area and selected experts. 
The three main goals of the workshops were to: 
1)  Examine the objectives of the project and the 
project cluster,
2)  Define the tasks necessary for achieving the  
objectives and set up a common rough project 
plan,
3)  Outline the project organization and determine 
the project management based on the task  
structure.
Figure 1
Overview of the 3 areas prevention, care and research,  
the 7 fields for action, the 15 projects, and the 10 project clusters of the National Strategy Against Cancer (NSC)
Fields for action Projects Project cluster
1. Prevention 1.1 Structural measures & health literacy A. Prevention & health promotion
2. Screening 2.1 Colon cancer screening programmes B. Screening programmes
2.2 Breast cancer screening programmes
2.3 Panel of experts in screening questions C. Panel of experts in screening questions
3.  Clinical pathways/ 3.1 Clinical pathways D. Clinical pathways
quality development 3.2 Guidelines and treatment guidelines
3.3 Tumour boards
4. Health services 4.1 Integrated health services organization E. Integrated health services organization
5. Education 5.1 Self-efficacy F. Self-efficacy
5.2 Competence building for experts G. Education
6. Promotion of research 6.1 Health services research H. Health services research
6.2 Clinical and translational research I. Clinical and translational research
7.  Epidemiology/ 7.1 Federal law on cancer registration (KRG) J. Epidemiology and monitoring
monitoring 7.2 Treatment data and data linking
7.3 Knowledge transfer to practice and policy
Prevention (1 / 2)  Care (3 – 5)  Research (6 / 7)
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Health services research in oncology
Three examples from the field of cancer will clarify the concrete questions and objectives  
of health services research.
1. Long-term survivors
Thanks to early detection, more precise diagnosis, and especially advances in treatment, the 
five-year survival rate for cancer is 55–60 %. At present there are close to 300,000 persons  
in Switzerland who will have a cancer diagnosis in their lifetime. This also means that cancer is 
increasingly becoming a chronic disease, which presents different and new challenges to our 
complex health care system. Long-term survivors make very different demands on research 
and society. Questions concerning the psychosocial, medical, or economic consequences of 
cancer treatment, for example, questions concerning rehabilitation and return to work, and  
so on, can only be addressed through health services research approaches. Depending on the  
issue under study, medical, economical, legal, and social science dispositives (“disposing 
knowledge”) must be integrated in the study design and combined properly. In this way health 
services research delivers previously missing important foundations for optimal treatment  
and health-policy decisions.
2. Older patients with cancer
The most important risk factor for cancer is age. Approximately 60 % of all new cancer diagno-
ses are for persons older than 65 years of age. Less well-known is that fact that most clinical 
studies in oncology are conducted largely with samples that exclude precisely this age group: 
Only 25 % of treated patients in clinical studies are older than 65. The reason for the exclusion 
is mostly the high comorbidity in this age group. That means that important results – such as 
the results of clinical trials for approval of new cancer drugs, which often also inform treatment 
guidelines – are generated in studies in which the main parties affected and their particular 
medical situation are clearly underrepresented. Here, we must necessarily depend on health 
services research studies that are willing and able to analyse treatment results under everyday 
conditions. In a second step, the data obtained can and must be taken into consideration in  
the optimization of treatment guidelines.
3. Quality of life and life situation
Many clinical research efforts still centre on the goal to cure, or successfully treat, persons with 
cancer. Survival (without remission) is the central endpoint of most trials. However, for persons 
with cancer, their families, and the persons treating them, many new, previously little researched 
questions have moved increasingly into focus that can only be studied adequately in health ser-
vices research: questions concerning quality of life, inpatient versus outpatient care, services and 
competencies of Spitex oncology outpatient care services, palliative care, and so on. There is a 
demonstrated, particularly great need for research on the specific needs of older and very elderly 
persons with cancer. This holds also for the service providers treating them ‒ primary care physi-
cian, oncologist, psychologist, and nursing professionals.
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Project cluster “Health services research”
Within the NSC field for action “Promotion of re-
search”, one of the prioritized objectives is to build 
up and strengthen health services research in Swit-
zerland. Health services research analyses the qual-
ity, effectiveness, and economic efficiency of medi-
cal services under everyday conditions (see box). On 
the occasion of the workshop on the project cluster 
“Health services research”, the project aims and 
measures defined in the NSC were discussed and ad-
justed (the changes are shown in italics).
1)  Health services research will be established and 
institutionalized. 
 –  A research committee will be established with 
the participation of the professional organiza-
tions and associations to promote exchange  
on relevant research issues. 
 –  Health services research will be institutional-
ized in an interdisciplinary form.
 –  An oncology-specific module for a National 
Research Programme (NRP) on health services 
research will be submitted.
2)  Practice-oriented research questions will be  
taken up and studied in interdisciplinary research 
studies.
 –  In the research work there will be a focus on 
research topics in public health, health econom-
ics, palliative care, and nursing. 
 –  Cooperation among the researchers at different 
universities and hospitals will be strengthened. 
3)  The Federal Office of Public Health (FOPH) and 
the Swiss Conference of Cantonal Ministers of 
Public Health (GDK) support health services  
research (including outcome data) in the frame-
work of their jurisdictions as an independent and 
relevant area of research and utilize the findings 
in planning.
At the workshop a “health services research” work-
ing group was set up under the lead of the director of 
the Swiss Cancer Research foundation, and the group 
has since been dedicated to the implementation of 
the aims and measures. In view of the interdiscipli-
nary nature of health services research and the paral-
lels with two other research-relevant project clus -
ters – “Epidemiology” and “Clinical and translational 
research” – coordination and continuous exchange 
among the working groups is essential. In addition, 
partnerships need to be formed outside of the cancer 
community, as the aims of the project cluster “Health 
services research” go beyond the field of oncology. 
Along with the NSC, several national initiatives are 
targeted at strengthening health services research in 
Switzerland.
Health services research in Switzerland
Although health services research in other countries 
such as the United States, the United Kingdom, the 
Netherlands, and Germany has been developed ex-
tensively for a long time, it is only in the last few 
years that awareness of the need for this field of 
research has grown in Switzerland. Health services 
research is not anchored in institutions, and there is 
no networking among the actors and no coordina-
tion of research activities. In addition, there is no 
comprehensive national promotion of the type of re-
search. Therefore, in many areas of health services 
provision, there exist none of the scientific founda-
tions that are indispensable for evidence-based health 
care policy making.
To improve health services provision and to address 
the main weaknesses of the Swiss health system 
(limited transparency, incomplete statistical and an-
alytical basis, inefficiencies and the fact that the 
poor quality of certain services goes unrecognized), 
in January 2013 the Federal Council set out the 
Council’s health policy priorities for the next eight 
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Health services research: Definitions and objectives 
Excerpted from: “A 1. Was ist Versorgungsforschung?”, in: Schweizerische Akademie der 
Medizinischen Wissenschaften (SAMW), ed. Stärkung der Versorgungsforschung in der  
Schweiz. Swiss Academies Reports 9(1) (pp. 19-21). Basel: SAMW; 2014.3
«Alongside basic and clinical research, health services research has become established as a 
third pillar of medical research in many countries. Basic biomedical research studies biological 
processes and their significance for medical applications, and clinical research investigates the 
effectiveness of new treatments with selected patients and participants under defined study 
conditions. In contrast, health services research analyses the effectiveness of medical care  
under everyday conditions. With this, it aims to minimize the gulf between the evidence from 
clinical trials and actual care practice (evidence/performance gap).
Health services research studies how people gain optimal access to adequate medical care and 
how this care can made as efficient as possible so that it has an optimal effect on patients. 
The term “health services” refers not only to patients but also to the healthy population to be 
served (for example, in the area of prevention), and thus to patient care as well as health care.
In the United States, the Agency for Healthcare Research and Quality (AHRQ) defines health 
services research as follows: “Health services research examines how people get access to 
health care, how much care costs, and what happens to patients as a result of this care. The 
main goals of health services research are to identify the most effective ways to organize,  
manage, finance, and deliver high quality care; reduce medical errors; and improve patient  
Figure 2
The three pillars of research in medicine and health care system  
(according to Pfaff & Schrappe, 2011) 3
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safety”.4 This definition by the AHRQ puts the core areas of health services research in a nut-
shell – namely, access, appropriateness, and the costs of care – and makes it clear that health 
services research is patient-centred and focused on outcome quality.
The definition of health services research most widely disseminated in German-speaking coun-
tries derives from Pfaff et al.5 Pfaff sees the “last mile” of the health system – that is, looking at 
patient care under the real life conditions of routine provision of medical services to the public ‒ 
as the central focus of health services research. Offering a methodological/functional definition, 
Pfaff describes health services research as an “interdisciplinary field of research which gives an 
account, and causal explanations, of health services and the framework within which they are 
delivered; promotes the development of scientifically based health service concepts; monitors 
the implementation of new health service concepts; and evaluates the effectiveness of health 
service structures and processes under everyday conditions”5 (Figure 2).
The goal of multi- and transdisciplinary health services research is to generate evidence-based 
information on how to optimize the structures of patient and health care, increase the quality 
and efficiency of health services, reduce underprovision and overprovision, and increase  
patient-centredness and patient safety. Thus, the findings of health services research benefit 
not only patients and service providers but also policy- and decision-makers in government 
and the economy.»
Sandzeichnung, Videostill, 2012
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years in the “Health2020” report.6 Among other 
things, the report calls explicitly for the establish-
ment and strengthening of health services research 
in Switzerland. A report issued in 2012 by the Swiss 
Conference of Cantonal Ministers of Public Health 
(GDK) and the FOPH on new models for the delivery 
of primary care 7 also places a priority on expanding 
and strengthening health services research in Swit-
zerland, as does also the Federal Council’s Master 
Plan of 2013,8 Massnahmen des Bundes zur Stärkung 
der biomedizinischen Forschung und Technologie 
(government measures to strengthen biomedical re-
search and technology).
Pioneering work by the SAMS
The Swiss Academy of Medical Sciences (SAMS) is 
playing a pioneering role. Together with the Gottfried 
& Julia Bangerter-Rhyner-Stiftung, SAMS launched a 
new funding programme in health services research 
in 2012 to establish and develop this area of research 
in Switzerland. To this purpose the Bangerter-Rhyner-
Stiftung is providing one million Swiss francs in fund-
ing for pilot projects, research studies, and scholar-
ships/grants.
For three years now, SAMS – with support from the 
Bangerter-Rhyner-Stiftung and in cooperation with 
different partners – has organized an annual national 
symposium on health services research. The purpose 
is transfer of knowledge, presentation of up-to-date 
research findings, awarding of prizes for outstanding 
research, and interdisciplinary exchange. It also serves 
the building of a health services research community, 
made up of representatives of the different special ar-
eas and professions. The first symposium in 2012, 
which was conducted with the active participation of 
the Swiss Group for Clinical Cancer Research (SAKK), 
the Swiss Cancer Research foundation, and the SCL, 
was dedicated to health services research in oncol-
ogy.
SAMS, as the lead organization and with the involve-
ment of various actors including also the Swiss Can-
cer Research foundation and the SCL, was requested 
by the Federal Office of Public Health (FOPH) to 
prepare a paper on strengthening health services re-
search in Switzerland.3 The paper was written in the 
framework of the Federal Council’s Primary Care 
Master Plan and published in March 2014. The paper 
essentially provides answers to the question as to 
what kind of health services research is needed in 
Switzerland. The report also offers recommendations 
for the medium- and long-term building of research 
expertise, infrastructures, database, promotion of 
young researchers, and funding sources in the area 
of health services research.
National Research Programme
Based on the SAMS paper and led by Prof. Thomas 
Rosemann, MD, PhD, head of the Institute of Primary 
Care and Health Services Research at University 
Hospital Zurich, SAMS submitted a proposal for a 
National Research Programme (NRP) on health ser-
vices research in Switzerland in January 2014.9 With 
this, the first aim of the NSC for the project “Health 
services research” was achieved. 
The NRP on health services research is intended to 
make possible research on urgent issues, such as 
overprovision, underprovision, inappropriate care in 
the Swiss health care system, optimal resource allo-
cation (interprofessional cooperation) in medical 
care, access and provision to vulnerable patients in 
the health care system, and care of patients with 
chronic diseases and multimorbidity. The NRP also 
provides Switzerland with an opportunity to catch 
up in the field of health services research. 
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A total of 69 proposals for new NRPs were submit-
ted to the State Secretariat for Education, Research 
and Innovation (SERI); the Swiss National Science 
Foundation (SNSF) will conduct a feasibility study 
for six of these research topics, including health ser-
vices research. The Federal Council is expected to 
determine the topics and the budgets of the new 
NRPs in the spring of 2015 and commission the 
SNSF to conduct the programmes. As there is broad 
support and a demonstrated need for the research, 
the chances for approval of an NRP on health ser-
vices research are good. And that brings another 
aim of the NSC – a cancer-specific health services 
research module – within reach.
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on detailed information on the individual research 
projects. In the past five years, approximately one-
third of the available monies of 3 to 3.6 million francs 
went to support research projects. This prioritization 
accords with numerous charitable donors’ wish that 
their donations be used for cancer research activities. 
Research funding is next largest budget position after 
help for persons with cancer. 
Funding of projects in different areas of research
The Geneva Cancer League funds a broad range of 
research projects:
–  Clinical research, with the exception of large  
clinical trials, the costs of which exceed the funds 
of the Geneva Cancer League. But the Geneva 
Cancer League supports the conducting of clinical 
pilot studies, such as a pilot study initiated by 
Prof. Pierre-Yves Dietrich, director of the Centre 
of Oncology at Geneva University Hospital, for 
which he was awarded the distinguished Cancer 
Researcher of the Year Award by the Gateway  
for Cancer Research. This innovative study is on 
immunotherapy for glioblastoma. Another exam-
ple is adjuvant treatment of melanoma using 
beta-blockers; the initial results obtained thanks 
to the support of the Geneva Cancer League 
served as the basis for the conducting of an inter-
national study.
–  Applied research on common types of cancer  
that affect a large part of the population (such  
as breast cancer), on types of cancer that are hard 
to detect in early stages (such as ovarian cancer), 
and on types of cancer that are difficult to treat 
(such as brain tumours, pancreatic cancer, and 
liver cancer).
The cancer league is organized as an association 
made up of 19 cantonal and regional cancer 
leagues as well as the umbrella organization,  
the Swiss Cancer League. In 2013, eight cantonal 
cancer leagues – including the Geneva Cancer 
League – gave a total of 3.1 million francs to cancer 
research projects and institutes. Providing funding  
of approximately one million francs per year, the 
Geneva Cancer League is the cantonal cancer 
league that invests the most money in cancer  
research. 
The Geneva Cancer League funds research projects 
at Geneva University Hospital (HUG) and at the Fac-
ulty of Medicine and Faculty of Sciences at the Uni-
versity of Geneva with the aim to contribute towards 
increasing the effectiveness of cancer treatments in 
the short and long term. The Geneva Cancer League 
has supported cancer research benefitting persons 
with cancer since its founding in 1924. The first re-
search project supported was a project on treating 
cervical cancer at the Institute of Radiation Therapy. 
Funding research is one of the main aims set out in 
the statutes of the Geneva Cancer League. 
The budget of the Geneva Cancer League is dis-
cussed and approved at the annual general assembly 
at the request of the board of directors. At a special 
session headed by the author of this article, the 
board decides on the allocation of the funds based 
Research funding by the cantonal  
and regional cancer leagues
Prof. Luc Perrin, MD, Dr h. c.
Member of the board of the Geneva Cancer League, honorary professor of virology  
at Geneva University Hospital (HUG), Geneva
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–  Research on new diagnostic instruments, such  
as for leukaemias or for better assessment of  
the prognosis of patients with breast cancer, and 
on the advisability of adjuvant chemotherapy 
with certain types of cancer.
–  Basic research to find new ways and targets for 
cancer treatment – a long-term perspective with 
great potential.
–  Funding for prevention and screening activities.
–  Funding for new services for research not yet  
financed by HUG. At present, for example, we  
are supporting the Centre for Oncology, which is 
participating in a programme on genetic charac-
terization of selected types of cancer.
Submission, review, and monitoring of research 
projects 
Grant applications for new research projects can be 
submitted to the Geneva Cancer League up to 1 Oc-
tober of the current year. Applications are submitted 
using standard forms that are similar to the forms 
used by the Swiss National Science Foundation 
(SNSF). The applications are reviewed by the person 
responsible for research, currently the author of this 
article, and the president of the Geneva Cancer 
League, Prof. Bernard Chapuis, who consult the ap-
plicants and, if needed, obtain the opinions of exter-
nal experts. Approximately 30 % to 50 % of the grant 
applications are submitted by women. These grant 
applications receive priority support in order to pro-
mote gender balance among future academic re-
searchers. The two reviewers exchange their opinions 
and prepare a report on each grant application that 
includes recommendations. The reports are forwarded 
to the manager of and to the board of the Geneva 
Cancer League, which – after discussion with the two 
reviewers – makes the final funding decisions. The re-
sults of the review are then communicated to the 
grant applicants. 
About one-half of the grant applications submitted 
can be supported. For a research project to receive 
funding, the following three conditions must be ful-
filled:
–  In publications emerging out of research that is 
funded fully or in part by the Geneva Cancer 
League, the funding by the Geneva Cancer League 
must be mentioned in the acknowledgements. 
–  The Geneva Cancer League must receive an an-
nual and/or final report, with enclosure of a copy 
of the supported publications. For research pro-
jects with a duration of several years, the research 
report serves as the basis for the League’s decision 
on continuing funding of the project. 
–  Each year, a financial report on the use of the 
granted funds must be prepared. For grants to 
university research groups, the report must be 
prepared by the financial services of the depart-
ment that is responsible for the administration  
of university funds.
Prof. Luc Perrin, MD, Dr h. c.
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Research funding by the cantonal cancer leagues
List of supported funded research projects and institutions in 2013
The list shows the financial contributions granted in 2013.
Basel Cancer League
Christofori Gerhard | CHF 55,000.–
Institut für Biochemie und Genetik, Universität Basel, Basel
High-content identification and modulation of signalling pathways underlying epithelial- 
mesenchymal transition (EMT) and cancer metastasis
Heinzelmann-Schwarz Viola | CHF 30,000.–
Klinik für Operative Gynäkologie und Gynäkologische Onkologie, Universitätsspital Basel, Basel
The human N-acetylglucosaminyltransferase MGAT3 as a potential specific biomarker in ovarian cancer
Hohmann Joachim | CHF 5,000.–
Klinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel
Comparison of 18F-FDG-PET/CT and ultrasonography (abdomen and peripheral lymph nodes)  
in the initial staging and the follow-up of patients with melanoma
Hynes Nancy | CHF 30,000.–
Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel
Aberrant Ret expression causes mammary tumours and developmental defects during  
the post-lactational transition
Kovac Michal | CHF 45,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Deep exome sequencing approach to investigate the evolution of multi-focal hepatocellular carcinoma  
through space and time
Müller Philipp | CHF 25,000.–
Departement Biomedizin, Universitätsspital Basel, Basel
Exploring the immunomodulatory mechanisms of the tyrosine kinase inhibiter axitinib in  
tumour-bearing hosts: implications for combination therapies with anti-cancer immunotherapy
Obermann Ellen | CHF 6,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Evaluation of the mechanical properties of metastatic tumour cells of the breast by atomic force  
microscope (AFM)
Rothschild Sacha | CHF 20,000.–
Klinik für Onkologie, Universitätsspital Basel, Basel
Methylphenidate for the treatment of cancer-related fatigue
Ruiz Christian | CHF 20,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Evaluation of the role of ANO1 as a potential therapeutic target in urinary bladder cancer
Spagnoli Giulio | CHF 64,000.–
Departement Biomedizin, Universitätsspital Basel, Basel
Expansion and functional analysis of “bulk”- and tumour-associated antigen specific stem cell  
memory CD8 + T-cells from peripheral blood of healthy donors and patients with melanoma or  
non-small cell lung carcinoma
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Bern Cancer League 
Bouchet Audrey | CHF 60,000.–
Institut für Anatomie, Universität Bern, Bern
Increased vascular permeability by synchrotron microbeam radiation generates a highly  
efficient drug delivery system for tumour treatment
Dufour Jean-François | CHF 20,000.–
Departement Klinische Forschung, Universität Bern, Bern
The Bern hepatocellular carcinoma (HCC) cohort
Höpner Sabine | CHF 40,000.–
Departement Klinische Forschung, Universität Bern, Bern
Lymphotoxin-  receptor (LTBR) signalling in leukaemic stem cells
Marti Thomas | CHF 60,000.–
Departement Klinische Forschung, Universität Bern, Bern
Targeting tumour-initiating cells in lung cancer
Müller Loretta | CHF 43,000.–
Departement Klinische Forschung, Universität Bern, Bern
Carcinogenic potential of gasoline car exhaust (including nanoparticles) and their effect  
on natural killer cells
Peng Ren-Wang | CHF 70,000.–
Departement Klinische Forschung, Universität Bern, Bern
Functional identification and molecular targeting of human lung cancer stem cells
Schäfer Stephan | CHF 70,000.–
Institut für Pathologie, Universität Bern, Bern
Molecular characterization of adenosquamous carcinoma of the lung as a prime type model of  
tumour heterogeneity
Schlapbach Christoph | CHF 50,000.–
Universitätsklinik für Dermatologie, Inselspital, Universitätsspital Bern, Bern
Characterizing human interleukin 9-producing T-helper memory cells and their role in anti-tumour  
immune response in malignant melanoma
Schucht Philippe | CHF 25,000.–
Universitätsklinik für Neurochirurgie, Inselspital, Universitätsspital Bern, Bern
Extent of resection thresholds as predictor of survival in patients with glioblastoma
Central Switzerland Cancer League
Diebold Joachim | CHF 50,000.–
Zentralschweizer Krebsregister, Luzerner Kantonsspital, Luzern
Do the new possibilities for targeted therapy lead to an improvement in survival rates of advanced  
lung cancer patients in Central Switzerland? 
Eastern Switzerland Cancer League
Ludewig Burkhard | CHF 100,000.–
Institut für Immunbiologie, Kantonsspital St. Gallen, St. Gallen
Systems biology approach to molecularly characterize the lung cancer microenvironment 
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Geneva Cancer League
Ansari Marc | CHF 50,500.–
Département de pédiatrie, Hôpitaux universitaires de Genève (HUG), Genève
Association of a CTH gene variant with veno-occlusive disease in children receiving busulfan before  
haematopoietic stem cell transplantation
Cohen Marie | CHF 99,168.–
Département de gynécologie et d’obstétrique, Hôpitaux universitaires de Genève (HUG), Genève
Novel therapeutic approaches against ovarian cancer recurrence
Curran Joseph | CHF 106,909.–
Département de microbiologie et médecine moléculaire, Université de Genève, Genève
The 5’UTR fingerprint: a new diagnostic marker for breast cancer
Dietrich Pierre-Yves | CHF 140,000.–
Service d’oncologie, Département de médecine interne, Hôpitaux universitaires de Genève (HUG), Genève
Identification and validation of glioma antigen: towards immunotherapies for brain tumours
Irminger Irmgard | CHF 50,000.–
Département de gynécologie et d’obstétrique, Hôpitaux universitaires de Genève (HUG), Genève
Regulation of the oncogenic isoforms of the tumour suppressor BARD1 in cancer by microRNAs and  
non-coding RNAs
Le Gal Frédérique | CHF 30,000.–
Département des spécialités de médecine, Service de dermatologie et vénérologie, Hôpitaux universitaires de 
Genève (HUG), Genève
Skin cancer screening using high-sensitivity infrared imaging
Le Gal Frédérique | CHF 120,000.–
Département des spécialités de médecine, Service de dermatologie et vénérologie, Hôpitaux universitaires de 
Genève (HUG), Genève
Beta-blockers in the adjuvant treatment of melanoma, an interventional clinical study
Mandriota Stefano | CHF 100,230.–
Département de pédiatrie, Division d’onco-hématologie, Hôpitaux universitaires de Genève (HUG), Genève
The ATM / p53 signalling pathway in the regulation of cellular senescence
Martinou Jean-Claude | CHF 96,000.–
Département de biologie cellulaire, Faculté des sciences, Université de Genève, Genève
Role of the mitochondrial pyruvate carrier in the proliferation and metastasis of breast cancer cells
Preynat-Seauve Olivier | CHF 99,986.–
Laboratoire d’immuno-hématologie transfusionnelle, Hôpitaux universitaires de Genève (HUG), Genève
Identification of miRNA targets for glioblastoma using a novel in vitro model
Reith Walter | CHF 111,159.–
Département de pathologie et d’immunologie, Faculté de médecine, Université de Genève, Genève
Identifying the cellular functions and regulatory networks that underlie the link between  
microRNA-155 and cancer
Thore Stéphane | CHF 90,000.–
Département de biologie moléculaire, Faculté des sciences, Université de Genève, Genève
Steroid receptor RNA activator: a new target for modulating the hormonal response in cancer cells
Tille Jean-Christophe | CHF 70,000.–
Département de pathologie clinique, Faculté de médecine, Université de Genève, Genève
Role of heparan sulfate in endometrioid carcinoma: tissue remodelling, angiogenesis and lymphangiogenesis
Wehrle-Haller Bernard | CHF 70,500.–
Département de physiologie cellulaire et métabolisme, Centre médical universitaire (CMU), Genève
Kinase-independent functions of the receptor tyrosine kinase c-kit in the persistence and adhesion of  
cancer stem cells to their environmental niche
Thurgau Cancer League 
Fleischmann Achim | CHF 53,714.–
Pathologie, Kantonsspital Münsterlingen, Münsterlingen
Promotion of cancer research, focused on the area of gynaecological and urological tumours
Legler Daniel | CHF 33,333.–
Biotechnologie Institut Thurgau, Universität Konstanz, Kreuzlingen
Breast cancer project
Reuter Christiane | CHF 25,000.–
Radioonkologie, Kantonsspital Münsterlingen, Münsterlingen 
Study of intraoperative radiotherapy of the breast
Ticino Cancer League (Fondazione ticinese per la ricerca sul cancro)
Catapano Carlo | CHF 100,000.–
Istituto oncologico della Svizzera italiana (IOSI), Bellinzona 
Non-coding RNAs and epigenetic networks in prostate cancer pathogenesis and novel therapeutic  
strategies
Ceppi Francesco | CHF 18,000.–
Hôpital Notre-Dame, Montréal, Canada
Post-graduate training in paediatric oncology
Civenni Gianluca | CHF 50,000.–
Istituto oncologico della Svizzera italiana (IOSI), Bellinzona
Isolation of stem cells from human prostate biopsy to study tumour initiation
Sandzeichnung, Videostill, 2012
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Frattini Milo | CHF 50,000.–
Istituto cantonale di patologia, Locarno
Investigation of the role of NEU3 in colorectal carcinogenesis
Molinari Francesca | CHF 50,000.–
Istituto cantonale di patologia, Locarno
Identification of new alterations in the small intestine adenocarcinoma through new sequencing  
methodology
Zurich Cancer League 
Bernasconi Michele | CHF 72,045.–
Experimentelle Infektiologie und Krebsforschung, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Role of proprotein convertases in paediatric sarcomas: useful theragnostic targets?
Bornhauser Beat | CHF 67,045.–
Forschungsgruppe Leukämie/Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Large scale drug response profiling to identify new targets in refractory leukaemia
Graf Rolf | CHF 69,720.–
Klinik für Viszeral- und Transplantationschirurgie, Universitätsspital Zürich, Zürich
Inflammation contributes to the regression of acinar-to-ductal metaplasia in the injured pancreas
Hottiger Michael | CHF 70,625.–
Institut für Veterinärbiochemie und Molekularbiologie, Universität Zürich, Zürich
Assessment of ADP-ribosylomes to identify specifically ADP ribosylated proteins that regulate  
PARP inhibitor sensitivity of cancer cells
Müller Anne | CHF 84,220.–
Institut für Molekulare Krebsforschung, Universität Zürich, Zürich
Epigenetic silencing of tumour suppressor genes in the pathogenesis of diffuse large B-cell lymphoma
Münz Christian | CHF 58,116.–
Institut für Experimentelle Immunologie, Universität Zürich, Zürich
Boosting of NY-ESO-1-specific re-directed T-cells
Nadal David | CHF 78,061.–
Abteilung Infektiologie und Spitalhygiene, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Natural killer cell control of Epstein-Barr virus-induced cancerous B-cell transformation
Rohrer Bley Carla | CHF 51,115.–
Abteilung für Radio-Onkologie, Universität Zürich, Zürich
In vivo profiling of DNA damage and repair kinetics after anti-neoplastic treatment:  
use of a minimally invasive approach
Tabatabai Ghazaleh | CHF 51,300.–
Klinik für Neurologie, Universitätsspital Zürich, Zürich
Thymosin beta-4 in malignant gliomas: a novel regulator of angiogenesis?
Weber Achim | CHF 40,000.–
Institut für Klinische Pathologie, Universitätsspital Zürich, Zürich
Role of innate lymphoid cells (ILC) in intestinal inflammation and carcinogenesis
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Presentation of supported funded research projects and institutions in 2013
Basel Cancer League
Christofori Gerhard | High-content identification  
and modulation of signalling pathways underlying  
epithelial-mesenchymal transition (EMT) and cancer 
metastasis 
Institut für Biochemie und Genetik, Universität Basel,  
Basel
Duration: 01. 09. 2013  – 01. 03. 2015
Most cancer deaths are due to the systemic dissemination 
of cancer cells and the formation of secondary tumours 
(metastasis) in distant organs. Obviously, the migratory 
and invasive capabilities of cancer cells are critical param-
eters in the metastatic cascade. 90 % of all cancers origi-
nate from epithelial tissues and to leave the primary tu-
mour and to invade into the surrounding tissue tumour 
cells dissolve their cell-cell contacts and adjust their cell-
matrix adhesion sites to a more transient, migratory and 
invasive mode. Such temporary and reversible phenome-
non is known as epithelial-to-mesenchymal transition 
(EMT), a multi-stage process that involves distinct genetic 
and epigenetic alterations and leads to metastasizing, 
tumour-seeding cells with stem cell-like capabilities, po-
tentially cancer stem cells. 
Employing various cellular models of EMT in vitro and 
mouse models of cancer in vivo, we take a focussed ap-
proach to identify the signalling pathways and their spe-
cific kinase and phosphatase components that function-
ally contribute to EMT and malignant tumour progression. 
Subsequently, we modulate the function of these signal-
ling pathways in order to prevent EMT or to differentiate 
cancer cells into non-malignant, differentiated tumour 
cells. The experiments aim at the identification of molec-
ular targets for the design and development of novel can-
cer therapies.
Heinzelmann-Schwarz Viola | The human  
N-acetylglucosaminyltransferase MGAT3 as a  
potential specific biomarker in ovarian cancer
Klinik für Operative Gynäkologie und Gynäkologische 
Onkologie, Universitätsspital Basel, Basel
Duration: 01. 08. 2013 – 31. 12 .2013
Advanced epithelial ovarian cancer has a poor survival rate 
(30 %) but prognosis improves if the cancer is diagnosed 
early. However, early diagnosis is often limited due to the 
lack of reliable and sensitive biomarkers. Identification of 
novel biomarkers for early detection of ovarian cancer is of 
immense interest. In an effort to search for ovarian cancer-
specific cell surface markers we previously detected a 
unique glycan (carbohydrate) structure on ovarian cancer 
cells, which was not detectable on normal ovarian surface 
epithelial (HOSE) cells. This unique structure comprises a 
bisecting monosaccharide (GlcNAc) which correlates with 
the expression of MGAT3 (a glycosyltransferase) gene, 
proposing bisecting GlcNac as a potential ovarian cancer 
biomarker. As MGAT3 appears to be repressed by DNA 
methylation in normal HOSE but demethylated in ovarian 
cancer cells, we investigated the molecular mechanism of 
this putative epigenetic regulation of MGAT3. 
Our results show that reduced DNA methylation at unique 
sites of the MGAT3 promoter correlates with increased ex-
pression of MGAT3 in ovarian cancer cells and that MGAT3 
and bisecting GlcNAc are re-expressed in HOSE cells by 
the DNA methyltransferase-inhibitor 5-Aza. We propose 
that increased MGAT3 expression in ovarian cancer cells is 
regulated by DNA demethylation. Preliminary results sug-
gest a similar mechanism for elevated MGAT3 expression 
in stem cell-like pools of HOSE cells from which ovarian 
cancer may develop.
Hohmann Joachim | Comparison of 18F-FDG-PET/CT 
and ultrasonography (abdomen and peripheral lymph 
nodes) in the initial staging and the follow-up of  
patients with melanoma
Klinik für Radiologie und Nuklearmedizin, Univer-
sitätsspital Basel, Basel
Duration: 01. 12. 2013 – 30. 11. 2014
The therapeutic options for patients with melanoma de-
pend strongly on the results of the staging examinations 
regarding especially lymph nodes and filiae in other or-
gans like the liver or the lung. The detection or exclusion 
of such manifestations of the primary tumour is the main 
task for the imaging modalities of radiology and nuclear 
medicine. Which modality is giving the best results is sub-
ject of controversial discussions. It might either be PET/CT 
or ultrasonography or a combination of both. However, 
there are several publications for both methods but there 
is a lack of studies comparing both modalities in the same 
patients. 
At the University Hospital Basel patients with melanoma 
are usually getting both examinations for several years. 
Therefore the aim of our study is to close the gap in the 
literature with the retrospective evaluation of the per-
formed PET/CT and ultrasonography examinations in 
these patients. The benefit of the study will be to find out 
the optimal examination strategy for the individual 
patient and furthermore a possible cost reduction for the 
health system.
Hynes Nancy | Aberrant Ret expression causes  
mammary tumours and developmental defects during 
the post-lactational transition
Friedrich Miescher Institut für biomedizinische Forschung 
(FMI), Basel
Duration: 01. 07. 2014 – 01. 11. 2014
The receptor tyrosine kinase (RTK) Ret, a key oncoprotein 
in thyroid carcinoma, has also been implicated in other 
types of cancers. Recently, Ret copy number gains and 
mutations have been reported at low frequencies in breast 
tumours. Furthermore, we and others have reported that 
Ret is overexpressed in about 40 % of human tumours and 
this correlates with poor patient prognosis. Using a trans-
genic mouse model with the MMTV promoter controlling 
Ret expression in the doxycycline-inducible system, we 
show that overexpression of Ret in the mammary epithe-
lium produces hyperplasia and mammary tumours display- 
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ing a solid morphology that recapitulates features of hu-
man solid ductal carcinoma in situ. Moreover, Ret-induced 
tumours express ErbB2 and are oestrogen receptor posi-
tive. Importantly Ret-induced tumours rapidly regress 
after doxycycline withdrawal indicating that Ret is the 
driving oncoprotein. 
It is well known that RTKs, which are implicated in breast 
cancer, e. g. the ErbB receptors, also have roles in normal 
development. We found that Ret is highly expressed in 
mid-lactation. Indeed, Ret appears to have a role in the 
post-lactation transition to involution since when Ret is in-
duced early in lactation we observe enhanced kinetics of 
involution. The involution period is well known to drive 
cancer progression. Thus, our results suggest that if Ret ex-
pression is deregulated during the lactation-involution 
transition this might contribute to breast cancer develop-
ment.
Kovac Michal | Deep exome sequencing approach to 
investigate the evolution of multi-focal hepatocellular 
carcinoma through space and time
Institut für Pathologie, Universitätsspital Basel, Basel
Duration: 01. 09. 2013 – 01. 09. 2014
The medical strategies targeting hepatocellular carcinoma 
(HCC) are often hindered by tumour recurrence that may 
be as high as 75 % in a 5-year period. A partial explana-
tion of this dismal figure is due to the simultaneous exist-
ence of various cancer cell types, or cancer clones, within 
the same tumour with different mutations in genes and 
molecular pathways of which only few are targetable. As 
more drugs targeting different members in same signal-
ling pathway are likely to come into market in the years to 
come, it becomes crucial for a physician to have a clear 
understanding of the clonal complexity of the patient’s 
tumour to decide, which combination of drugs should be 
used to achieve the longest disease-free survival. Under-
standing of clonal structure of multi-focal HCC tumours 
thus poses another challenge to be met, which has now 
become possible using deep next generation sequencing 
followed by mathematical modelling of the data.
The proposed project will provide a deeper understanding 
of the complexity of multi-focal HCC with the specific aim 
to establish the influence of tumour microenvironment 
and clonal structure on patient’s survival. This is impor-
tant clinically, as it will provide knowledge that will assist 
in the introduction of the personalized medicine approach 
to cancer, as in a heterogeneous tumour the major clone 
may not be the one that gives rise to recurrent, meta-
static, or therapy-resistant tumour cells.
Müller Philipp | Exploring the immunomodulatory  
mechanisms of the tyrosine kinase inhibiter axitinib in 
tumour-bearing hosts: implications for combination 
therapies with anti-cancer immunotherapy
Departement Biomedizin, Universitätsspital Basel, Basel
Duration: 01. 07. 2013 – 30. 06. 2014
Recent experimental work provides strong evidence that 
anti-angiogenic therapies can normalize the tumour vas-
culature, thereby enhancing the efficacy of anti-cancer 
immunotherapies such as immune checkpoint-directed, 
therapeutic antibodies. Tumour resident c-kit positive 
mast cells have been shown to promote tumour angio-
genesis. They can also increase the number of immuno-
suppressive myeloid derived suppressor cells and regula-
tory T-cells at the tumour site. The second-generation 
vascular endothelial growth factor receptor (VEGFR) in-
hibitor axitinib, which inhibits tumour angiogenesis by 
blocking VEGFRs, also interferes with c-kit signalling. 
Therefore axitinib may offer the benefit of a two-pillar 
treatment approach targeting tumour angiogenesis and 
c-kit dependent mast cells at the same time. Using ad-
vanced in vivo as well as in vitro tumour models we will 
provide an accurate immunological definition of the ther-
apeutic relevance of this two-pillar approach as well as 
elucidate the immunological basis of synergies between 
axitinib and immune checkpoint-directed, therapeutic 
antibodies. Our work will provide a rational for the de-
sign of early clinical trials assessing these combination 
therapies in cancer patients.
Obermann Ellen | Evaluation of the mechanical  
properties of metastatic tumour cells of the breast  
by atomic force microscope (AFM)
Institut für Pathologie, Universitätsspital Basel, Basel
Duration: 01. 09. 2014 – 31. 08. 2015
Breast cancer is the most frequent malignancy in women 
in Switzerland. Tumours are nowadays often detected at 
an early stage and can often be cured. However, the 
chances of a complete cure drop significantly if metasta-
ses develop. Therefore it is important to understand, 
when and why a tumour metastasizes. Nanomechanical 
characteristics play an important role in the development 
of metastases. Nanomechanical properties of cells are for 
example the “stiffness” of single tumour cells. This stiff-
ness can be assessed by using atomic force microscopes. 
We were able to show in a pilot study utilizing a special 
type of atomic force microscope (ARTIDIS®) that breast 
cancer cells in transgenic mice were significantly softer 
than normal breast tissue. The current study helps to es-
tablish the ARTIDIS®-technology for the use in human 
samples. We systematically analyse breast cancer and 
normal tissue for their nanomechanical properties. Our 
aim is to understand mechanisms of metastatic disease, 
predict precisely the likelihood of a tumour to seed metas-
tases, and define potential novel therapeutic targets.
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Rothschild Sacha | Methylphenidate for the treatment 
of cancer-related fatigue
Klinik für Onkologie, Universitätsspital Basel, Basel
Duration: 01. 01. 2014 – 31. 12. 2020
Cancer-related fatigue (CRF) is a subjective symptom ex-
perienced by patients at all stages of disease and increas-
ing with advanced disease. For cancer patients fatigue is 
one of the most important and distressing symptoms and 
is clearly correlated to overall patient satisfaction and 
quality of life. Overall, 50–90 % of cancer patients expe-
rience fatigue. Treatment interventions for CRF may be 
categorized as non-pharmacologic and pharmacologic. 
Non-pharmacologic interventions include psychosocial 
interventions, exercise, dietary management and sleep 
therapy. The classes of drugs that have been studied most 
in managing CRF include stimulants (methylphenidate, 
modafinil), antidepressants, corticosteroids and others. 
Clinical data from these studies are conflicting. Therefore, 
there is no accepted standard therapy for CRF. The aim 
of this placebo-controlled trial of methylphenidate is to 
evaluate its efficacy for alleviating cancer-related and 
therapy-associated fatigue in patients with advanced/
metastatic adenocarcinoma of the lung undergoing main-
tenance therapy with pemetrexed after platinum-based 
first-line chemotherapy (cohort 1) or in patients with met-
astatic renal cell carcinoma undergoing first-line targeted 
therapy with pazopanib (cohort 2).
Ruiz Christian | Evaluation of the role of ANO1 as a 
potential therapeutic target in urinary bladder cancer
Institut für Pathologie, Universitätsspital Basel, Basel
Duration: 01. 10. 2013 – 30. 09. 2014
Urothelial bladder cancer is the most common type of 
cancer of the urinary tract in industrialized countries. In 
contrast to other tumour types, such as lung or breast 
cancer, patients with urinary bladder cancer cannot profit 
from a new generation of drug therapies, called targeted 
therapeutics. The aim of this study is to determine if the 
gene ANO1 may serve as a target of such a therapy. Im-
portantly, the gene ANO1 is located in a genomic region, 
which is amplified in up to 11 % of the bladder carcino-
mas. It has been shown that the gene ANO1 is involved 
in migration, a process that contributes to metastasis. In 
this study, we aim at analysing the expression of this gene 
in a larger cohort of bladder cancers and its potential clin-
ical significance. We will analyse primary tumours, as well 
as lymph node and distant metastases from patients with 
bladder cancer. Further, we will also perform experiments 
with commercially available bladder cancer cell lines in 
order to define if the inactivation of the gene ANO1 in 
culture leads to a reduction in migration and in cell 
growth. These experiments are one of the first steps to 
discover, if the gene ANO1 may be suited as a target for 
specific therapies, at least for ANO1 positive bladder can-
cer patients.
Spagnoli Giulio | Expansion and functional analysis  
of “bulk”- and tumour-associated antigen specific  
stem cell memory CD8+ T-cells from peripheral blood 
of healthy donors and patients with melanoma or  
non-small cell lung carcinoma
Duration: 01. 06. 2013 – 31. 05. 2014
Experimental immunology studies have investigated the 
nature of T-cells best promoting the rejection of estab-
lished cancers and/or the prevention of recurrences. Un-
expectedly, lymphocytes killing tumour cells have proven 
remarkably ineffective in this regard, largely due to their 
inability to expand in vivo following interaction with tar-
get cells and short life span. In contrast, memory T-lym-
phocytes devoid of cytotoxic capacity and characterized 
by the ability to vigorously proliferate and produce cy-
tokines in response to antigen stimulation has been shown 
to mediate rejection of established experimental tumours. 
In our studies we are addressing the identification of such 
lymphocytes specifically recognizing human tumour asso-
ciated antigens and the development of in vitro protocols 
promoting their expansion in healthy donors and patients 
with cancer. A successful implementation of this project 
might set the stage for basic immunology investigations 
and for clinical immunotherapy studies based on the use 
of own memory T-cells in patients with cancer.
Bern Cancer League
Bouchet Audrey | Increased vascular permeability by 
synchrotron microbeam radiation generates a highly 
efficient drug delivery system for tumour treatment
Institut für Anatomie, Universität Bern, Bern
Duration: 01. 01. 2014 – 31. 12. 2016
Despite recent improvements, glioblastoma multiforme 
is still the most common and most devastating brain 
tumour. As the specific anatomic characteristics of solid 
tumours in the brain as well as the presence of a biologi-
cal barrier (the blood-brain barrier) generally blocks the 
access of chemotherapeutic agents to all tumour cells, the 
efficiency of blood-borne chemotherapies is limited. Mi-
crobeam radiation therapy (MRT) is a novel radiotherapy 
based on micro-fractionation of X-ray beams delivered 
through thin beams separated by few hundred microns. 
Our recent observations indicate that at low dose, the 
MRT dramatically increased the vascular permeability 
without destroying the vessel integrity in a time interval 
beginning few minutes after MRT, a time span that we 
termed “therapeutic window”.
The experimental use of the therapeutic window proved to 
be highly effective: indeed a combined treatment, MRT 
followed by chemotherapy, dramatically reduced the pro-
gression of glioblastoma in a mouse model; some of the 
tumours even disappearing. The best explanation for these 
positive results lies in the disruption of the barrier leading 
to penetration of the chemotherapeutic agents into the tu-
mour. Based on the promising preliminary data, we intend 
to establish a novel treatment protocol based on the “ther-
apeutic window” which should overcome the biological 
barrier and be more efficient.
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Dufour Jean-François | The Bern hepatocellular  
carcinoma (HCC) cohort
Departement Klinische Forschung, Universität Bern, Bern
Duration: 01. 08. 2013 – 31. 07. 2016
Worldwide hepatocellular carcinoma is the 5th most com-
mon solid tumour. In terms of mortality from solid tumour 
it is number 3 worldwide. In Europe, every 11 minutes a 
person dies from hepatocellular carcinoma. Early diagno-
sis dictates the prognosis: when symptoms lead to the di-
agnosis, patients survive only a few months. However, 
when the diagnosis is made early, meaning when the tu-
mour is small, patients can be cured. About 80 % of hepa-
tocellular carcinoma arise in the context of cirrhosis what-
ever the underlying cause. Therefore, patients with 
cirrhosis are at risk. These patients should be screened 
regularly. Despite these facts, hepatocellular carcinoma is 
often overlooked and many patients are diagnosed too 
late.
This project aims at gathering epidemiological and clini-
cal data on every patient with hepatocellular carcinoma 
seen at the University Hospital in Bern, who accepts to 
participate. Practically, patients provide specific informa-
tion, including blood and urine samples, and answer 
questionnaire on the quality of life. This will provide for 
the first time in Switzerland a precise information regard-
ing stage at diagnosis, quality of life, treatments and sur-
vival of patients with this type of cancer. This information 
is essential to understand the barriers to early diagnosis 
and to improve the management of patients with hepa-
tocellular carcinoma.
Höpner Sabine | Lymphotoxin-  receptor (LTBR)  
signalling in leukaemic stem cells
Departement Klinische Forschung, Universität Bern, Bern
Duration: 01. 10. 2013 – 01. 10. 2015
This project aims at investigating leukaemic stem cells and 
at studying the way they divide and fight off the immune 
response. It has been shown that the tumour necrosis 
factor (TNF) receptors and their ligands play a crucial role. 
TNF receptor form a large network, which affects the pro-
liferation, the survival and the programmed death, called 
apoptosis. Using a leukaemic mouse model, we were able 
to study one selected TNF receptor at a time. We could 
show for the first time that leukaemic stem cells (LSC) in 
the bone marrow express the TNF receptor LTBR (Lym-
photoxin -receptor). LTBR could play a role as a new 
therapeutic target, as there are LTBR signalling pathways 
promoting the progression of chronic myeloid leukaemia 
as well as signalling pathways supporting cells of the im-
mune system against cancer cells. With this project, we 
want to investigate further whether the LTBR signalling 
pathway could be a relevant therapeutic target.
Marti Thomas | Targeting tumour-initiating cells in 
lung cancer
Departement Klinische Forschung, Universität Bern, Bern
Duration: 01. 10. 2013 – 30. 09. 2016
Lung cancer is the most common cause of cancer-related 
deaths in developed nations, having a 5-year survival rate 
of approximately 30 % in these countries. More than 
80 % of lung tumours are non-small cell lung cancers 
(NSCLC). It was postulated that the propagation of tu-
mour is mediated by so-called tumour-initiating cells. 
Those cells can self-renew as well as differentiate to give 
rise to the majority of the cells in the tumour. In NSCLC, 
tumour-initiating cells were identified and subsequent 
analysis indicated that a specific enhancement of the 
metabolism drives tumour-initiating cells growth and 
tumourigenesis. Those cells showed enhanced glycine 
decarboxylase activity as well as a deregulation of the 
DNA damage response signalling pathway, the pathway 
responsible to repair the DNA. This study aims at identify-
ing key proteins of the DNA damage response pathway 
that are deregulated in NSCLC tumour-initiating cells. This 
approach might identify novel targets for pharmacologi-
cal or genetic intervention to treat lung cancer.
Müller Loretta | Carcinogenic potential of gasoline  
car exhaust (including nanoparticles) and their effect 
on natural killer cells
Departement Klinische Forschung, Universität Bern, Bern
Duration: 01. 06. 2013 – 31. 05. 2016
The majority of cars in Switzerland are gasoline cars, but 
– in contrary to diesel exhaust – little is known about po-
tential adverse health effects of gasoline exhaust emis-
sions. In addition, new gasoline technologies and after-
treatment systems (e. g. particle filter) have recently been 
introduced on the market, making investigations about 
potential impacts of gasoline exhaust on the human 
health timely. Most of the emitted particles are nanopar-
ticles, meaning particle between 1 and 100 nanometres in 
size, and contain various known or potential carcinogens. 
Since the emitted particles are extremely small, they can 
easily penetrate into cells.
Respiratory epithelial cells are among the first cells in the 
respiratory system to be exposed to inhaled air pollutants 
and are considered as the switchboard between the res-
piratory system and immune response. They are affected 
by exhaust emissions and interact with immune cells, such 
as natural killer cells. Furthermore, they are the cells that 
are mainly affected in the development of lung cancer. 
Natural killer cells are cells of the immune system impor-
tant for fighting against infections. This project will inves-
tigate the carcinogenic potential of gasoline car exhaust 
on two different levels. First, direct effects on epithelial 
cells and on bacteria will be tested. Secondly, we will test 
whether the functionality of natural killer cell may be im-
paired by gasoline car exhaust which could make the de-
velopment of tumours more likely
Peng Ren-Wang | Functional identification and  
molecular targeting of human lung cancer stem cells 
Departement Klinische Forschung, Universität Bern, Bern
Duration: 01. 01. 2014 – 31. 12. 2014
Lung cancer is the number one cause of cancer lethality 
worldwide, with an overall 5-year survival rate of about 
10 %. This poor prognosis is due to therapeutic resistance 
and tumour recurrence. Precisely how resistance and re-
currence occur is unknown. Recent data indicate that tu-
mour initiation, sustained growth and recurrence could be 
attributed to a subset of cancer cells: the cancer stem 
cells. Those cells might also be responsible for resistance 
to chemo- and radiotherapy, making the targeting and 
permanent incapacitation of cancer stem cells a promising 
strategy for next-generation anti-cancer therapy. The 
identity of human lung cancer stem cells remains contro-
versial. In addition, whether and how lung cancer stem 
cells are connected with resistance to chemotherapy and 
whether cancer stem cells prevalence is associated with 
the poor prognosis of lung cancer is unclear. The goal of 
this project is to identify the cancer stem cells subset in 
non-small cell lung cancer – the most common type of 
lung cancer – to elucidate the molecular signature of can-
cer stem cells and characterize vulnerabilities of these cells 
for therapeutic intervention.
Schäfer Stephan | Molecular characterization of  
adenosquamous carcinoma of the lung as a prime  
type model of tumour heterogeneity
Institut für Pathologie, Universität Bern, Bern
Duration: 01. 01. 2014 – 31. 12. 2014
Adenosquamous carcinoma of the lung is a distinct sub-
type of non-small cell lung cancer that accounts for about 
4 % of all lung cancers. It is defined by the coexistence of 
both adenocarcinoma and squamous cell carcinoma com-
ponents. In this regard, adenosquamous carcinoma can be 
seen as a prime example of tumour heterogeneity. Tumour 
heterogeneity means that different tumour cells within 
one tumour show distinct morphological profiles. As the 
search for therapeutically relevant genetic alterations is 
directed by the morphological subtype, adenosquamous 
carcinomas of the lung and tumour heterogeneity in gen-
eral pose a problem. Indeed, small biopsies are used for 
molecular analysis in advanced tumour stages are poten-
tially prone to sampling errors, which might result in inad-
equate treatment. Understanding of tumour heterogeneity 
is of utmost importance and will allow a better under-
standing of the causes and progression of the cancer.
The aim of this study is the molecular characterization of 
adenosquamous carcinoma of the lung, focusing on thera-
peutically relevant mutations. In addition, we aim at iden-
tifying alterations that are specific for either component 
Sandzeichnung, Videostill, 2012
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and to compare our results to pure adenocarcinoma and 
squamous cell carcinoma of the lung. The results will en-
hance the understanding of the molecular basis of mor-
phological differentiation and resistance emergence in the 
context of targeted therapy.
Schlapbach Christoph | Characterizing human inter-
leukin 9-producing T-helper memory cells and their 
role in anti-tumour immune response in malignant  
melanoma 
Universitätsklinik für Dermatologie, Inselspital,  
Universitätsspital Bern, Bern
Duration: 01. 10. 2013 – 30. 09. 2014
Human T-helper (TH) cells are crucial mediators of the 
immune system. They help the activity of other immune 
cells by releasing T-cell cytokines, which are small pro-
teins important for signalling. To respond to the myriad 
of infectious and non-infectious challenges, they have 
evolved into functionally distinct subsets such as TH1, 
TH2, etc. TH9 cells produce a specific cytokine called 
IL-9. Those cells have recently been proposed as a novel 
subset of T-helper cells and studies in animal models sug-
gest that they play a protective role in tumour immunity. 
However, studies of human TH9 cells are lacking.
Recent studies in mice have shown that IL-9 promotes ro-
bust anti-tumour immune responses against melanoma 
and other cancers. These promising results put TH9 cells 
in the limelight for novel approaches in cancer. However, 
the role of TH9 cells in human melanoma remains to be 
investigated. Our preliminary data indicate for the first 
time the existence of human TH9 cells, thus raising the 
possibility to address important questions regarding their 
identity and functional properties. In addition, we found 
large numbers of IL-9 expressing cells in the immune 
infiltrate of human melanoma, thus warranting further 
investigation of the role of TH9 cells in the human anti-
melanoma immune response. The overarching aim of this 
project is to investigate the identity and properties of hu-
man TH9 cells and their role in the anti-melanoma im-
mune response.
Schucht Philippe | Extent of resection thresholds as 
predictor of survival in patients with glioblastoma 
Universitätsklinik für Neurochirurgie, Inselspital,  
Universitätsspital Bern, Bern
Duration: 01. 07. 2013 – 30. 06. 2017
Glioblastoma is a malignant, locally invasive brain tumour 
whose prognosis remains grim despite various improve-
ments in treatment. In the past, radical surgery was met 
with scepticism due to the aggressive infiltrative charac-
ter of the tumour. However, an increasing number of ret-
rospective studies over the last decade reported a pro-
longed overall survival after more extensive resection. 
Thus, the removal of majority of the tumour – the con-
trast enhancing part of it – has become a major aim of 
surgical treatment. Extending surgery from mere biopsies 
towards radical resections of contrast enhancing tumour 
requires costly technical assistance and carries risks of 
neurological deficits if the tumour has infiltrated func-
tionally intact brain areas.
In recent years we have developed in Bern refined meth-
ods to increase the safety of radical surgery. The crucial 
question is, however, whether and to what extent radical 
resection prolongs survival. This study will investigate 
this question. After a homogenous group of patients is 
generated, the surgeon will perform surgery. In some 
case radical resection will be achieved in others it will not. 
It must be stressed that in contemporary neurosurgery 
small remnants after resection are still considered as a 
good result as long as more than 90 to 95 % of the tu-
mour bulk is resected. We will analyse whether there is a 
difference in survival in the two groups where surgery 
was performed, meaning whether there is a correlation 
between radical surgery and better outcome.
Central Switzerland Cancer League
Diebold Joachim | Do the new possibilities for targeted 
therapy lead to an improvement in survival rates of  
advanced lung cancer patients in Central Switzerland?
Zentralschweizer Krebsregister, Luzerner Kantonsspital, 
Luzern
Duration: 01. 01. 2011 – 31. 12. 2013
Based on the numbers from the Cancer Registry of Cen-
tral Switzerland, we will examine the following questions: 
in how many patients are the new targeted therapies an 
option at all? How many patients are effectively treated 
with the new treatment in question? And will this new 
therapy lead to an improved survival? The correlation of 
the cancer registry data with the histopathological find-
ings and the genetic analysis will lead to an information 
gain that will contribute to the correct application of the 
new targeted therapies and to an improved patients’ 
prognosis.
Eastern Switzerland Cancer League
Ludewig Burkhard | Systems biology approach  
to molecularly characterize the lung cancer micro-
environment
Institut für Immunbiologie, Kantonsspital St. Gallen, 
St. Gallen
Duration: 01. 01. 2012 – 31. 12. 2015
Tumour cells display distinct genetic alterations that per-
mit their unrestricted growth. In contrast, stromal cells 
that provide the growth scaffold and nutrients for the tu-
mour most likely exhibit universal signatures that deter-
mine their function. The aim of this project is to gain novel 
knowledge on stromal cells that determine the growth-
supporting micro-environment of lung cancer. Research-
ers at the Cantonal Hospital St. Gallen have developed 
unique tools and methods to label, characterize and mo-
lecularly ablate lung cancer stromal cells. We expect that 
our research will identify critical target structures on lung 
cancer stromal cells and that this knowledge will foster 
the development of novel diagnostic and therapeutic 
avenues.
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Geneva Cancer League
Ansari Marc | Association of a CTH gene variant with 
veno-occlusive disease in children receiving busulfan 
before haematopoietic stem cell transplantation 
Département de pédiatrie, Hôpitaux universitaires  
de Genève (HUG), Genève
Duration: 01. 01. 2013 – 31. 12. 2014
Haematopoietic stem cells (HSC) reside in the bone mar-
row and have the unique ability to give rise to all of the 
different mature blood cell types. HSC transplant are now 
being used for the treatment of malignant diseases, such 
as leukaemia as well as non-malignant diseases. Most 
patients respond well to the transplant; unfortunately not 
all. It is impossible to predict which patients are going to 
develop complications or relapse after an HSC transplant. 
However, it has been observed that clinical outcome is 
related to the conditioning treatment given to patients 
prior to the transplant. Conditioning treatments are im-
portant because they eliminate the existing cancerous 
cells and reduce the immune response, allowing for better 
engraftment of the donor stem cells.
Busulfan is one of the main drugs used in this condition-
ing regiment and it has been observed that patients ex-
posed to high busulfan levels are more at risk of a worse 
clinical outcome, while low drug levels correlate with re-
lapse of the disease. Varying exposure of busulfan is cur-
rently being controlled by adjusting for age and weight, 
but there are still 20 % of patients who suffer life-threat-
ening adverse effects or relapse. We believe that genes, 
which make proteins involved in busulfan’s elimination 
from the body, may influence this variability as busulfan 
might be eliminated faster or slower, allowing to more or 
less effect of the drug, depending which genes are ex-
pressed.
Thus our hypothesis is that genes involved in busulfan’s 
elimination and function will aid in predicting who is go-
ing to need higher or lower doses and provide a better 
clinical outcome from the transplant. Our objective is to 
identify which genes will be the most useful at predicting 
a better outcome after a transplant where the patient has 
had a busulfan conditioning regimen.
Cohen Marie | Novel therapeutic approaches against 
ovarian cancer recurrence
Département de gynécologie et d’obstétrique,  
Hôpitaux universitaires de Genève (HUG), Genève
Duration: 01. 01. 2012 – 31. 12. 2014
Ovarian cancer affects 600 to 700 women each year 
in Switzerland. It is the leading cause of death among 
gynaecological cancers. Most ovarian cancers are diag-
nosed at an advanced stage of the disease, when the sur-
vival rate is very low. At an advanced stage, standard 
treatment is cytoreductive surgery followed by chemo-
therapy. Following this, most patients enter remission, 
but unfortunately most of them relapse. One strategy 
to reduce mortality from ovarian cancer would be to 
minimize relapse using targeted therapy after standard 
treatment.
The glucose-related protein 78 (GRP78) is a chaperone 
protein involved in the folding of proteins required for the 
survival of stressed cells such as cancer cells. GRP78 is 
suspected to induce tumour cell invasion and appears to 
play a critical role in certain cancer cells’ resistance to 
chemotherapy. This protein is localized in the endoplas-
mic reticulum, but it is also observed on the surface of 
cancer cells and thus could be a “tumour-associated an-
tigen”. We have recently shown the presence of anti-
GRP78 auto-antibodies in the serum of ovarian cancer 
patients. These antibodies promote apoptosis and de-
crease the invasiveness of cancer cells. Membrane locali-
zation of GRP78 specifically in cancer cells suggests that 
it may be a therapeutic target. That is why we propose to 
develop a targeted treatment combining photodynamic 
therapy, chemotherapy and immunotherapy to fight the 
recurrence of ovarian cancer. For this purpose, we will 
use vectors that are loaded with anti-cancer and/or pho-
tosensitizer agents and are covered with antibodies rec-
ognizing the same epitopes as the antibodies purified 
from serum of ovarian cancer patients. The drugs and/or 
photosensitizers will be encapsulated into the vectors.
Curran Joseph | The 5’UTR fingerprint: a new  
diagnostic marker for breast cancer
Département de microbiologie et médecine moléculaire, 
Université de Genève, Genève
Duration: 01. 01. 2013 – 31. 12. 2015
Breast cancer is the second most commonly diagnosed 
cancer in the world. It is aetiologically and genetically het-
erogeneous. As a consequence there is a continual need 
to establish new genetic markers that will aid in tumour 
typing, assist in evaluating the risk of recurrence and pro-
vide signatures that can guide therapies. In a pilot study in 
which we compared the transcriptome from a breast 
tumour cell line and a non-tumoural control, we observe 
cell type specific heterogeneity in the 5’ untranslated re-
gion of nearly 100 genes. Many of these are known to 
play central roles in cell growth control and a number have 
already been associated with breast cancer. These changes 
alter the protein readout and may serve as a molecular fin-
gerprint of the tumoural phenotype. The proposal aims at 
establishing if this fingerprint has potential as a diagnos-
tic marker for breast cancer.
Dietrich Pierre-Yves | Identification and validation  
of glioma antigen: towards immunotherapies for brain 
tumours
Service d’oncologie, Département de médecine interne, 
Hôpitaux universitaires de Genève (HUG), Genève
Duration: 01. 01. 2011 – 31. 12. 2013
For more than 10 years, the goal of our research is to bet-
ter understand how our immune system can defend us 
against the development of tumours in the brain and, on 
this basis, to develop new therapeutic strategies such 
as immunotherapies. Triggering an effective immune re-
sponse and using lymphocytes as “killer cells” targeting 
tumour cells seems realistic, but it is essential that this 
response is selective, meaning that the lymphocytes kill 
specifically tumour cells, while leaving the normal cells of 
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the brain untouched. Up to now, this selectivity seemed 
impossible in the absence of structures (called antigens) 
selectively expressed by tumour cells (and not expressed 
on normal cells).
This is no longer the case. Indeed, thanks to collaboration 
with a spin-off of the University of Tübingen (Immatics), 
we have identified 10 interesting glioma antigens. The 
goal of this project is to characterize these antigens to 
ensure that they are (1) overexpressed by tumour cells 
(almost no expression on normal cells should greatly re-
duce the risk of autoimmunity and toxicity); (2) immuno-
genic, meaning capable of eliciting an immune response, 
not only in healthy individuals but also in glioma patients; 
and (3) expressed in glioma stem cells, which play an 
essential role in the resistance of cancers to standard ther-
apies (radiotherapy, chemotherapy). We hope to confirm 
that these glioma antigens are ideal targets for future im-
munotherapies in both vaccine and cellular therapy strat-
egies.
Irminger Irmgard | Regulation of the oncogenic  
isoforms of the tumour suppressor BARD1 in cancer  
by microRNAs and non-coding RNAs
Département de gynécologie et d’obstétrique, Hôpitaux 
universitaires de Genève (HUG), Genève
Duration: 01. 01. 2012 – 31. 12. 2013
BARD1 is the constitutive partner of BRCA1, some muta-
tions of which predispose to breast cancer. The ubiquitin 
ligase activity of BARD1-BRCA1 has a role in numerous 
onco-suppressor functions, especially within the cell cycle, 
in regulating the transcription and distribution of dam-
aged DNA. The expression of different isoforms of BARD1, 
the outcome of alternative splicing, is incriminated in 
breast, colon, and lung cancers. Studying the mechanisms 
regulating BARD1 expression is therefore of key impor-
tance.
Our preliminary findings showed that the microRNA miR-
203 regulates the expression of BARD1 in cancer cells. 
MicroRNAs are thought to be important regulators of car-
cinogenesis and may be used clinically as biomarkers and 
agents or as therapeutic targets. We have discovered a 
new non-coding isoform of BARD1 (9’L) expressed in can-
cer cells. Its expression is correlated to the expression of 
other BARD1 isoforms; it is significantly overexpressed in 
cancer tissues. We therefore hypothesize that RNA 9’L 
inhibits tumour-suppressor microRNAs and induces the 
expression of oncogenic isoforms of BARD1. This micro-
RNA regulatory mechanism by “decoy” RNAs had been 
described only recently and appears to play a significant 
role in carcinogenesis.
In this project, we aim at evaluating in greater depth the 
role of miR-203 and other microRNAs in the regulation of 
BARD1. We will confirm the decoy RNA properties of 9’L 
and evaluate its functions in the regulation of BARD1 and 
microRNAs. We will also evaluate the diagnostic utility of 
9’L and miR-203 for the clinical care of patients in a large 
cohort. Finally, we will extrapolate our research findings 
into a trial for clinical application. The research project de-
scribed here is therefore not only of fundamental scientific 
value for future cancer biology but will also enable the up-
take of its results for the promotion of innovative clinical 
methods.
Le Gal Frédérique | Skin cancer screening using  
high-sensitivity infrared imaging
Département des spécialités de médecine, Service  
de dermatologie et vénérologie, Hôpitaux universitaires  
de Genève (HUG), Genève
Duration: 01. 01. 2013 – 31. 12. 2014
Incidence of skin cancers is very high in Switzerland and 
rising worldwide. Their prognosis depends on the precoc-
ity of diagnosis. Detection of skin cancer is essentially 
clinical and greatly depends on the clinician’s expertise. 
Though, as early tumours often lack specific signs, many 
benign lesions are excised to be on the safe side. Moreo-
ver some skin cancers do not have visible limits, which can 
induce complex or multistep surgery. Therefore, detection 
and treatment of these tumours generate big health costs. 
Compared to benign lesions, malignant tissue has specific 
thermal properties that can be exploited to diagnose 
skin cancer. In collaboration with the Zurich University of 
Applied Sciences  (Zürcher Hochschule für Angewandte 
Wissenschaften, ZHAW), we plan to optimize and test a 
new highly sensitive infrared imaging device to detect skin 
cancers and define their actual limits. Lock-in thermogra-
phy is an objective non-invasive method that can optimize 
the management of skin cancers and reduce its costs.
Le Gal Frédérique | Beta-blockers in the adjuvant 
treatment of melanoma, an interventional clinical study
Département des spécialités de médecine, Service  
de dermatologie et vénérologie, Hôpitaux universitaires 
de Genève (HUG), Genève
Duration: 01. 01. 2013 – 31. 12. 2014
Malignant metastatic melanoma is the leading cause of 
death among skin cancer patients and its incidence is in-
creasing worldwide. Despite recent advances in the iden-
tification of recurrent mutations linked to melanoma and 
the development of new drugs targeting these mutations, 
no long-term treatment is currently available to efficiently 
improve the dramatic outcome of this disease. Our project 
is based on recent retrospective studies on human mela-
noma patients and experiments we conducted in animals 
xenografted with human melanoma cells which suggest 
that beta-adrenergic antagonist’s treatment effectively 
improve the survival of patients with malignant mela-
noma. Our study attempts to understand the mechanisms 
governing beta blockers action on melanoma by identify-
ing the targets of these molecules, the signalling pathways 
involved, and the regulation of tumour development. We 
will now investigate the benefit of an adjuvant treatment 
with propanolol on melanoma progression in a clinical 
trial. 
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Mandriota Stefano | The ATM/p53 signalling pathway 
in the regulation of cellular senescence
Département de pédiatrie, Division d’onco-hématologie, 
Hôpitaux universitaires de Genève (HUG), Genève
Duration: 01. 01. 2012 – 31. 12. 2014
The p53 tumour suppressor protein plays a key role in the 
induction of cellular senescence, which is an important 
barrier to cancer development. However, very little is 
known about the physiological mediators of cellular se-
nescence induced by p53. CEACAM1 is an immunoglobu-
lin superfamily member whose expression is frequently 
lost in human tumours and exhibits tumour suppressor 
features in several experimental systems including 
CEACAM1 knockout mice. 
There is currently little understanding of the pathways 
and mechanisms by which CEACAM1 exerts its tumour 
suppressor function. We recently found that CEACAM1 is 
strongly upregulated during the cellular response to DNA 
double strand breaks (DSBs) and that upregulation is me-
diated by the ataxia telangiectasia mutated (ATM)/p53 
pathway. Stable silencing of CEACAM1 showed that 
CEACAM1 is required for the induction of p53-mediated 
cellular senescence in response do DNA damage. These 
findings identify CEACAM1 as a key component of the 
ATM/p53- mediated cellular response to DNA damage 
and as the first established tumour suppressor gene medi-
ating cellular senescence downstream of p53.
In this project, we propose to further elucidate the role of 
CEACAM1 in the induction of cellular senescence. In view 
of the novelty of the identification of CEACAM1 as a com-
ponent of the ATM/p53 regulated DNA damage response 
and the well-defined features of CEACAM1 as a tumour 
suppressor, we strongly feel that the proposed project will 
provide important and fertile new insights into p53 and 
CEACAM1 tumour suppressor function and into the reg-
ulation of cellular senescence.
Martinou Jean-Claude | Role of the mitochondrial  
pyruvate carrier in the proliferation and metastasis of 
breast cancer cells
Département de biologie cellulaire, Faculté des sciences, 
Université de Genève, Genève
Duration: 01. 01. 2013 – 31. 12. 2014
Many cancer cells are known to consume high amounts 
of glucose, which they transform into pyruvate, then into 
lactate, thereby producing energy without involving the 
mitochondria. This process is classically called the “War-
burg effect”. Although frequent, this process does not 
apply to all tumours. This is the case for a number of 
breast cancers, in which pyruvate, the end-product of 
glycolysis, is not transformed into lactate but rather 
transported into mitochondria. There, pyruvate is further 
oxidized allowing production of energy through oxidative 
phosphorylation. Until recently the molecular identity of 
the mitochondrial pyruvate carrier was unknown. We 
have recently identified this carrier, which plays a key role 
in cell metabolism. Importantly, this carrier has been 
found to be highly expressed in some breast cancers. In 
this research proposal, we propose to investigate the role 
of the mitochondrial pyruvate carrier in tumour cell pro-
liferation and metastasis.
Preynat-Seauve Olivier | Identification of miRNA  
targets for glioblastoma using a novel in vitro model
Laboratoire d’immuno-hématologie transfusionnelle, 
Hôpitaux universitaires de Genève (HUG), Genève
Duration: 01. 01. 2013 – 31. 12. 2015
Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumour in adults and represents one of the 
most aggressive human cancers. MicroRNAs (miRNAs) 
open an exciting and promising area for the development 
of new therapeutic targets. They regulate a high number 
of mRNA transcripts and, consequently, represent a key 
molecular checkpoint in the control of biological pro-
cesses. Based on the use of stem cells, our team has re-
cently developed an in vitro model of human GBM devel-
opment within a human brain-like tissue with a high 
degree of similarity to the in vivo cancer development 
in patients. We then took advantage of this system to 
analyse the entire microRNome through an ultra-deep 
sequencing. The main objectives were to identify: (1) 
miRNAs induced or upregulated when the tumour inter-
acts with brain-like tissue and (2) miRNAs specifically ex-
pressed in GBM patients. Using this approach, we identi-
fied new miRNAs not previously described in GBM. We 
propose to study the impact of the modulation of these 
novel miRNAs on GBM aggressiveness and resistance to 
drugs and radiation with the goal of proposing new ther-
apeutic targets.
Reith Walter | Identifying the cellular functions and 
regulatory networks that underlie the link between  
microRNA-155 and cancer
Département de pathologie et d’immunologie, Faculté  
de médecine, Université de Genève, Genève
Duration: 01. 01. 2012 – 31. 12. 2014
MicroRNAs constitute a class of small, single-stranded, 
non-coding and well-preserved RNAs. By binding to tar-
get messenger RNAs, they cause them to be broken down 
or silence their ability to translate proteins. Post-transcrip-
tional regulation by these microRNAs is involved in a great 
variety of essential physiological functions as well as in 
several diseases, in particular in the onset and develop-
ment of cancer. MicroRNA-155 (miR-155) has been impli-
cated in the development of cancer, but the target genes 
of this microRNA have yet to be identified.
The objective of this study is to attain a better under-
standing of the link between miR-155 and cancer by shed-
ding light on its biological functions and its target genes 
in dendritic cells (DCs). Recently we studied the role of 
microRNAs in the differentiation, maturation and func-
tion of DCs. We showed that activation of miR-155 is a 
general and preserved characteristic in the maturation of 
DCs. Moreover, analysis of DCs in knockout mice for miR-
155 revealed that induction of miR-155 is necessary for 
the maturation of DCs. Using functional approaches and 
genomic analyses, we demonstrated that the c-Fos tran-
scription factor is a direct target of miR-155 and that 
its expression needs to be suppressed in order for DCs to 
mature.
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In future experiments, we suggest studying in detail the 
expression, enzyme activity and regulation of a new po-
tential target of miR-155: arginase 2. In view of the known 
role of arginase in tumour progression and development, 
we will investigate the consequences of deregulating its 
expression, in particular on T-cell activation and prolifer-
ation. These studies should enable us to gain a better 
understanding of the mechanisms controlled by miR-155 
in tumour development.
Thore Stéphane | Steroid receptor RNA activator:  
a new target for modulating the hormonal response  
in cancer cells
Département de biologie moléculaire, Faculté  
des sciences, Université de Genève, Genève
Duration: 01. 01. 2011 – 31. 12. 2013
Specific cancers of some organs, such as those affecting 
the breast, pancreas or colon, share a common feature: 
their growth and dangerousness are closely dependent on 
the presence of a number of hormones. Studying the im-
pact of these hormones on the physiology of the cell, 
whether healthy or cancerous, is therefore of prime im-
portance. These studies will enable us to develop treat-
ments that target biological mechanisms identified as be-
ing hormone-dependent and thus to be more effective at 
eliminating cancer cells. In the past decade, it has been 
shown that the regulation of transcription by hormone 
receptors is one of the fundamental hormone-linked 
mechanisms. In studies on the regulation of transcription 
by hormones, an RNA known as steroid receptor RNA 
activator (SRA RNA) was shown to have a modulator role, 
being able to amplify or inhibit the action of hormones on 
transcription. This RNA is the first of its kind to display an 
action of this type, which alone represents a new level for 
the hormone-based regulation of activation pathways.
Obtaining molecular models that describe the specific as-
sociation of SRA RNA with various nuclear hormone re-
ceptors or partners involved in the cell response to hor-
mones is essential for our understanding of its action. 
Moreover, these atomic models may be used to identify 
and/or develop molecules able to modify its action. 
Thanks to these research programmes, we will have 
greater means at our disposal for combating hormone-
positive cancers. Newly identified molecules of this kind 
could be used alone or in combination, thereby limiting 
the possibilities that the cancer cells might develop resist-
ance capabilities, a recurrent problem in cancer treat-
ment.
Tille Jean-Christophe | Role of heparan sulfate in  
endometrioid carcinoma: tissue remodelling, angio-
genesis and lymphangiogenesis
Département de pathologie clinique, Faculté de  
médecine, Université de Genève, Genève
Role of heparan sulfate in endometrioid carcinoma:  
tissue remodelling, angiogenesis and lymphangiogenesis
Duration: 01. 01. 2011 – 31. 12. 2013
Angiogenesis and lymphangiogenesis enable the forma-
tion of new blood and lymph vessels in the endometrium 
in a process that occurs physiologically during the ovarian 
cycle and pathologically in tumour growth. Heparan sul-
phate anti-coagulants bind and activate anti-thrombin 
such as heparin. They are present in the endothelial base-
ment membrane and endow healthy endothelium with 
anti-thrombotic properties. The distribution and modula-
tion of heparan sulphate anti-coagulants during tissue 
plasticity are not known. They appear to be reduced un-
der the pathophysiological conditions that permit cellular 
invasion of the tissues. We are investigating the function 
of heparan sulphate anti-coagulants in vascular and tissue 
plasticity during tumour invasion of the endometrium in 
vivo and in vitro. The data obtained in this study will en-
able evaluation of the therapeutic potential of heparan 
sulphate anti-coagulants as modulators of tissue invasion 
in endometrial cancer.
Wehrle-Haller Bernard | Kinase-independent functions 
of the receptor tyrosine kinase c-kit in the persistence 
and adhesion of cancer stem cells to their environ-
mental niche 
Département de physiologie cellulaire et métabolisme, 
Centre médical universitaire (CMU), Genève
Duration: 01. 01. 2012 – 31. 12. 2015
Leukaemia are cancers of the blood that often develop re-
sistance against drugs that block the enzymatic activity 
required for cell proliferation and cancer growth. One hy-
pothesis for the observed resistance against these treat-
ments is the capacity of tumour cells to switch back into 
a dormant state, by crawling into environmental niches 
in which they can survive without being stimulated to 
divide. This crawling process is also responsible for the 
formation of tumour metastasis. The process of crawling, 
or niche-adhesion is regulated by two types of adhesion 
systems that synergize in such a way that they function 
even in the absence of the critical enzymatic activity re-
quired for tumour cell proliferation. Here in this grant, we 
propose to explore the mechanisms of this crawling and 
adhesion mechanism and would like to develop an exper-
imental system to test whether the forced exit of tumour 
cells from their niches can restore there sensibility to ther-
apy.
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Thurgau Cancer League
Fleischmann Achim | Promotion of cancer research,  
focused on the area of gynaecological and urological 
tumours
Pathologie, Kantonsspital Münsterlingen, Münsterlingen
Duration: 01. 01. 2014 – 31. 12. 2015
This project focuses on prognostic and predictive bio-
markers in urological tumours, especially in metastatic 
bladder and prostate cancers. These tumours are rela-
tively frequent and make it possible to more accurately 
characterize the lethal tumour components, namely the 
metastases. Initially the prognostic significance of histo-
pathological tumour characteristics and key figures of the 
surgical procedure will be investigated. The group of uro-
pathology will evaluate subsequent tumour markers at the 
cellular, protein, DNA and microRNA level in relation to 
tumour heterogeneity, prognostic relevance and predic-
tive potential as well as tumour regression by bladder can-
cer after chemotherapy. These studies will allow to assess 
the prognosis of the disease, to plan individual adjuvant 
therapies and to better understand processes in metas-
tasis. The project consists of a collaboration with various 
national and international research groups.
Legler Daniel | Breast cancer project
Biotechnologie Institut Thurgau, Universität Konstanz, 
Kreuzlingen
Duration: 01. 01. 2013 – 31. 12. 2016
The latest findings from the current research at the Bio-
technology Institute Thurgau suggest that a new signalling 
pathway was discovered, which seems to be responsible 
for the efficient migration of breast cancer cells in the 
lymph nodes and thus for metastasis. This project aims at 
investigating whether a naturally occurring mutation may 
serve as a diagnostic marker for breast cancer and on the 
other hand to explore the role of the newly discovered sig-
nalling pathway on cell migration and metastasis of breast 
cancer cells.
Reuter Christiane | Study of intraoperative radiother-
apy of the breast
Radioonkologie, Kantonsspital Münsterlingen,  
Münsterlingen 
Duration: 01. 01. 2013 – 31. 12. 2014
After breast-conserving surgery, the remaining breast tis-
sue should be irradiated to reduce the risk of intramam-
mary recurrence by a factor of 3 to 4. The irradiation of 
the operated breast must be in frequent small doses to 
cause as few side effects as possible. Therefore, a post-
operative irradiation of the breast lasts five to six weeks 
with daily irradiation sessions, where on one side the 
whole breast tissue is irradiated and on the other hand, 
the tumour is specifically irradiated (boost). In order to 
shorten the exposure time and to irradiate the targeted 
tumour specifically, an intraoperative irradiation was de-
veloped. Surgeons place a spherical radiation source intra-
operatively in the excision and the irradiation is performed 
under control of the radio-oncologist during the opera-
tion, resulting in an anaesthesia time that is extended by 
about 40 minutes. These intraoperative irradiations elimi-
nate the need for boost irradiation, decreasing the post-
operative radiotherapy by at least one week. In a strictly 
defined patient group with low risk the intraoperative 
radiotherapy will replace the postoperative radiotherapy 
altogether.
The radiation oncology division of the Hospital Thurgau 
AG began an observational study that will track accurately 
whether with intraoperative irradiation relapse rates, cure 
rates, side effects, quality of life, and cosmetic is better 
than with standard radiotherapy alone. To this end, pho-
tos of patients will be evaluated by a computer pro-
gramme and the quality of life will be determined using 
questionnaires. In order to do this project, it is necessary 
to operate a database and to appoint a study coordinator. 
The Thurgau Cancer League supports scientific work aim-
ing at the monitoring and the evaluation of the study. The 
patients of the canton Thurgau will be monitored very 
closely in the application of this new radiotherapy method 
allowing for the evaluation of this method.
Ticino Cancer League  
(Fondazione ticinese per la ricerca sul cancro)
Catapano Carlo | Non-coding RNAs and epigenetic 
networks in prostate cancer pathogenesis and novel 
therapeutic strategies
Istituto oncologico della Svizzera italiana (IOSI),  
Bellinzona 
Duration: 01. 01. 2013 – 31. 12. 2013
Prostate cancer is the most common cancer in the male 
population in Western countries. Obviously, there is a 
need to find novel diagnostic and prognostic biomarkers 
and more effective treatment strategies. Several genetic 
factors are known to contribute to the development of 
prostate cancer, but we know that there are also external 
(so called epigenetic) factors, which might modulate the 
expression of the genetic defects. Those epigenetic pro-
cesses are known to have an impact on tumours’ initiation 
and progression. In this study we intend to identify novel 
so-called noncoding RNAs (small structures of ribonucleic 
acid), which might play an important role in the develop-
ment of prostate tumours. We will do that in prostate 
tumour cell lines, but also in tumour biopsies. We hope 
that this study will help developing some new therapeu-
tic approaches to this cancer, mainly in cases resistant to 
endocrine treatment.
Ceppi Francesco | Post-graduate training in paediatric 
oncology 
Hôpital Notre-Dame, Montréal, Canada
Duration: 01. 01. 2013 – 31. 12. 2013
Francesco Ceppi finished his training as paediatric oncol-
ogist in Lausanne and is now specializing in some aspects 
of the treatment of childhood cancer in Canada.
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Civenni Gianluca | Isolation of stem cells from human 
prostate biopsy to study tumour initiation
Istituto oncologico della Svizzera italiana (IOSI),  
Bellinzona
Duration: 01. 01. 2013 – 31. 12. 2013
Prostate cancer is the most common cancer in men in 
Western countries. However, its origin remains not well 
understood. The clinical evaluation of prostate cancer is 
very heterogeneous: in some cases it is very favourable, 
while other patients will die rather rapidly due to metas-
tasis generated by the prostate cancer. It has been postu-
lated, that this very different behaviour might be related 
to different characteristics of the stem cells in different 
cases of prostate cancer. In our study we will try to isolate 
stem cells both from normal prostatic tissues as well as 
from biopsies obtained in patients suffering from prostate 
cancer. By comparing the biological characteristics of 
these stem cells, we hope to be able to gain new insights 
into the biology of prostate cancer, which might in turn 
generate new therapeutic approaches.
Frattini Milo | Investigation of the role of NEU3 in  
colorectal carcinogenesis
Istituto cantonale di patologia, Locarno
Duration: 01. 01. 2013 – 31. 12. 2013
In recent years we made progress in the treatment of colo-
rectal cancer. We know that response to different treat-
ments varies depending on the expression of EGFR (epi-
thelial growth factor receptor), but we do not know which 
factors can modulate the expression of EGFR. In this 
study, we will evaluate the potential role NEU3 (an en-
zyme) in modulating the expression of EGFR in cell lines. 
In addition, we will try to understand the conditions 
under which new targeted therapies may be more active 
depending on the expression of EGFR and NEU3.
Molinari Francesca | Identification of new alterations 
in the small intestine adenocarcinoma through new  
sequencing methodology
Istituto cantonale di patologia, Locarno
Duration: 01. 01. 2013 – 31. 12. 2013
Adenocarcinomas of the small intestine represent a rare 
tumour with an aggressive clinical behaviour. Surgical in-
tervention is the main treatment, but unfortunately no ef-
fective standard chemotherapy has been established that 
would prolong survival of patients. So far, the molecular 
alterations involved in the development of this tumour 
have been only marginally investigated, limiting the pos-
sibility to discover genetic lesions, which might become 
the target for new treatments. In this study, alterations 
occurring in a cohort of patients affected by this tumour 
will be investigated with a new methodology for genetic 
profiling, which is able to analyse simultaneously hun-
dreds of mutations occurring in cancer-associated genes. 
Importantly, this can be done also on fixed material, 
which is already present at our institute. The definition of 
this, so far, unknown genetic lesions could prompt the de-
velopment of more targeted treatment for this rare form 
of tumour.
Zurich Cancer League 
Bernasconi Michele | Role of proprotein convertases  
in paediatric sarcomas: useful theragnostic targets?
Experimentelle Infektiologie und Krebsforschung,  
Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Duration: 01. 01. 2011 – 31. 12. 2013
The treatment of childhood cancer has specific require-
ments, because excessive use of chemotherapy and espe-
cially radiotherapy can lead to significant long-term 
sequelae. Next to the development of entirely new thera-
peutic options, one of our objectives is to identify new 
therapeutic targets. We have identified a family of pro-
teases (proteolytic enzymes) that play an important role 
in the growth of paediatric sarcomas. We will investigate 
the role of these proteases in paediatric sarcomas in order 
to use them as targets for new therapies. In this project, 
we hope to be able to develop new protocols for the treat-
ment of paediatric sarcomas with fewer side effects.
Bornhauser Beat | Large scale drug response profiling 
to identify new targets in refractory leukaemia
Forschungsgruppe Leukämie/Onkologie, Kinderspital 
Zürich, Universitäts-Kinderkliniken, Zürich
Duration: 01. 01. 2011 – 31. 12. 2013
Treatment of relapsed childhood leukaemia is a major chal-
lenge. Using a microscope-based analysis platform, we 
record systematically the response of leukaemia samples 
to a variety of new therapeutic substances and compare 
these profiles with genetic information in order to iden-
tify specific patterns. We hope to develop new therapies 
for the treatment of relapsed patients.
Graf Rolf | Inflammation contributes to the regression 
of acinar-to-ductal metaplasia in the injured pancreas
Klinik für Viszeral- und Transplantationschirurgie,  
Universitätsspital Zürich, Zürich
Duration: 01. 01. 2013 – 31. 12. 2013
Tissue damage occurs during a pancreatitis, which is am-
plified by inflammation. Nevertheless, the pancreas heals 
by regenerative processes, during which the cells change 
dramatically and form cancer-like structures. Preliminary 
results show that inflammatory factors have a positive 
effect on the changed pancreatic cells.
Hottiger Michael | Assessment of ADP-ribosylomes  
to identify specifically ADP ribosylated proteins that 
regulate PARP inhibitor sensitivity of cancer cells
Institut für Veterinärbiochemie und Molekularbiologie, 
Universität Zürich, Zürich
Duration: 01. 01. 2013 – 31. 12. 2015
The goal of this project is to determine all of the ADP- 
ribosylated proteins in PARP inhibitor-sensitive and non-
sensitive cell lines with newly developed methods and 
thereby to identify proteins, which should improve the 
individualized use of PARP inhibitors in future cancer ther-
apies.
Müller Anne | Epigenetic silencing of tumour  
suppressor genes in the pathogenesis of diffuse  
large B-cell lymphoma
Institut für Molekulare Krebsforschung, Universität  
Zürich, Zürich
Duration: 01. 01. 2013 – 31. 12. 2015
The goal of the project is to investigate the functional im-
pact of newly identified epigenetically silenced putative 
tumour suppressor genes in diffuse B-cell lymphoma in 
vitro and in vivo.
Münz Christian | Boosting of NY-ESO-1-specific  
re-directed T-cells
Institut für Experimentelle Immunologie, Universität  
Zürich, Zürich
Duration: 01. 01. 2013 – 31. 12. 2014
With the infiltration of monoclonal antibodies in T-cells, 
the cells can be reprogrammed and therefore specifically 
directed against tumour cells. The efficiency of this new 
immunotherapeutic approach will be testes in so-called 
humanized mice, i. e. mice with a human immune system.
Nadal David | Natural killer cell control of Epstein-Barr 
virus-induced cancerous B-cell transformation
Abteilung Infektiologie und Spitalhygiene, Kinderspital 
Zürich, Universitäts-Kinderkliniken, Zürich
Duration: 01. 01. 2013 – 31. 12. 2013
We are investigating how the body’s own natural killer 
cells prevent the formation of Epstein-Barr virus-related 
cancers, in order to create potent therapies against this 
common and often deadly form of childhood cancer.
Rohrer Bley Carla | In vivo profiling of DNA damage 
and repair kinetics after anti-neoplastic treatment: use 
of a minimally invasive approach
Abteilung für Radio-Onkologie, Universität Zürich,  
Zürich
Duration: 01. 01. 2013 – 31. 12. 2013
This project will study the speed and amount of DNA 
damage formation of tumour cells after radiotherapy as 
well as the repair of the damage by the cell’s own repair 
mechanism in various tumours. The goal of this profiling 
of DNA damage formation and repair is to provide indi-
vidual prognostic information and to improve the therapy 
by additional measures.
Sandzeichnung, Videostill, 2012
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Tabatabai Ghazaleh | Thymosin beta-4 in malignant 
gliomas: a novel regulator of angiogenesis?
Klinik für Neurologie, Universitätsspital Zürich, Zürich
Duration: 01. 01. 2013 – 31. 12. 2014
Glioblastoma are malignant highly-vascularized primary 
brain tumours. In the projects, we investigate the contri-
bution of the thymosin beta-4 signalling pathway to vessel 
formation in glioblastoma.
Weber Achim | Role of innate lymphoid cells (ILC)  
in intestinal inflammation and carcinogenesis
Institut für Klinische Pathologie, Universitätsspital Zürich, 
Zürich
Duration: 01. 01. 2013 – 31. 12. 2014
The formation and growth of cancer cells are significantly 
influenced by the environment of the tumour cells. The 
role of a particular type of inflammatory cells, the so-
called innate lymphoid cells, will be examined in a mouse 
model for inflammatory bowel disease (IBD) and sponta-
neous cancer development. Form the results we expect a 
better understanding of the role of these immune cells in 
cancer development in the context of IBD and the identi-
fication of new therapeutic approaches in IBD and colon 
cancer.
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Genome stability, DNA repair and cancer
Basic biomedical research
Cancer usually develops on a time scale of years or 
decades. It is a complicated and long process of nor-
mal body cells transforming into abnormal cells with 
several unfavourable characteristics. The transforma-
tions are genetic in nature. They are passed on from 
the mother cell to the daughter cell during cell divi-
sion and thus spread in cell clones. Thorough explo-
ration and investigation of the aetiology and mecha-
nisms of these genetic processes is essential for our 
understanding of the nature of cancer, its develop-
ment, its ability to adapt again and again to even the 
most adverse conditions, and also its weak spots, 
which can be exploited therapeutically.
Identity and alteration of cells
To understand these transformations and alterations 
of cells, we must recall how the normal identity of a 
body cell is determined. Although a great variety of 
types of cells having very specialized functions exist 
in the human body, each and every one of them car-
ries an identical copy of the person’s entire genetic 
blueprint in its cell nucleus. This genetic information 
lies in the DNA in a coded form as a specific sequence 
of its four chemical building blocks. Together, the 
more than three billion building blocks of the human 
genome (the complete set of genetic information 
coded in the DNA) contain thousands of genes that 
are responsible for specific biological functions.
The differentiation into different body cells occurs 
because for each type of cell only one certain selec-
tion of these genes is transcribed, and those are the 
genes that make the cell functions that are specifi-
cally needed for the organ or tissue. This cell type-
specific expression of the genome is controlled by 
epigenetic mechanisms. Through the chemical modi-
fication of the DNA and/or its protein structure a kind 
of higher-level genetic code is generated that finally 
determines what genes can be transcribed and what 
genes cannot be transcribed. This epigenetic code is 
set based on signals from the environment during the 
differentiation of a cell type and is subsequently fur-
Prof. Primo Schär, PhD
Professor of molecular genetics and research group leader at the Department of Biomedicine,  
University of Basel
Fotogramm / Linde, 2013
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ther inherited within a cell line with each cell division. 
Identity and function of a tissue cell are thus deter-
mined by the combined workings of two levels of ge-
netic information: the genetic code stored in the DNA 
sequence and the higher-level epigenetic program-
ming of the activity of this code.
As long as both the genetic information and also its 
epigenetic programming remain stable and are passed 
on unaltered at cell division, the normal, intended 
function of a cell line is preserved. But if there are 
alterations in the DNA sequence of a certain cell, so 
that gene functions are impaired or even destroyed 
(genetic mutations), or if there are alterations in the 
epigenetic programming pattern, so that genes that 
are supposed to be active in a cell type suddenly be-
come inactivated or vice versa, a cell can begin to 
change its characteristics and can finally degenerate. 
A look at the genome of cancer cells reveals that 
there are a number of these genetic and epigenetic 
alterations. These modifications typically affect cell 
functions that deregulate cell division and cell death 
in such a way that cells can grow uncontrollably. De-
pending on the stage of a tumour, there are further 
alterations, such as changes that allow the cells to 
circumvent the immune defence, to optimize metab-
olism, and to detach from the tissue of their origin 
and establish colonies in other parts of the body. 
Cancer is thus the result of progressive genetic and 
epigenetic instability that ultimately leads to the loss 
of cell identity and gives the altered cells a high level 
of adaptability (plasticity) and thus a selective advan-
tage over normal body cells. For this reason, one of 
the central questions in cancer research is why such 
changes occur and whether we can stop them.
The (in)stability of the (epi)genome
Genetic mutations arise mainly as a result of DNA 
damage and/or replication errors in the process of 
producing two replicas of the DNA before cell divi-
sion. Chemically, DNA is a very large, relative reactive 
molecule that in the surrounding of the cell nucleus is 
exposed to effects of many chemical reactions (such 
as oxidation, hydrolysis, or modification through by-
products of cell metabolism). In addition to this en-
dogenous type of DNA damage, there is also DNA 
damage caused by environmental factors: Well-
known examples include ultraviolet components of 
sunlight, ionizing radiation, tobacco smoke, and a 
number of chemical substances, including some 
prominent chemotherapy drugs like the various de-
rivatives of cisplatin. Measurements show that the 
DNA damages occur in our cells more than 50,000 
times per day per cell. The majority of these are 
caused by cell-internal processes; the frequency and 
severity of environmentally caused damages vary 
greatly depending on the amount of exposure. All of 
these sources can have a mutagenic effect and/or 
alter epigenetic modification patterns.
DNA damages impair in different ways the structure 
and function of DNA as a genetic master copy. With-
out the cellular control and repair systems, these 
damages would in most cases lead to errors in the 
transcription of DNA during DNA replication and, 
through this, result in genetic mutations. However, 
cells put a lot of work into protecting their genome. 
They have a complex network of specialized func-
tions and mechanisms to detect and eliminate DNA 
damages in a coordinated way. Through the com-
bined workings of these systems, the frequency of 
mutations is kept in check. The result is a good bal-
ance between genetic change and stability; this bal-
ance leaves the possibility of evolution open but also 
protects us from the consequences of overly progres-
sive genetic instability, such as premature aging and 
cancer.
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DNA damage, DNA repair and cancer
Genetic mutations cannot be completely prevented, 
because their occurrence is a given through the chem-
ical characteristics of our genetic substance (DNA). 
Consequently, it is inevitable that our cells amass mu-
tations over the course of our lives. The older we are, 
the greater the risk of malignant cell transformations. 
If the mutation rate of our genome is additionally in-
creased due to high-level exposure to DNA-damag-
ing agents such as excessive sunbathing without sun 
protection or tobacco smoking (both of which are 
known risk factors for cancer), this process is acceler-
ated. This acceleration becomes especially clear if we 
look at the effects of rare genetic defects in the DNA 
control and repair systems. Defects in these systems 
usually cause complex syndromes that have in com-
mon an increased incidence of cancer at a relatively 
young age. For example, defective functions in the 
ultraviolet damage repair pathway increase the risk of 
skin cancer even as early as in childhood.1 Defects in 
genes that are responsible for repair of DNA breaks 
are the most common forms of inheritable breast 
cancer 2, and a lack of correction of DNA mismatches 
generated during DNA replication leads to premature 
development of hereditary colorectal cancer.3 
These and many other examples show that defective 
DNA control and repair, which has been shown to in-
crease the rate of genetic mutations, accelerates the 
development of specific types of cancer. The relation-
ship between these genome-stabilizing functions and 
tumour development is not directly comparable to the 
effect of active tumour-promoting or tumour-inhibit-
ing cancer genes, which are called oncogenes and 
tumour suppressor genes and which usually interfere 
directly in the control of the growth of cells. 
Defects in DNA maintenance work indirectly, in that 
they increase genetic (and epigenetic) instability, and 
through this, foster the mutation of cancer genes. 
Defects in the DNA control and repair mechanisms, 
therefore, do not trigger cancer directly but instead 
promote the initiation and progression of tumours.
Usefulness for fighting cancer 
Knowledge of the causes and mechanisms of genetic 
(in)stability is required for an understanding of can-
cer development and cancer’s fundamental charac-
teristics. Insights into the causes of genetic mutations 
help us to recognize environmental or lifestyle risks 
(such as exposure to UV light without protection, or 
smoking) and to minimize them through our behav-
iour. In addition, understanding the fundamental 
mechanisms makes it possible for us to develop ge-
netic tests for the identification of heightened cancer 
risk. Today, for instance, family predispositions for 
breast and colorectal cancer can be found through 
preventive care before problems arise. Monitoring, 
preventive measures help persons affected to coun-
teract the early development of cancer.
But this knowledge will have real usefulness for can-
cer treatment when the dynamic characteristics of 
cancer genomes become clear and predictable. This 
is essential, because (epi)genetic instability is the crit-
ical unknown that in the background of a tumour-
promoting mutation (a mutation increasing survival 
and growth) is responsible for high plasticity of the 
cancer cells. This adaptability is a major determinant 
of the characteristics of a tumour, including its re-
sponse and resistance to therapy. Today’s treatment 
approaches are mainly aimed at tumour-promoting 
mutations, but future strategies will have to include 
the DNA control and repair systems, so that in addi-
tion to growth inhibition we can also control this 
plasticity of cancer – which its actually its Achilles 
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heel – and utilize it in a targeted way to its detriment. 
The more we know about the fundamental mecha-
nisms and their interactions, the better we under-
stand the genetic dynamics of a tumour with its 
specific defects, then the better we will be able to 
predict its behaviour and the better we will be able to 
fight cancer in a targeted and comprehensive man-
ner. Although with our current state of knowledge we 
are only at the beginning of being able to do this, an 
increasing number of studies on medications that 
affect DNA repair enzymes or epigenetic regulators 
are showing initial promising successes in this direc-
tion. 4, 5
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Aguet Michel | Role of BCL9/BCL9L in regulating 
Wnt-mediated epithelial-mesenchymal transition,  
stem cell traits and drug sensitivity in Wnt-activated 
human cancers (KFS 2674-08-2010)
The concept of cancer stem cells (CSCs) has stimulated 
new directions for addressing the problem of cancer 
treatment. CSCs are increasingly viewed as responsible, 
at least in part, for the emergence of resistance to ther-
apy and tumour recurrence. Therapy-refractory tumour 
cells from a variety of solid tumours have been reported 
to exhibit stem cell-related traits and may represent CSC-
enriched tumour cell populations selected under thera-
peutic constraint. Targeting CSCs has therefore emerged 
as a tempting new therapeutic strategy.
We recently described a mouse model of colon adenocar-
cinoma in which a signalling branch of the Wnt pathway 
(BCL9) was critically involved in CSC maintenance. We 
showed that inactivating this branch resulted in virtual 
loss of stemness and other malignancy associated traits. 
This project aimed at validating these findings in other 
models, including human cancer cell lines. We were able 
to identify a human colon cancer cell line based upon ex-
pression of intestinal stem cell markers, which appeared 
to consist of heterogeneous subpopulations of stem cell-
like as well as more differentiated cells, pointing to a 
spontaneously occurring differentiation cascade. Prelimi-
nary findings suggest that the same Wnt signalling branch 
is involved in regulating this equilibrium and that more 
differentiated cells lose stemness as well as associated 
malignancy traits.
The aim was to explore to what extent pharmacological 
inhibition of BCL9 proteins may be of benefit in the con-
text of a combination therapy to reduce the CSC pool and 
the risk of tumour recurrence.
Project coordinator
Prof. Dr. Michel Aguet
Institut suisse de recherche expérimentale  
sur le cancer (ISREC)
EPF de Lausanne
CH-1011 Lausanne
michel.aguet@epfl.ch
Andres Anne-Catherine | The molecular mechanisms 
provoking the ephrin-B2 induced deregulation of the 
mammary stem cell niche and leading to metastatic  
tumour growth (KLS 2825-08-2011)
Stem and progenitor cells are thought to represent the 
origin of carcinogenesis and to be responsible for meta-
static tumour growth. Thus, the elaboration of efficient 
treatment strategies depends at least in part upon a pro-
found understanding of the mechanisms controlling stem 
cell development. We showed previously that deregu-
lated expression of the receptor EphB4 and its ligand 
ephrin-B2 in the mammary epithelium alters the stem cell 
niche and thereby contributes to metastatic tumour 
growth.
In this project, we investigated whether the abnormal be-
haviour of the stem cells originates from the stem cells 
themselves or is the consequence of abnormal stimula-
tion by the neighbouring cells constituting their niche. 
Moreover, we aimed to identify the molecular pathway 
transmitting the EphB4-ephrin-B2 emitted signals. To 
these ends, we isolated the mammary epithelial cells of 
transgenic mice exhibiting deregulated expression of 
EphB4 or ephrin-B2 and separated these cells into four 
distinct cell populations: luminal and basal progenitors, 
bi-potent progenitors, and the stem cells. From each of 
these cell populations we determined the gene expres-
sion profile and compared these profiles to those of nor-
mal mammary epithelial cells.
These experiments revealed that components of the Wnt 
signalling pathway and the oestrogen receptor are pre-
dominantly affected by the aberrant EphB4 or ephrin-B2 
expression. The oestrogen receptor is the main inducer of 
mammary epithelial proliferation in the adult, whereas 
signalling by Wnt growth factors is involved in a variety 
of morphogenic processes such as determination of tissue 
boundaries and pattern formation. Interestingly, the main 
discrepancies were found in the bi-potent progenitor cells 
and the stem cell population, which both do not express 
the transgenes.
These results demonstrate that EphB4 and ephrin-B2 ex-
ert their effect indirectly by activating the Wnt and oes-
trogen signalling cascade. Thus, our project has led to the 
identification of a particular aspect of the control mecha-
nisms ensuring the homeostasis of the stem cell niche that 
might be a suitable target for stem cell specific therapeu-
tic intervention.
Project coordinator
Prof. Dr. phil. nat. Anne-Catherine Andres
Departement Klinische Forschung
Universität Bern
CH-3010 Bern
anne-catherine.andres@dkf.unibe.ch
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Brisken Cathrin | Mechanisms of action of progester-
one in the human breast (KFS 2462-08-2009)
Sex hormones are known culprits in breast cancer. For ex-
ample, women undergoing combined hormone replace-
ment therapy with artificial progesterone mimics (called 
progestins) and oestrogen have an increased risk of get-
ting breast cancer.Unfortunately, it is difficult to study 
the effects of these hormones on normal breasts. Fresh 
breast cells grown in the lab quickly lose their hormone 
receptors for reasons that we still do not understand. 
Mouse models can be useful, but mouse mammary glands 
are different from human mammary glands, and the 
animals tend to get unique types of breast cancers that 
are not seen in humans. We studied fresh pieces of breast 
tissue taken from women (with no previous history of 
breast cancer) undergoing breast reduction surgery and 
developed a tissue microstructure technique that pre-
serves breast cells’ natural environment in the lab.
We found that progesterone boosts cell growth in normal 
breasts. Cells in breast milk ducts start to produce large 
amounts of a secreted protein called RANKL in response 
to progesterone. RANKL seems to be the loudspeaker that 
progesterone uses to command breast cells to proliferate. 
If these cells are repeatedly stimulated by progesterone, 
breast cancer risk may increase. Inhibiting progesterone 
or RANKL with denosumab, a drug already used to treat 
bone diseases, could potentially benefit women under 50 
who are at high-risk of developing breast cancer.
Project coordinator
Prof. Dr. Cathrin Brisken
Institut suisse de recherche expérimentale  
sur le cancer (ISREC)
EPF de Lausanne
CH-1015 Lausanne
cathrin.brisken@epfl.ch
Brown Steven A. | The mechanism of cancer and circa-
dian clock interactions and its usefulness in the design 
of therapeutic strategies (KFS 2642-08-2010)
The circadian clock and the cell cycle are two autono-
mous regulatory cascades that control cellular physiol-
ogy, metabolism and division. Dysfunction of either can 
lead to cancer. In our project, we sought to understand 
the mechanisms linking these two cascades, and how 
exploiting these connections might lead to improved 
therapeutic strategies.
Aims of the study
First, we sought to understand whether primary human 
tumours show the wide range of circadian function shown 
in tumour cell lines, using glioblastoma multiforme as a 
model. Second, we wished to understand how the pres-
ence or absence of a functional circadian clock could 
change tumour growth and physiology.
Methods
With the help of virally delivered bioluminescent report-
ers, we examined cell-autonomous circadian rhythms of 
gene expression in cells from different primary tumours. 
In a second step, we injected clock-containing and simi-
lar clock-less tumours expressing the same biolumi-
nescent reporters into mice and examined both tumour 
growth rates and circadian cell division in vivo.
Results
In vitro, we showed that some human tumour cells possess 
perfectly functional circadian clocks and others no clock 
at all, even in tumours of the same grade. Surprisingly, in 
an experimental mouse model no differences in tumour 
growth rate were observed between clock-containing and 
clock-less tumours, and both types showed circadian cell 
division in vivo. Therefore, the host animal’s circadian 
clock gates tumour cell division systemically, even in the 
absence of local clock function.
Potential relevance for patients
If tumour growth is gated by host circadian function, 
then reduction in tumour growth rates might be achieved 
both by supporting host circadian function and by opti-
mized timing of chemo- and radiotherapy.
Project coordinator
Prof. Dr. Steven A. Brown
Institut für Pharmakologie und Toxikologie
Universität Zürich
CH-8057 Zürich
steven.brown@pharma.unizh.ch
Christofori Gerhard | The functional role of the  
transcription factors DIx2 and Lhx2 in epithelial- 
mesenchymal transition (EMT) and in malignant  
tumour progression (KLS 2535-02-2010)
Most cancer deaths are due to the systemic dissemination 
of cancer cells and the formation of secondary tumours 
(metastasis) in distant organs. The majority of cancers 
originate from epithelial tissues. To leave the primary tu-
mour and to invade into the surrounding tissue, tumour 
cells dissolve their cell-cell contacts and adjust to a more 
transient, migratory and invasive mode. This temporary 
and reversible phenomenon is known as an epithelial-to-
mesenchymal transition (EMT), a multistage process that 
involves a dramatic reprogramming of cancer cells and 
leads to metastasizing cells with stem cell-like capabili-
ties.
We identified an increased expression of the transcription 
factors Dlx2 and Lhx2 during EMT. Gain and loss of func-
tion experiments have delineated the regulatory func-
tions of Dlx2 and Lhx2 during EMT in vitro and during 
metastasis formation in mouse models of cancer in vivo. 
Employing chromatin-immunoprecipitation experiments, 
we identified direct targets of Dlx2 and Lhx2 transcrip-
tional control and analysed the functional contribution of 
some of these target genes to EMT and malignant tumour 
progression. Finally, we assessed whether the gene ex-
pression signatures identified here may provide prognos-
tic tools for the prediction of clinical outcome in patients.
We found that Dlx2 exerts critical functions during malig-
nant tumour progression by counteracting TGF -induced 
cell cycle arrest and apoptosis by at least two molecular 
mechanisms: Dlx2 acts as a transcriptional repressor of 
TGF  receptor II expression and thus overcomes TGF - 
mediated cell cycle arrest. On the other hand, Dlx2 in-
duces the expression of the epidermal growth factor 
(EGF) family member Betacellulin, which promotes cell 
survival by stimulating EGF receptor signalling. Finally, 
Dlx2 expression supports experimental tumour growth 
and metastasis and correlates with tumour malignancy in 
a variety of human cancer types. For Lhx2 we found that 
it promotes vessel maturation, primary tumour growth, 
tumour cell intravasation and metastasis by inducing the 
expression and secretion of platelet-derived growth factor 
(PDGF)-B by tumour cells. The data indicate that Lhx2 
exerts a dual role in malignant tumour progression by pro-
voking autocrine PDGF-B signalling required for meta-
static dissemination and paracrine PDGF-B signalling to 
support blood vessel functionality and primary tumour 
growth. 
Project coordinator
Prof. Dr. phil. Gerhard Christofori
Institut für Biochemie und Genetik
Departement Biomedizin
Universität Basel
CH-4058 Basel
gerhard.christofori@unibas.ch
Constam Daniel | Role of activin signalling in  
metastatic melanoma (KFS 2487-08-2009)
Aim of the study
Melanoma, the deadliest type of skin cancer, has a poor 
prognosis once it forms metastases. What triggers meta-
static spread is not well understood. Activin and related 
secreted growth factors that regulate the development of 
stem cells in healthy tissues are also found in several can-
cers including melanoma, especially during the progres-
sion towards metastatic growth. We therefore asked 
whether such factors promote melanoma progression, 
and by what mechanism(s).
Methodology
To address this question, we assessed the effects of ac-
tivin and the consequences of inhibiting activin by genetic 
approaches in mice that received grafts of melanoma 
cells. We also tested whether activin influences the tu-
mour cells directly or indirectly by altering their microen-
vironment in the host tissue.
Fotogramm / Erle, 2011
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Results
In immunodeficient mice, we found that grafts of human 
melanoma cell lines formed metastases irrespective of the 
presence or absence of activin but that tumour-derived 
activin was responsible for a dramatic loss of body weight, 
consistent with its known inhibitory effect on muscle stem 
cells. A similar weight loss was induced by activin in mice 
with a normal immune system that received mouse mela-
noma cells. However, in this context, activin in addition 
dramatically accelerated the growth of primary tumours 
and of lung metastases, suggesting that its tumourigenic 
effect consists largely in suppressing an anti-tumour im-
mune response. Concurring with this conclusion, direct 
effects of activin on melanoma cells themselves varied 
among cell lines and were not sufficient to promote tu-
mourigenesis.
Significance
Metastatic growth and tumour-induced muscle loss are 
the major cause of cancer deaths, but neither process is 
sufficiently understood at the molecular level to design 
effective therapies. Another major challenge is that an ab-
normal high frequency of gene mutations enables cancer 
cells to rapidly develop drug resistance. Our new findings 
suggest that existing or future activin inhibitors will likely 
benefit at least a subset of melanoma patients by blocking 
tumour-induced immune evasion. Moreover, since activin 
primarily acts on the host immune system rather than on 
the genetically unstable cancer cells, resistance to such 
drugs is less likely to develop.
Project coordinator
Prof. Dr. Daniel Constam
Institut suisse de recherche expérimentale  
sur le cancer (ISREC)
EPF de Lausanne 
CH-1015 Lausanne 
daniel.constam@epfl.ch
Gönczy Pierre | Mechanisms of centrosome duplica-
tion: from model organism towards therapeutic  
opportunities (KLS 2584-02-2010)
We focused the bulk of our study on the analysis of two 
proteins, HsSAS-6 and CPAP, which are necessary for 
centrosome duplication, a process that is essential for cell 
proliferation and that is often aberrant in cancer cells.
Aims of the study
The centrosome contains two centrioles and is the orga-
nelle that ensures microtubule organization in animal cells. 
Centrosome duplication occurs only in proliferating cells 
and is necessary for correct cell division. Cancer cells 
often exhibit aberrations in the number or structure of 
centrosomes. Therefore, centrosome duplication offers 
therapeutic opportunities in the fight against cancer.
Methods
We combined the advantages of two experimental sys-
tems, the nematode C  elegans and human cells in culture, 
to obtain novel information regarding the mechanisms of 
centrosome duplication, in particular through analysis of 
the HsSAS-6 and CPAP proteins.
Results of the study
In C. elegans, we have begun to study the consequences 
of abnormal centriole number or structure in a stem cell 
lineage. Moreover, we analysed in detail the way in which 
HsSAS-6 and CPAP contribute to the formation of centri-
oles in human cells in culture. Further, using proteomic 
methods, we identified proteins that are associated with 
HsSAS-6 and that may modulate its function in normal 
cells, as well as in tumour cells. In the long term, we ex-
pect this research to lead to the identification of new 
drugs that target preferentially proliferating cells harbour-
ing centrosome aberrations, as is characteristic of numer-
ous cancer cells.
Project coordinator
Prof. Dr Pierre Gönczy
Institut suisse de recherche expérimentale  
sur le cancer (ISREC)
EPF de Lausanne
CH-1015 Lausanne 
pierre.gonczy@epfl.ch
Grassi Fabio | Purinergic signalling in the pathophysi-
ology of central nervous system infiltration in T-cell 
leukaemia (KFS 2445-08-2009)
Adenosine-triphosphate (ATP) is usually confined inside 
the cell, where it constitutes the source of chemical en-
ergy for cellular functions. ATP is also released by cells as 
a signalling molecule. In T-cells extracellular ATP regu-
lates T-cell proliferation and activity but can also promote 
cell death via purinergic P2 receptors.
Aim of the study
The aim of this study was to address whether pharmaco-
logical inhibition of P2 receptors might be useful in 
T-acute lymphoblastic leukaemia (T-ALL) therapy and 
ameliorate central nervous system infiltration, a dramatic 
complication of T-ALL.
Method and procedure
We tested in vitro the effect of periodate-oxidized ATP 
(oATP), a P2 receptors inhibitor, on the proliferation of 
T-ALL cells from mice with leukaemia. Among the leukae-
mic cell population, only a small subset of cancer stem 
cells can initiate, regenerate and maintain leukaemia af-
ter transplantation. The haematopoietic niche in the bone 
marrow constitutes a reservoir of T-ALL stem cells. We 
addressed whether purinergic antagonism might control 
haematopoietic stem cells pool size and self-renewal in 
the bone marrow. Finally, we tested treatment in vivo 
with oATP in immunodeficient mice transplanted with 
T-ALL cells.
Results of the study
The treatment with oATP prominently inhibited expansion 
of T-ALL cells in vitro, thus suggesting that ATP contrib-
utes to the expansion of T-ALL cells via P2 receptors. We 
showed that oATP decreased the number of proliferating 
cells in the haematopoietic niche of the bone marrow 
(BM), which is exploited by T-ALL stem cells for constant 
regeneration, indicating that P2 activation contributes to 
leukaemogenesis. Since P2 stimulation by ATP can in turn 
induce ATP release, self-perpetuating release of ATP by 
T-ALL stem cells might play an important role in control-
ling their activity and constant generation of circulating 
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leukaemic cells. In vivo treatment with oATP revealed the 
importance of BM niche as a site of T-ALL proliferation, 
as a prelude to central nervous system infiltration by 
leukaemia.
Potential benefits for patients
This research project revealed the importance of ATP in 
regulating leukaemogenic potential of T-ALL cells resid-
ing in the BM and of BM as a prominent site for progres-
sion to the neuropathological form of the disease.
Project coordinator
Dr Grassi Fabio
Istituto di ricerca in biomedicina (IRB)
CH-6500 Bellinzona
fabio.grassi@irb.unisi.ch
Hall Jonathan | Targeting pre-let-7 biogenesis in  
cancer (KFS 2648-08-2010)
Many human cancers exhibit dysregulation of microRNA 
expression, in which they are non-functional or over- 
expressed. A prominent example is the let-7 family, in 
which let-7 prevents normal cells from becoming tumour-
igenic. In several cancers levels of let-7 are very low. This 
is due to the RNA-binding protein Lin28, which binds to 
the precursor of let-7, preventing its correct processing. 
New studies have shown also that the Lin28/let-7 plays 
an important role in maintenance of cancer stem cells. In 
the previous project, we synthesized short antisense oli-
gonucleotides that bind to the let-7 precursor and protect 
it from degradation by Lin28. This leads to increased lev-
els of let-7 in cells and inhibition of cancer cell growth. 
One goal of this project was to improve the properties of 
the antisense oligonucleotides through chemical modifi-
cation. This should lead to a stronger effect on the precur-
sor and will be examined in mouse cancer models. The 
results of the study have provided new insights into the 
mechanisms of anti-microRNA antisense oligonucleotides 
in living models of cancer.
Project coordinator
Prof. Dr. Jonathan Hall
Institut für Pharmazeutische Wissenschaften
ETH Zürich
CH-8093 Zürich
jonathan.hall@pharma.ethz.ch
Hynes Nancy | Role of the bone marrow niche in 
breast cancer metastasis and therapy response  
(KFS 2743-02-2011)
Metastatic breast cancer, the major cause of breast can-
cer deaths, is currently not treatable. To uncover new ap-
proaches to block metastasis, we established mammary 
carcinoma models with bone marrow (BM) tropism using 
tumour cell lines representing common breast cancer sub-
types. To characterize BM specific changes, metastatic 
cancer cells were isolated, and gene expression profiling 
was carried out and compared to patterns obtained from 
cancer cells isolated from primary mammary tumours. A 
number of differentially expressed genes were uncovered. 
For example, in bone metastases, the expression of ID1 
was significantly increased compared to its level in tumour 
cells growing in the mammary gland. ID (inhibitor of dif-
ferentiation/DNA binding) is a family of helix-loop-helix 
proteins that do not possess a DNA binding domain but 
function as dominant-negative regulators of basic helix-
loop-helix transcription factors that regulate the differen-
tiation programme of multiple cell lineages. Moreover, 
ID1 expression correlates with less differentiated pheno-
types, high malignant potential and poor clinical outcome 
in breast cancer. Thus, it is possible that ID1 is required 
for the establishment of bone metastases. We are testing 
this hypothesis now, by introducing tumour cells with a 
specific knockdown of ID1 into the bone and examining 
their ability to form metastases.
To complement the analyses of tumour cells growing in 
the bone vs. the mammary gland, we also asked how sub-
populations of BM environmental cells are affected by the 
presence of cancer cells. For this, BM stromal cell subsets 
of endothelial, osteoblastic and mesenchymal cells were 
FACS purified from tumour-free vs. bone tumour-bearing 
mice and subjected to transcriptome analyses. A number 
of genes that were significantly up- or downregulated in 
response to the presence of tumour cells were uncovered. 
An ingenuity pathway analysis also allowed us to deline-
ate the signalling pathways specific for the individual sub-
populations of stromal cells that are altered in the pres-
ence of bone metastases. These analyses provide us with 
new opportunities to test specific inhibitors, a project that 
is ongoing in the lab.
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Meraldi Patrick | How does overexpression of the  
Aurora-A oncogene override the spindle checkpoint?  
(KFS 2707-08-2010)
Amplification or overexpression of the Aurora-A gene is 
frequently observed in human cancers and has been asso-
ciated in human patients with resistance to taxanes, one 
of the major classes of anti-cancer agents. Aurora-A is a 
protein kinase that regulates the entry into mitosis and 
controls the formation of the bipolar spindle, the structure 
that separates the sister chromatids during cell division. 
However, the pathological effects of Aurora-A overex-
pression are less well understood. The leading hypothesis 
is that elevated Aurora-A kinase activity impairs the 
spindle checkpoint, a surveillance mechanism that pre-
vents mitotic exit in the presence of erroneous attach-
ment of chromosomes to the mitotic spindle. Importantly, 
Aurora-A kinase inhibitors are a new class of drugs that 
are currently being tested as anti-cancer agents in clinical 
trials.
Our aim was to understand how overexpression of the 
protein kinase Aurora-A affects the spindle checkpoint at 
the molecular level. Our results confirm previous studies 
showing that Aurora-A overexpression leads to errors in 
chromosome segregation during cell division. However, to 
our surprise we found that overexpression of Aurora-A 
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impairs the fidelity of cell division in a kinase-independent 
manner and that it does not disrupt the spindle check-
point. Instead, Aurora-A overexpression leads to chromo-
some bridges, fine threads to DNA that link the two divid-
ing chromosome masses as cells divide. These chromosome 
bridges can impair cell division, leading to cells with the 
double amount of chromosomes. This suggests a new 
mechanism by which Aurora-A affects dividing cells.
Our current aim is to understand how the overexpression 
of Aurora-A results in such DNA bridges. Finally, our data 
suggest that Aurora-A kinase inhibitors might not be able 
to target cells overexpressing Aurora-A, since Aurora-A 
overexpression seems to affect mitosis in a kinase-inde-
pendent manner.
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Michielin Olivier | Rational design of anti-MART-1 TCR 
sequences for adoptive transfer immunotherapies  
(KFS 2555-02-2010)
The adoptive cell transfer immunotherapy against cancer 
relies on the ability of the killer T-cells of the immune sys-
tem to recognize and specifically destroy cancer cells. 
This recognition is achieved thanks to a receptor called 
T-cell receptor (TCR), which recognizes specifically a can-
cer antigen presented at the cancer cell surface by the 
major histocompatibility complex (MHC). The recogni-
tion of the cancer antigen by the TCR starts a cascade of 
biochemical events that will finally destroy the cancer 
cell. The adoptive cell transfer immunotherapy consists 
in extracting killer cells from the patient that are specific 
for the disease, expanding them ex vivo, and re-injecting 
them in the patient to create an efficient immune re-
sponse against the tumour.
The objective of this project was to optimize the structure 
of a TCR binding specifically to melanoma cancer cells us-
ing rational computer-aided protein engineering, to opti-
mize its binding to tumour cells and thus their killing. We 
have developed a new method based on the 3D structure 
of the TCR/antigen complex and free energy simulation, 
with which we could modify rationally the sequence of 
a TCR targeting a cancer antigen called NY-ESO-1. We 
obtained a 150-fold increase in the TCR potency for the 
binding to melanoma cancer cells. We showed that by 
engineering in vitro the patient T-cells to express these 
modified TCRs, it is possible to dramatically increase the 
immune response against melanoma cells.
In this project, we applied this method to rationally mod-
ify a TCR targeting another very common melanoma an-
tigen, i. e. Melan-A. We have chosen to rationally opti-
mize a Melan-A-specific Mel5 TCR, whose structure in a 
complex with the Melan-A antigen presented by the HLA-
A*0201 MHC was available. We designed 26 mutations 
possibly enhancing the binding to this antigen. These mu-
tants were produced and tested for binding in titration 
ELISA as compared to the wild-type (natural) TCR. 19 mu-
tants out of 26 (73 %) were found more active than the 
wild-type TCR. Thanks to this success, we now have at our 
disposal a pool of optimized TCR recognizing specifically 
several melanoma antigens, which could be of major im-
portance for the design of enhanced adoptive cell transfer 
immunotherapy.
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Ochsenbein Adrian F. | Immunogenicity of chronic  
myeloid leukaemia stem cells (KLS 2342-02-2009)
Chronic myeloid leukaemia (CML) is a clonal myeloprolif-
erative disease that originates from a transformed haema-
topoietic stem cell or progenitor cell. This results in leukae-
mia stem cells (LSCs). LSCs are resistant to most of the 
current treatments including chemotherapy, radiotherapy 
and tyrosine kinase inhibitors. LSCs are therefore the main 
reason for relapse after treatment, and cure of the disease 
implies the elimination of LSCs. We established a murine 
CML model by transducing bone marrow cells with the on-
cogene BCR/ABL. In this model, leukaemia-specific cyto-
toxic T-lymphocytes (CTLs) are activated and contribute 
to the elimination of more differentiated leukaemia cells. 
Surprisingly, specific CTLs did not eliminate LSCs but in 
contrast increased their numbers. We identified two mech-
anisms by which CTLs contribute to the proliferation and 
expansion of LSCs.
First, we analysed the role of the CD27 signal transduction 
in leukaemogenesis. CD27 is a co-stimulatory molecule 
that induces T-cell expansion and memory generation. We 
documented that CD27 is expressed on LSCs and that 
CD27 signalling increases LSCs proliferation and differen-
tiation into more mature granulocytes. The ligand of CD27 
(CD70) is exclusively expressed on activated lymphocytes 
and on mature dendritic cells. Therefore, the activated im-
mune system contributes to leukaemia progression. Im-
portantly, blocking the CD27/CD70 interaction by treat-
ment with monoclonal antibodies eliminated LSCs and 
prolonged survival.
In a second study we focused on the inflammatory 
cytokine interferon-gamma (IFNγ). Activated cytotoxic 
T-lymphocytes produce large amounts of IFNγ when 
transferred to a CML-bearing mouse. IFNγ induced the 
proliferation of CML stem cells and increased their num-
bers. Therefore, immunotherapy with CTLs is the most 
efficient in a setting with a reduced leukaemia load after 
chemotherapy or in combination with a strategy to block 
IFNγ. Knowledge of these molecular pathways can be 
used to improve immunotherapy against LSCs.
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Pertz Olivier | A Slit/Robo signalling pathway regulat-
ing contact-mediated repulsion during cell migration: 
implications of its deregulation for the acquisition of 
an invasive phenotype during breast cancer  
(KFS 2485-08-2009)
In healthy tissue, individual cells are kept in the right or-
der through constant interaction with neighbouring cells. 
This process involves sampling of adjacent cells and sens-
ing of repulsive cues that suppress cell motility. During 
the metastatic switch, cancer cells acquire the ability to 
move out and to squeeze between surrounding cell lay-
ers, finally spreading through the body and colonizing 
distinct organs. Thus, cell sensing may serve as an impor-
tant early mechanism to impede the invasive phenotype. 
The aim of this project was to apply a gene inactivation 
approach to identify signalling pathways that generate 
and/or sense repulsive signals.
In this study we identified the Slit-Robo-srGAP pathway 
as a central regulator of cell repulsion. This pathway con-
sists of the extracellular activator molecule Slit, which 
binds to its receptor Robo that is present in the plasma 
membrane. This interaction triggers the activation of the 
receptor and subsequent recruitment and activation of 
srGAP proteins by Robo. Active srGAP molecules induce 
the reorganization of the cytoskeleton, which leads to cell 
repulsion.
Downregulation of Slit, Robo and srGAP protein levels in 
cells leads to prolonged cell-cell contact duration and in-
creased cell-cell overlap. Moreover, those cells protrude 
very efficiently and are able to invade neighbour cells. 
We were also able to show that Slit and srGAP proteins 
localize to the front edge of migrating cells. This means 
that migrating cells are already prepared to adequately 
respond to collisions encountered on their way. This col-
lision detector functions as a “bumper” to prevent unin-
tended cell movements. This may be an important mech-
anism in tumour metastasis. Indeed, inactivation of the 
Slit-Robo pathway has been reported in human cancers, 
although the precise mechanisms of action are not yet 
fully understood. Thus, understanding the molecular 
mechanisms underlying metastasis will be crucial for suc-
cessful cancer therapy.
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Pruschy Martin | Differential response to proton  
versus photon radiotherapy: biological implications  
for new indications and combined treatment  
concepts (KFS 2551-02-2010)
There is presently a widening gap between the rapid 
introduction of proton therapy in clinical practice world-
wide and the introduction of new proton treatment con-
cepts with an apparent lack of solid radiobiological evi-
dence and data to support the expansion of new clinical 
indications, particularly when combined with other treat-
ment modalities.
In collaboration with the Paul Scherrer Institute (PSI)-
based Centre for Proton Therapy, we investigated under-
lying mechanisms for proton radiation-induced cell kill-
ing. The major questions arise from the observed (in the 
absence of systematic molecular and cellular investiga-
tions) differential biological effectiveness of clinically rel-
evant proton versus clinically relevant photon irradiation.
In genetically defined cellular systems we analysed: (1) 
underlying biological and molecular parameters that may 
contribute to the relative biological effectiveness, (2) a 
differential mode of cell death in response to the differ-
ent types of radiation, and (3) the treatment responses 
to combined treatment modalities with currently relevant 
anti-signalling agents and the two types of radiation. We 
have identified that a deficiency in one of the major DNA 
damage repair machineries renders mammalian cells more 
sensitive to proton versus photon irradiation.
This project will be continued, and the anticipated results 
will further promote and improve proton radiotherapy 
from the biological perspectives. 
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Radtke Freddy | Candidate genes implicated in  
melanoma – genetic and developmental in vivo  
analysis (KFS 2272-08-2008)
Melanoma derives from melanocytes and is currently one 
of the most aggressive forms of skin cancer. Melanocytes 
are pigment cells found in skin, hair, inner ear and eye. The 
significance of malignant melanoma incidence has been 
increasing in recent years, with an annual growth of over 
2 %. The fatal outcome of melanoma is mostly due to me-
tastasis. Although most of the frequently mutated genes 
in melanoma are known, treatment for metastatic mela-
noma remains a challenge. A better understanding of the 
biological mechanisms regulating melanoma development 
and progression is therefore critical for developing effec-
tive therapeutic interventions against advanced mela-
noma.
Aim of the study
Here we addressed the role of two candidate pathways 
(Notch and c-Myc) for their role during normal melano-
cyte development as well as in the context of malignant 
melanoma.
Methods
We used and combined different genetically engineered 
mouse models in which Notch receptors or the c-Myc gene 
can specifically be inactivated or overexpressed in murine 
pigment cells and melanomas. Moreover, we correlated 
c-Myc protein levels in primary and metastatic murine and 
patient-derived melanoma samples with disease aggres-
siveness.
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Results
Our experiments showed that both Notch signalling and 
c-Myc are essential for melanocyte development. More-
over, we established the functional significance of the 
Notch cascade in pigmented eye structures. Mice with 
loss- and gain-of-function studies for Notch developed 
ocular hypotony and ocular hypertension, respectively, 
mimicking the human diseases phthisis bulbi and closed 
angle glaucoma. Genetic studies of c-Myc in a murine 
melanoma model established the essential role of c-Myc 
for melanoma development and for melanoma mainte-
nance. c-Myc protein levels were found to be lower in pri-
mary melanoma compared to metastatic lesions both in 
mice and in human tumour samples, which correlated 
with the aggressiveness of the tumour. Moreover, c-Myc 
positive melanoma cells have a higher tumour initiation 
potential compared to c-Myc negative cells.
Relevance
Our studies regarding pigmented eye structures provide 
novel insights on the role of Notch signalling in the eye, 
and the genetic models developed represent robust tools 
to study the aetiology, pathology and treatment of dis-
eases related to aberrant intraocular pressure, such as 
phthisi bulbi and closed angle glaucoma. Our studies on 
melanoma revealed important roles for c-Myc as a poten-
tial prognostic marker for progression and aggressiveness 
of murine and human melanoma.
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Ruiz i Altaba Ariel | Role and prevalence of hedgehog 
signalling in human colorectal cancer  
(KFS 2359-02-2009)
In this project we addressed the unresolved question of 
the role of this important signalling pathway in colon can-
cer. In tumours, as in normal tissues, cells communicate 
with each other, and understanding how they do it is of 
utmost importance for the fate of the tissues and, in our 
case, the cancers, but also for designing rational and tar-
geted therapies. There are only a handful of different 
communication pathways that are used over and over but 
in different modes, strengths and contexts. In our case, 
we focused on the HEDGEHOG (HH)-GLI pathway, 
which is important for the development of the embryo, 
the construction of many tissues and their maintenance 
in adulthood, and for cancers of many types.
In terms of colon cancer, before our studies it was 
proposed that the HH-GLI pathway was not important. 
Our findings have proven otherwise. We show that its 
requirement for tumour growth and metastasis is wide-
spread. Importantly, we have used patient samples ob-
tained from our surgeon collaborators and have shown in 
vitro and in mouse grafts (the closest to a patient that we 
can manage for experimentation in the laboratory) that 
blocking the activity of this signalling pathway leads to 
tumour regression, prevents recurrence, and leads to tu-
mour cell death. Importantly, we also show that cancer 
stem cells, the cells in the tumour that appear responsible 
for maintaining tumour growth and expanding it locally 
and distally in metastasis, also show a dependence on 
this pathway.
Our results thus prove the role of the HH-GLI pathway in 
human colon cancers and their stem cells and thus open 
the possibility for their treatment with HH-GLI blockers. 
Since several companies have developed and are devel-
oping such blockers, our data set the stage for rational, 
well-designed clinical trials.
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Schäfer Beat W. | Preclinical and mechanistic evalua-
tion of FGFR4 signalling in rhabdomyosarcoma  
(KLS 2784-02-2011)
The FGFR4 is a key receptor transmitting signals from 
outside to the cell nucleus, which is strongly activated 
in the paediatric tumour alveolar rhabdomyosarcoma 
(aRMS). FGFR4 downstream signalling is mediated by a 
range of distinct signalling pathways that can influence 
the efficacy of current or future therapies. In this project, 
we aimed to identify and characterize FGFR4 signals so as 
to better understand therapy resistance and to find 
promising, more effective therapies in the future.
Aim of the study
Characterization of FGFR4 signalling under established 
and experimental therapies in aRMS cells.
Methods
Eight aRMS cell lines were treated with different estab-
lished and experimental drugs in presence of bFGF to ac-
tivate FGFR signalling. Activation of programmed cell 
death was then measured using common assays. Differ-
ences between the cell lines were studied on the molec-
ular level and validated in a large cohort of 45 aRMS 
tumours by gene expression analysis and immunohisto-
chemical stainings.
Results
bFGF blocked the induction of cell death in a subgroup of 
cell lines, with no effect on the other cells. The two sub-
groups differed in the molecular sensor involved in acti-
vation of cell death under our treatment conditions. In 
cells where cell death was blocked, this sensor is the pro-
tein Bim or Bad, whereas in the other cells it is the protein 
Bmf. FGFR4 signalling is able to inactivate Bim by a com-
bination of mechanisms, but Bmf is not affected. The two 
subtypes of cells are also detectable in aRMS tumours. 
They are present in different ratios in different tumours, 
with some tumours being composed mainly of cells from 
one or the other subtype and other tumours containing a 
mixture of the two cell types. Specific inhibition of the 
FGFR4 makes it possible to overcome the block of cell 
death in presence of bFGF.
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Relevance
Our results show for the first time that two physiologi-
cally different tumour cell types are present in aRMS. This 
implies that novel therapeutic approaches have to be 
evaluated for effectiveness in both of these. The inhibi - 
tory effect of FGFR4 signalling on tumour cell death 
during therapies might be overcome by using a combina-
tion including FGFR4 inhibitors.
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Schär Primo | DNA repair, epigenetic stability, and 
CpG island hypermethylation in colorectal tumouri-
genesis (KFS 2585-02-2010)
Cancer arises through genetic and epigenetic changes 
that transform normal cells into malignant cells. Epige-
netic changes concern small chemical chromatin modifi-
cations that act as flags to instruct cell type-specific gene 
expression. A prominent epigenetic modification is the 
methylation of cytosine in DNA, which, established in 
tissue-specific patterns, is disturbed in many cancers. 
Cancer cells can acquire a “methylator phenotype” char-
acterized by widespread aberrant hypermethylation of 
gene promoters, implicating an as yet unidentified mal-
function in the DNA methylation system. We previously 
discovered a role for thymine-DNA glycosylase (TDG)-
mediated DNA excision repair in the maintenance of pro-
moter hypomethylation. This project examined whether 
malfunction of this system can account for aberrant 
promoter methylation associated with colorectal carcino-
genesis.
Aims of the study
Our objectives were to profile DNA methylation patterns 
of the methylator phenotype in colorectal cancer (CRC), 
to correlate the expression of TDG and associated de-
methylation proteins with the methylator phenotype, and 
to determine the contribution of TDG-dependent pro-
cesses to the maintenance of methylation stability at gene 
promoters.
Methods
Genome-wide approaches were combined with bioinfor-
matic analyses for DNA methylation profiling of the 
colonic mucosa, CRCs and CRC cell lines. Expression of 
demethylation factors in these tissues was assessed at the 
mRNA and protein levels. Association of TDG and TET 
proteins with relevant gene promoters was examined by 
chromatin immunoprecipitation.
Results
We were able to discriminate age-dependent and cancer-
associated DNA methylation changes at a genomic level 
and, thereby, to identify > 800 loci, the methylation sta-
tus of which may predict the risk of developing CRC. Im-
portantly, we found that methylator and non-methylator 
cancers differ primarily in levels rather than the genomic 
distribution (targets) of aberrant DNA methylation, and 
we showed that the TET-TDG demethylation capacity is 
downregulated in methylator cancers, thus explaining 
gene promoter hypermethylation by reduced demethyla-
tion.
Relevance
The study provides unprecedented insight into the contri-
bution of DNA methylation instability to colorectal car-
cinogenesis. It identifies a comprehensive set of genomic 
loci as potent biomarkers for the detection of carcinogen-
esis in the aging colonic mucosa, and it uncovers a molec-
ular mechanism explaining the hypermethylation pheno-
type of colorectal cancers.
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Schorderet Daniel | Retinoblastoma: understanding its 
development for better treatment (KFS 2565-02-2010)
Retinoblastoma is a malignant tumour of the developing 
retina that manifests in early childhood. Retinoblastoma 
development requires the loss of both RB1 alleles, but 
accumulation of additional genomic/epigenetic changes 
are involved in the tumour progression. Highly prolifera-
tive retinoblastoma exhibit altered gene copy numbers 
and expression of oncogenes and tumour suppressor 
genes. These additional modifications following RB1 inac-
tivation during retinoblastoma development progressively 
lead to resistance of tumour cells to cell death, including 
resistance to chemotherapeutic agents.
Aims of the study
We aimed to target mitochondria, a key element in the 
different programmed cell death pathways, i. e. apoptosis, 
autophagy and necroptosis, with small therapeutic drugs 
to induce tumoural cell death. We aimed to highlight new 
factors involved in retinoblastoma tumour progression in 
order to develop new therapeutic approaches to counter-
act any tumoural modification and any cell death resist-
ance.
Methods
Cellular and animal models are used to characterize in-
volved signalling pathways and to study the effect of new 
therapeutics molecules.
Results
The study focusing on the mitochondria revealed that 
two molecules, BIRO1 and ABT-737, trigger cell death in 
human retinoblastoma cell lines. In in vivo studies, BIRO1 
and ABT-737 drugs were injected intravitreally in the ret-
inoblastoma mice model. Whereas ABT-737 was ineffec-
tive in inducing tumoural cell death alone, its efficiency 
was enhanced in combination therapy with an E2F inhib-
itor. BIRO1 was able to reduce tumour growth with inap-
propriate side effects on healthy retina, promoting mas-
sive death of the intact retinal cells. In the second part 
of the project, several factors were highlighted in retino-
blastoma development, and we are now studying the 
validation of their functional role in tumour progression 
using cellular and zebrafish models.
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Potential benefits for patients
The discovery of new therapeutics molecules should allow 
better management and treatment of the advanced stages 
of the disease. In addition, as the RB1 gene is found mu-
tated in various cancer types, these new drugs should have 
a more general impact in oncology.
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Schwaller Jürg | Dissecting the cellular origin and  
molecular targets in MLL acute leukaemia  
(KFS 2778-02-2011)
Chromosomal translocations leading to the expression of 
mixed lineage leukaemia (MLL) fusion genes are hallmarks 
of poor prognosis in patients with acute leukaemia. How-
ever, there are remarkable differences from patient to pa-
tient that are not fully understood. Previous studies have 
shown that MLL fusions act as aberrant transcriptional 
regulators and activate a myriad of downstream target 
genes that are essential for their leukaemogenic activity.
Biochemical studies revealed that MLL fusion proteins 
form dynamically assembled multi-protein complexes 
binding to their target gene promoters. Here we used a 
novel and fully reversible transgenic mouse model for the 
acute myeloid leukaemia (AML)-associated MLL-AF9 
fusion to address the role of the cellular origin for the clin-
ical outcome. We were able to show that activation of the 
fusion in haematopoietic stem cells resulted in a signifi-
cantly more aggressive disease than activation in more 
committed progenitor cells. Comparative gene expression 
profiling of mouse leukaemia and AML patients allowed us 
to identify several origin-related downstream targets that 
were associated with a poor clinical outcome.
These genes are currently being validated for their role for 
induction and maintenance of MLL-fusion gene induced 
leukaemia. We also explored the possibility of directly in-
terfering with the MLL-fusion complex by dissecting the 
critical domains of its interaction with the lens epithelial-
derived growth factor (LEDGF) adapter protein. Here we 
identified two critical protein-protein interfaces that can 
potentially be targeted by small molecules. Moreover, we 
performed a large RNA interference-based screen to 
search for potentially pharmacologically blockable protein 
kinases that are essential for the leukaemogenic activity of 
MLL-fusion proteins.
We have identified over 50 candidates mediating growth, 
survival, self-renewal and/or aberrant differentiation of 
MLL-AF9 immortalized cells. Current efforts aim to further 
validate their role for induction and maintenance of the 
disease in multiple in vitro and in vivo models. Taken to-
gether, our work has provided experimental proof of con-
cept that the cellular origin is a critical factor of disease 
outcome in AML induced by MLL fusion proteins. Our 
work also identified several target genes that might not 
only serve as prognostic biomarkers but could also open 
the way for origin-related therapeutic interventions.
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Thome-Miazza Margot | Analysis of the role of the 
protease MALT1 in human lymphomas  
(KFS 2561-02-2010)
The activation and subsequent proliferation of lympho-
cytes is part of the normal immune response to infection. 
This process is altered in leukaemias and lymphomas be-
cause of cellular alterations that allow an unlimited prolif-
eration of lymphocytes. Our objective was to explore the 
role of the protease MALT1 in this process, since MALT1 
plays an important role in lymphocyte proliferation. By 
comparing normal and activated lymphocytes, we showed 
previously that MALT1 protease activity is detectable only 
in activated lymphocytes. In addition, we showed that 
MALT1 is hyperactive in a particular subtype of lym-
phoma, the ABC-DLBCL, and that MALT1 inhibition leads 
to impaired growth of such cancer cells in vitro.
The goal of this project was to investigate whether MALT1 
protease activity is also relevant for other lymphoma cell 
types, such as cutaneous T-cell lymphomas and lympho-
mas induced by the oncogenic human herpesvirus-8 
(HHV-8). In cell lines derived from human cutaneous lym-
phomas, no MALT1 activity was detectable. However, 
treatment with a MALT1 inhibitor was toxic to a latently 
HHV-8-infected B-cell lymphoma cell line. In addition, we 
identified two viral proteins of HHV-8 as potential MALT1 
substrates. These findings suggest a potential role for 
MALT1 in HHV-8-induced lymphomas that we will further 
explore. We hope that these investigations of the rele-
vance of MALT1 in different lymphomas will lead to new 
strategies in their diagnosis and treatment.
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Widmann Christian | The 317–326 sequence of  
RasGAP as potential anti-metastatic agent  
(KFS 2543-02-2010)
Dissemination of cancer cells from a primary tumour is 
one of the events most dreaded by oncologists. Indeed, 
metastasis formation is the main cause of death due to 
cancer. We discovered previously that a peptide derived 
from a fragment of the RasGAP protein is capable in vitro 
of increasing the adhesiveness of cells to their substratum 
and of blocking their migratory activity. Based on these 
properties, it can be envisioned that this peptide has anti-
metastatic activities.
In this project, we confirmed the capacity of the RasGAP-
derived peptide to inhibit the invasion capacity of tumour 
cells. We also demonstrated that the activity borne by the 
peptide was able to inhibit metastatic progression in a 
murine tumour model. Identification of the peptide’s tar-
get would facilitate the development of anti-metastatic 
compounds. Therefore, we looked for proteins that could 
be required for the anti-metastatic activity of the Ras-
GAP-derived peptide. We found that the DLC1 tumour 
suppressor was not only necessary for the peptide to in-
crease cell adherence and block cell migration but that 
the peptide was able to bind DLC1. DLC1 is thus a direct 
target of the peptide. 
We can thus now search for small molecules that are able 
to bind DLC1, as the peptide does, and determine 
whether these molecules have anti-metastatic activities. 
If they do not induce too strong side effects, these com-
pounds could be used in patients to diminish the risk of 
metastasis formation after the primary tumour is treated 
by surgery, chemotherapy or radiotherapy, for example.
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Wymann Matthias P. | Identification and modulation 
of targets to reprogramme glioblastoma cancer stem 
cells (KFS 2680-08-2010)
Glioblastoma multiforme (GBM) is a very aggressive brain 
tumour. A signalling pathway connecting a lipid kinase 
(phosphoinositide 3-kinase (PI3K)) to a nutrient sensor 
complex (target of rapamycin, mTOR) constitutes a 
central piece of GBM aetiology. Up to now, little is known 
regarding relevant signalling downstream of PI3K. 
Exploring structural determinants of putative phosphoi-
nositide-interacting proteins, we assembled pathway 
modules to be targeted in GBM.
We developed enrichment protocols for GBM-derived 
cancer stem cells (GBM CSCs). Monitoring phenotypic 
outputs of pharmacologically and genetically modulated 
PI3K-dependent pathways revealed two interdependent 
protein kinases that are key to GBM proliferation. Inhibi-
tion of these protein kinases drives GBM cells towards 
differentiation and cell death. Mechanistic studies and 
Fotogramm / Drei Kreise, 2013
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first small molecules with a “proof-of-concept” status in-
dicate that the knowledge gained should be further pur-
sued with the aim to develop novel treatment strategies 
for this devastating disease.
Project coordinator
Prof. Dr. Matthias P. Wymann
Institut für Biochemie und Genetik
Departement Biomedizin
Universität Basel
CH-4058 Basel
matthias.wymann@unibas.ch
Zavolan Mihaela | Identification of cancer-related  
targets of individual members of the miR-17-92 cluster 
of miRNAs (KFS 2477-08-2009)
MicroRNAs (miRNAs) are small (22 nucleotides long) 
RNA molecules that form complexes with the Argonaute 
proteins, guiding these proteins to protein-coding tran-
scripts to induce their degradation and to repress the pro-
duction of proteins. MiRNAs are thereby involved in 
many important cellular processes such as cell division, 
viability, differentiation and self-induced death. Aberrant 
expression of individual miRNAs leads to various dis-
eases, including cancers, in which miRNAs play either a 
facilitating role (oncogenic miRNAs or oncomirs) or an in-
hibitory role (tumour suppressor miRNAs). Among the 
oncogenic miRNAs, one of the most studied is the cluster 
of miR-17-92 miRNAs, which are encoded in a single 
gene, from which six individual miRNAs are processed. 
The protein-coding targets and thereby functions of the 
individual miRNAs in the cluster are not well understood.
In this study we employed high-throughput experiments 
with computational modelling and biochemical follow-up 
studies to determine the targets of individual miR-17-92 
cluster members. An important part of our study con-
sisted in the development of the experimental methods 
that allow us to isolate binding sites of miRNAs with very 
high resolution, from minimally manipulated cells. These 
methods consist in the crosslinking of proteins to RNAs 
with ultraviolet light in living cells, followed by the isola-
tion of the Argonaute protein together with the associ-
ated RNAs, and sequencing of the Argonaute-bound 
RNA fragments that represent the miRNA binding sites. 
Analysis of these data revealed that although individual 
miRNAs do not concertedly act on their targets, they tar-
get functionally related genes and pathways.
Among the top targets that we identified with our meth-
ods is the important tumour suppressor PTEN, which is 
targeted by the miR-19a miRNA, factors that are involved 
in cell division and death, such as the cyclin D2 and the 
transcription factor E2F1, which are controlled by miR-17, 
Aurora kinase-A and the MDM2 ubiquitin ligase that are 
regulated by miR-19a, and components of the miRNA 
pathway itself, particularly the miRNA-processing en-
zyme DICER1 and the Argonaute-associated factor 
TNRC6b, which are controlled by miR-18. Although the 
responses of these complex networks to perturbations 
are difficult to predict, we expect that the targets that we 
found to be bound by miR-17-92 cluster miRNAs in vivo 
will lead to a better understanding of the oncogenic role 
of this miRNA cluster.
Project coordinator
Prof. Dr. Mihaela Zavolan
Departement Biozentrum
Universität Basel
CH-4056 Basel
mihaela.zavolan@unibas.ch
Further completed research projects in 2013
Dufour Jean-François | KFS 2541-02-2010 | CHF 202,200.–
Universitätsklinik für Viszerale Chirurgie und Medizin, Universität Bern, Bern
Hepatocarcinogenic roles of mTOR, raptor and rapamycins in absence of Pten
Krek Wilhelm | KFS 2690-08-2010 | CHF 226,000.–
Institut für Zellbiologie, ETH Zürich, Zürich
Roles of the URI oncoprotein in B-RAF signalling and melanoma cancer cell proliferation
Petrova Tatiana | KLS 2570-02-2010 | CHF 198,300.–
Centre pluridisciplinaire d’oncologie (CePO), Centre hospitalier universitaire vaudois (CHUV)
et Université de Lausanne, Epalinges 
Lymphatic endothelial calcineurin/NFAT signalling in tumour lymphangiogenesis and metastasis
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Basic biomedical research
List of approved research projects in 2013
Total funds allocated: CHF 5,624,000.–
Affolter Markus | KLS 3177-02-2013 | CHF 111,800.–
Departement Biozentrum, Universität Basel, Basel
Cellular analysis of tumour neoangiogenesis in the zebrafish embryo
Auwerx Johan | KFS 3082-02-2013 | CHF 203,300.–
Laboratory of Integrative and Systems Physiology, EPF de Lausanne, Lausanne
The role of the sirtuin ageing proteins on the development of colorectal cancer
Bachmann Martin | KFS 3111-02-2013 | CHF 239,800.–
Dermatologische Klinik, Universitätsspital Zürich, Zürich
Bispecific anti-tumour antibodies: combining tumour-specificity with cytokine agonism
Caflisch Amedeo | KFS 3098-02-2013 | CHF 249,900.–
Biochemisches Institut, Universität Zürich, Zürich
Development of ATAD2 bromodomain inhibitors to fight breast and lung cancer
Carbone Giuseppina | KFS 3243-08-2013 | CHF 241,800.–
Laboratorio di oncologia sperimentale, Istituto oncologico della Svizzera italiana (IOSI), Bellinzona
Deregulated ETS transcriptional network and clinical implications for prostate cancer progression
Cejka Petr | KFS 3089-02-2013 | CHF 249,600.–
Institut für Molekulare Krebsforschung, Universität Zürich, Zürich
Maintenance of genome stability by hDNA2 in complex with BLM or WRN proteins
Clavien Pierre-Alain | KFS 3262-08-2013 | CHF 144,400.–
Klinik für Viszeral- und Transplantationschirurgie, Universitätsspital Zürich, Zürich
lnositol tris-pyrophosphate (ITPP) and its anti-hypoxic potential in colorectal metastases of the liver
Dormond Olivier | KFS 3128-02-2013 | CHF 227,600.–
Service de chirurgie viscérale, Centre hospitalier universitaire vaudois (CHUV), Lausanne
Mechanisms of acquired resistance of cancer cells to PI3K inhibition
Fajas Lluis | KFS 3236-08-2013 | CHF 210,600.–
Département de physiologie, Université de Lausanne, Lausanne
Cancer-induced metabolic changes in the host organism: beyond the Warburg effect
Foti Michelangelo | KFS 3246-08-2013 | CHF 209,300.–
Département de physiologie cellulaire et métabolisme, Université de Genève, Genève
Role of miR-22 in hepatocellular carcinoma
Gilliet Michel | KLS 3161-02-2013 | CHF 221,300.–
Service de dermatologie et vénéréologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne
Targeting intracellular nucleic acid receptors for melanoma immunotherapy
Hall Jonathan | KFS 3293-08-2013 | CHF 229,500.–
Institut für Pharmazeutische Wissenschaften, ETH Zürich, Zürich
Targeting the Lin28/pre-let-7 interaction in cancer
Hantschel Oliver | KLS 3132-02-2013 | CHF 225,400.–
Institut suisse de recherche expérimentale sur le cancer (ISREC), EPF de Lausanne, Lausanne
Identification and targeting of allosteric regulatory sites in oncogenic cytoplasmic tyrosine kinases
Huelsken Joerg | KFS 3135-02-2013 | CHF 229,800.–
Institut suisse de recherche expérimentale sur le cancer (ISREC), EPF de Lausanne, Lausanne
Immunotherapy against cancer stem cells
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Lefort Karine | KFS 3301-08-2013 | CHF 197,500.–
Département de biochimie, Université de Lausanne, Epalinges
Notch signalling in lung squamous cell carcinoma
Levesque Mitchell | KLS 3151-02-2013 | CHF 201,900.–
Dermatologische Klinik, Universitätsspital Zürich, Zürich
Functional genomics of melanoma heterogeneity and invasion
Michielin Olivier | KFS 3180-02-2013 | CHF 236,700.–
Service d'oncologie médicale, Centre hospitalier universitaire vaudois (CHUV), Lausanne
Adoptive cell transfer for stage IV melanoma using rationally designed TCR
Müller Antonia | KFS 3183-02-2013 | CHF 201,900.–
Klinik für Hämatologie, Universitätsspital Zürich, Zürich
Improving graft-versus-tumour effects by donor vaccination with WT1-peptide and transplantation  
of tailored haematopoietic grafts
Münz Christian | KFS 3234-08-2013 | CHF 214,000.–
Institut für Experimentelle Immunologie, Universität Zürich, Zürich
Collaboration of Epstein Barr virus and Kaposi sarcoma-associated herpes virus during lymphomagenesis
Schäfer Beat W. | KFS 3238-08-2013 | CHF 229,500.–
Abteilung Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Novel in vivo models of rhabdomyosarcoma tumourigenesis
Swartz Melody | KFS 3312-08-2013 | CHF 247,400.–
Institut interfacultaire de bioingénierie, EPF de Lausanne, Lausanne
Targeting tumour-associated lymphatics for cancer immunotherapy
Thome-Miazza Margot | KFS 3265-08-2013 | CHF 216,900.–
Département de biochimie, Université de Lausanne, Epalinges
Identification of a ubiquitin ligase driving lymphomagenesis
Tritschler Isabel | KFS 3305-08-2013 | CHF 246,600.–
Klinik für Neurologie, Universitätsspital Zürich, Zürich
TGF-  family members and proprotein convertases: potential therapeutic targets in glioblastoma?
van den Broek Maries | KFS 3233-08-2013 | CHF 214,000.–
Institut für Experimentelle Immunologie, Universität Zürich, Zürich
The role of immune defense and platelets in the development of spontaneous metastases
Weller Michael | KLS 3110-02-2013 | CHF 223,700.–
Klinik für Neurologie, Universitätsspital Zürich, Zürich 
CD317 immunotoxin therapy for glioblastoma
Zaugg Kathrin | KLS 2901-02-2012 | CHF 199,800.–
Universitätsklinik für Radio-Onkologie, Inselspital, Universitätsspital Bern
Dose-rate effect of novel radiation technologies: relevance for the clinical use
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Approved bursaries in 2013
Total funds allocated: CHF 685,000.–
Bonalli Mario | MD PhD 3237-06-2013 | CHF 145,000.–
Isolation and characterization of novel transcription factors involved in neural crest  
stem cell maintenance and melanoma formation
Destination: Anatomisches Institut, Universität Zürich, Zürich
Bührer Elias | MD PhD 3238-06-2013 | CHF 180,000.–
The role of CD27 signalling in acute myeloid leukaemia
Destination: Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsspital Bern, Bern
Jauch Annaïse | MD PhD 3239-06-2013 | CHF 180,000.–
The role of TSLP mediated inflammation in melanoma development and progression
Destination: Institut suisse de recherche expérimentale sur le cancer (ISREC), EPF de Lausanne, Lausanne
Waeber Sabine | MD PhD 3240-06-2013 | CHF 180,000.–
The role of inflammation in cancer progression: contribution of myeloid-derived suppressor  
cells (MDSC) and the pro inflammatory cytokines IL-1β and IL-18
Destination: Institut universitaire de pathologie de Lausanne (IUP), Centre hospitalier universitaire  
vaudois (CHUV), Lausanne
Basic biomedical research
Presentation of approved research projects in 2013
Affolter Markus | Cellular analysis of tumour  
neoangiogenesis in the zebrafish embryo  
(KLS 3177-02-2013)
Duration: 01. 04. 2013 – 31. 03. 2014
The connection between tumour growth and tumour ne-
oangiogenesis has been a long-standing interest in basic 
angiogenesis research and for applied cancer treatment. 
One therapeutic approach that has emerged recently is 
founded on the observation that tumour vessels are often 
disorganized and do not support efficient blood flow, 
thus causing a chronic hypoxic condition within tumours. 
This hypoxia promotes metastatic behaviour of tumour 
cells, which is further aided by the fact that tumour blood 
vessels are often leaky and thus facilitate tumour cell ex-
travasation. 
These observations have led to the proposition that tu-
mour metastasis may be effectively suppressed and the 
efficacy of chemotherapy increased by normalizing the 
tumour vasculature. Despite the enormous efforts put 
into angiogenesis research, it has remained difficult to 
characterize the cellular events underlying angiogenesis. 
This is due to the fact that live imaging approaches have 
thus far not been possible to develop in mice. More re-
cently, the zebrafish has been used to study angiogenesis 
and tumour development using live imaging. 
We will use our expertise on live imaging of angiogenesis 
processes in the zebrafish in order to better characterize 
the process of tumour neoangiogenesis. We will charac-
terize in detail the cellular activities (cell migration, cell 
polarization, lumen formation, cell rearrangements) dur-
ing neoangiogenesis and compare them to developmental 
angiogenesis processes. Using chemical and genetic ma-
nipulations, we will investigate whether any abnormalities 
in tumour vessels might be reverted or enhanced. These 
studies should produce better insights into tumour neoan-
giogenesis at the cellular and molecular level.
Project coordinator
Prof. Dr. Markus Affolter
Departement Biozentrum
Universität Basel
CH-4056 Basel
markus.affolter@unibas.ch
Auwerx Johan | The role of the sirtuin ageing proteins 
on the development of colorectal cancer  
(KFS 3082-02-2013)
Duration: 01. 01. 2014 – 31. 12. 2016
Colorectal cancer is the consequence of an interaction be-
tween genetic predisposition and environmental factors, 
which include in particular age, diet and chronic inflam-
mation. Sirtuins are a group of enzymes that are extremely 
well conserved in the animal kingdom. In mammals, the 
sirtuin protein family is composed of seven related pro-
teins, SIRT1 to SIRT7. Although similar in structure and 
activity, these different sirtuin proteins are present in dis-
tinct tissues and in different cell compartment (nucleus or 
cytoplasm).
We propose here to identify the impact of SIRT1, 6 and 7 
(named SirtX below), which are the three sirtuins that are 
present in the cell nucleus, on colitis-associated colorec-
tal cancer (CAC) using a multifaceted strategy using ge-
netically engineered mouse models in which the Sirtuin 
genes are deleted specifically in the intestine (SirtXint-/-). 
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Our strategy is based on achieving the following three 
specific aims: (1) generation and global characterization 
of intestinal-specific SirtXint-/- deficient mice, (2) determi-
nation of the role of intestinal specific SirtX gene deletion 
in the onset of CAC, and (3) characterization of SirtX-
driven pathways involved in CAC development. Since the 
activity of the sirtuins proteins can be easily modified by 
small molecules (such as a number of drugs), the eventual 
confirmation of the relevance of nuclear sirtuins in colitis-
associated colorectal cancer will lay the foundations for 
future new treatments for this disease.
Project coordinator
Prof. Dr med. et Dr phil. Johan Auwerx
Laboratory of Integrative and Systems Physiology
EPF de Lausanne
CH-1015 Lausanne
johan.auwerx@epfl.ch
Bachmann Martin | Bispecific anti-tumour antibodies: 
combining tumour-specificity with cytokine agonism 
(KFS 3111-02-2013)
Duration: 01. 07. 2013 – 30. 06. 2016
The immune system has the capacity to fight cancer, and 
strong local immune responses may result in shrinkage 
or even elimination of tumours. Such inflammation is 
mediated by cytokines. By targeting pro-inflammatory 
cytokines to a tumour, it may be possible to harness the 
immune system for treatment of cancer. Here we will 
develop novel molecules in the mouse that allow the tar-
geting of pro-inflammatory cytokines into tumours and 
testing of their anti-tumour activity in murine models of 
cancer. If successful, similar biologics will be developed 
for use in humans.
Project coordinator
Prof. Dr. Martin Bachmann
Dermatologische Klinik
Universitätsspital Zürich
CH-8091 Zürich
martin.bachmann@usz.ch
Caflisch Amedeo | Development of ATAD2 bromodo-
main inhibitors to fight breast and lung cancer  
(KFS 3098-02-2013)
Duration: 01. 04. 2013 – 31. 03. 2016
Epigenetic proteins, influencing which genes are ex-
pressed, represent a promising and new area of research 
for targeted cancer therapeutics. The ATAD2 protein is 
one such target that is highly expressed in several types of 
solid tumours, and its overexpression is correlated with 
rapid mortality in breast and lung cancer. We will identify 
and validate small molecules that selectively inhibit the 
binding of the bromodomain region of ATAD2 to histone 
proteins around which DNA is wound, through a multidis-
ciplinary approach. 
Our strategy involves: (1) computational simulations to 
characterize regions of ATAD2 forming selective interac-
tions with identified small molecules (Amedeo Caflisch), 
and (2) synthesis and medicinal chemistry-optimization 
of promising compounds to improve their potency, selec-
tivity and pharmaceutical properties (Cristina Nevado, 
Department of Chemistry, University of Zurich). The re-
sulting collection of inhibitors will be tested on several 
tumour cell lines to shed light on the role of ATAD2 in 
cancer. Promising compounds will be further developed 
and tested on mice models in view of their human appli-
cation.
Project coordinator
Prof. Dr Amedeo Caflisch
Biochemisches Institut
Universität Zürich
CH-8057 Zürich
caflisch@bioc.uzh.ch
Carbone Giuseppina | Deregulated ETS transcriptional 
network and clinical implications for prostate cancer 
progression (KFS 3243-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Prostate cancer is the most common cancer in men and a 
leading cause of cancer death in developed countries. 
Prostate cancer has very heterogeneous clinical behav-
iour, ranging from indolent to aggressive forms. Once the 
disease progresses, there are limited treatment options. 
Thus, an important issue is to identify the factors that 
determine tumour behaviour and find more specific treat-
ment strategies for the different tumour subtypes. Our 
data indicate that deregulated expression of ETS tran-
scription factors plays important role in disease progres-
sion and tumour heterogeneity. 
The overall goal of this study is to apply novel strategies 
for molecular classification of prostate tumours and to 
further understand the biology of prostate cancer. To 
reach these goals we will combine novel bioinformatic 
approaches using multiple datasets from primary and 
metastatic prostate tumours with functional experiments 
in cell lines in vitro and in vivo. We plan to evaluate crit-
ical pathways in tumours with altered ETS expression, 
with particular emphasis on alterations of epigenetic 
effectors to understand the mechanisms of their deregu-
lation and their influence on disease progression. This 
knowledge will represent an important step towards 
understanding the molecular and clinical heterogeneity 
of prostate tumours and will open new avenues for 
assessment of the prognosis and application of context-
dependent therapeutic strategies.
Project coordinator
Dr Giuseppina Carbone
Laboratorio di oncologia sperimentale 
Istituto oncologico della Svizzera italiana (IOSI)
CH-6500 Bellinzona
giuseppina.carbone@ior.iosi.ch
Cejka Petr | Maintenance of genome stability by 
hDNA2 in complex with BLM or WRN proteins  
(KFS 3089-02-2013)
Duration: 01. 04. 2014 – 31. 03. 2018
Deoxyribonucleic acid (DNA) stores genetic information 
that is essential for the proper function of all living organ-
isms. The replication and maintenance of DNA integrity 
and the repair of damage in DNA is thus an essential pro-
cess. Defects in these mechanisms may lead to cancer. 
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We are investigating the function of the key DNA repair 
protein DNA2. DNA2 was found to be overexpressed in 
various human cancers, and high expression correlated 
with poor prognosis. However, the exact function of 
DNA2 remains unknown. We are going to identify the 
protein partners of DNA2, which will point towards its 
cellular role. Further, we will determine its biochemical 
activity on a number of model DNA substrates. Finally, 
we will investigate the relationship of DNA2 to BLM and 
WRN proteins. All these factors function in multiple 
complex processes that affect cancerogenesis. Detailed 
understanding of these molecular mechanisms will lay a 
groundwork that will be important for the design of future 
treatment strategies.
Project coordinator
Prof. Dr. Petr Cejka
Institut für Molekulare Krebsforschung
Universität Zürich
CH-8057 Zürich
cejka@imcr.uzh.ch
Clavien Pierre-Alain | lnositol tris-pyrophosphate 
(ITPP) and its anti-hypoxic potential in colorectal  
metastases of the liver (KFS 3262-08-2013)
Duration: 01. 02. 2014 – 31. 01. 2016
Inositol tris-pyrophosphate (ITPP) is an extraordinary drug 
that increases tissue oxygen levels without any toxicity. 
Most solid tumours feature low oxygen levels (hypoxia), 
which are thought to promote tumour aggressiveness and 
spread (i. e. metastasis formation, the primary cause of 
death due to cancer). 
We propose to study the efficacy and working mode of 
ITPP in colorectal (CRC) liver metastases. To do so we 
have established two liver metastasis mouse models and 
a non-invasive method for tumour follow-up. First trials 
have confirmed the antihypoxic action of ITPP that trans-
lates into improved survival of tumour-laden mice. We 
now are analysing tissue to assess the malignant potential 
of ITPP-treated tumours. A specific focus will be on the 
long-term effects of ITPP. 
To estimate how ITPP might perform in patients, we will 
compare the standard treatment for CRC liver metastasis 
(FOLFIRI chemotherapy plus bevacizumab, a tumour ves-
sel inhibitor) with FOLFIRI plus ITPP. Tumour vessels are 
functionally compromised, and their inhibition is sus-
pected to increase the metastatic risk. In contrast, ITPP is 
expected to stabilize tumour vessels and hence to reduce 
this risk. Together with its highly favourable toxicity pro-
file, ITPP has an unmatched anticancer potential that 
needs to be explored.
Project coordinator
Prof. Dr. Pierre-Alain Clavien
Klinik für Viszeral- und Transplantationschirurgie
Universitätsspital Zürich 
CH-8091 Zürich
clavien@access.uzh.ch
Dormond Olivier | Mechanisms of acquired resistance 
of cancer cells to PI3K inhibition (KFS 3128-02-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Targeting oncogenes has been viewed as a promising ap-
proach in cancer therapy. In this context, a protein called 
PI3K is a promising target. Indeed, activating mutations of 
this enzyme are frequent in human cancers, which results 
in tumour growth. For this reason, several PI3K inhibitors 
have been developed and have been tested in clinical 
studies. Overall, the anti-cancer efficacy of PI3K inhibitors 
is modest, suggesting that cancer cells develop resistance 
mechanisms to these inhibitors. It is therefore important 
to identify these mechanisms in order to design new ther-
apies aiming to ameliorate the anticancer efficacy of PI3K 
inhibitors. 
In preliminary studies, we observed that PI3K inhibitors 
block AKT, a downstream effector of PI3K, only tran-
siently. This suggests that cancer cells are able to reacti-
vate AKT signalling in the presence of PI3K inhibitors to 
counteract the anticancer efficacy of these inhibitors. In 
this study, we therefore aim to identify the molecular 
mechanisms that drive AKT activity in the presence of 
PI3K inhibitors. Using different approaches, we wish to 
identify at the molecular level the mechanisms that reac-
tivate AKT following PI3K inhibition. Once these mecha-
nisms are identified, we plan to design therapeutic strate-
gies combining PI3K inhibitors with inhibitors that block 
AKT reactivation. These strategies will then be tested in 
various models both in vitro and in vivo.
Project coordinator
Dr Olivier Dormond
Service de chirurgie viscérale
Centre hospitalier universitaire vaudois (CHUV)
CH-1011 Lausanne
olivier.dormond@chuv.ch
Fajas Lluis | Cancer-induced metabolic changes in the 
host organism: beyond the Warburg effect  
(KFS 3236-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
It has long been known that the metabolism of cancer cells 
is very different from normal cells. This project focuses 
mainly on lipid metabolism. Lipids (fat) are among the most 
important molecules in the cell. This is especially important 
as a cell becomes cancerous. Indeed, cancer cells produce 
their own lipids. This is called “de novo synthesis”. In this 
research project we aim to find out how cancer cells trigger 
this process of production of lipids. The second important 
objective of the project is to understand how our bodies 
adapt to cancer growth. Cancers take over the control of 
our whole body metabolism to create the best conditions 
for growth. Our studies will identify new targets involved 
in the metabolism of cancer cells.
Project coordinator
Prof. Dr Lluis Fajas
Département de physiologie
Université de Lausanne 
CH-1005 Lausanne
lluis.fajas@unil.ch
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Foti Michelangelo | Role of miR-22 in hepatocellular 
carcinoma (KFS 3246-08-2013)
Duration: 01. 04 .2014 – 30. 03. 2016
Hepatocellular carcinoma (HCC) is a frequent cancer and 
the third cause of cancer-related death in the world. HCC 
develops in the setting of various liver diseases, including 
viral infections, alcohol consumption, obesity and diabe-
tes. Given the worldwide rise in obesity and diabetes, in-
cidence of HCC is expected to dramatically increase in the 
future. HCC is a cancer with a very poor prognosis, and 
surgical resection or liver transplantation are the only 
treatments with (poor) curative potential. However, criti-
cal issues are associated with these therapies, and it is 
necessary and urgent to explore other ways to treat HCC. 
Recently, numerous studies have demonstrated the role of 
microRNAs in cancer. In particular, an aberrant expression 
of a specific microRNA, the miR-22, is associated with sev-
eral common and deadly human cancers (e. g. breast, 
lung, colorectal, pancreas and prostate) including HCC. 
These recent observations suggest that miR-22 likely plays 
an important role in cancer development. However, direct 
in vivo evidence establishing the importance and role of 
miR-22 in carcinogenesis is lacking. The goal of this pro-
ject is to investigate in vitro and in vivo in mice, the role 
of miR-22 in liver carcinogenesis, with or without obesity 
as an additional risk factor. The potential therapeutic ben-
efits of pharmacological miR-22 agonists on HCC will also 
be investigated. 
Our experimental approach will integrate different mice 
models of HCC, in which miR-22 expression is genetically 
altered, or modulated by pharmacological treatments with 
miR-22 agonists. This will allow us not only to understand 
the role of miR-22 in liver cancer but also to envisage in 
the mid-term new therapeutic perspectives for HCC. In 
addition, these studies will likely provide important in-
sights, new knowledge and concepts to understand and 
fight cancer in general.
Project coordinator
Prof. Dr Michelangelo Foti
Département de physiologie cellulaire et  
métabolisme
Université de Genève
CH-1206 Genève
michelangelo.foti@unige.ch
Gilliet Michel | Targeting intracellular nucleic acid  
receptors for melanoma immunotherapy  
(KLS 3161-02-2013)
Duration: 01. 08. 2013 – 31. 07. 2015
Treatment opportunities for metastatic melanoma remain 
poor, since chemotherapy and irradiation are of limited 
efficacy. Melanoma is a potentially immunogenic tumour, 
and immunotherapy seems to be a promising therapeutic 
strategy. However, the discovery of potent adjuvants is 
urgently needed. Studies of antiviral immunity have 
taught us that strong innate immune activation is pivotal 
for the induction of adaptive immune response mediated 
by T-lymphocytes and B-lymphocytes. 
In this study, we generalize principles learned from suc-
cessful antiviral vaccination to generate anti-tumour im-
munity with viral-like stimuli. Our hypothesis is that the 
targeting of intracellular nucleic acid receptors (important 
players in antiviral immunity) leads to the establishment 
of an anti-tumour immune response in a mouse model of 
melanoma. Our first aim is to improve efficacy of nucleic 
acid sequences with known anti-tumoural activity. We 
also want to investigate the capacity of signalling path-
ways described recently in antiviral immunity but not yet 
exploited in cancer immunotherapy. Lastly, we aim to un-
cover new molecules targeting intracellular nucleic acid 
sensors with efficient anti-tumoural activity. Thus, this 
research study will uncover new strategies to improve 
immunotherapy for metastatic melanoma or other pa-
tients with advanced-stage cancer.
Project coordinator
Prof. Dr Michel Gilliet
Service de dermatologie et vénéréologie
Centre hospitalier universitaire vaudois (CHUV)
CH-1011 Lausanne
michel.gilliet@chuv.ch
Hall Jonathan | Targeting the Lin28/pre-let-7 interac-
tion in cancer (KFS 3293-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
This project is a direct follow-on from the project Target-
ing pre-let-7 biogenesis in cancer (KFS 2648-08-2010). 
As described previously, many human cancers exhibit a 
dysregulation of microRNA expression in which they are 
non-functional or overexpressed. A prominent example is 
the let-7 family in which let-7 prevents normal cells from 
becoming tumourigenic. In several cancers levels of let-7 
are very low. This is due to the RNA-binding protein Lin28, 
which binds to the precursor of let-7 preventing its correct 
processing. New studies have shown also that the Lin28/
let-7 plays an important role in maintenance of cancer 
stem cells. 
We synthesized short antisense oligonucleotides that bind 
to the let-7 precursor and protect it from degradation by 
Lin28. This leads to increased levels of let-7 in cells and 
inhibition of cancer cell growth. One goal of this study is 
to improve the properties of the antisense oligonucleo-
tides through chemical modification. This should lead to 
a stronger effect on the precursor and will be examined in 
mouse cancer models. The results of the study will provide 
new insights into the mechanisms of anti-microRNA anti-
sense oligonucleotides in living models of cancer. 
Project coordinator
Prof. Dr. Jonathan Hall
Institut für Pharmazeutische Wissenschaften
ETH Zürich
CH-8093 Zürich
jonathan.hall@pharma.ethz.ch
Hantschel Oliver | Identification and targeting of  
allosteric regulatory sites in oncogenic cytoplasmic  
tyrosine kinases (KLS 3132-02-2013)
Duration: 01. 11. 2013 – 31. 10. 2015
An important protein class with cancer-causing properties 
are protein kinases, which act as molecular switches and 
are normally in the off-position in normal cells. In con-
trast, kinases are always in the on-position in cancer cells. 
Since 2001, 22 new drugs have been discovered that are 
able to block the on-position of particular kinases and 
confine the growth of tumours. Unfortunately, patients 
with cancer often only benefit from these new drugs for 
a short time, as changes in the molecular structure of the 
kinase prevents effective action of the drug. 
In this research project, we will attempt to understand al-
ternative mechanisms by which kinases can be turned on, 
and to target them. To understand the underlying molec-
ular mechanisms, we are preparing purified proteins to 
analyse their biochemical properties. In addition, cancer 
cells will be used to compare the normal kinase with vari-
ants that are impaired in these regulatory mechanisms for 
their ability to influence cell growth. Finally, we plan to 
identify molecules that bind the regulatory control site in 
one particular kinase that causes leukaemia. Altogether, 
this project can lead to the identification of additional 
ways in which tumour cells can be attacked, with the hope 
that these new insights can be translated into useful ther-
apies for patients with cancer.
Project coordinator
Prof. Dr. Joerg Huelsken
Institut suisse de recherche expérimentale  
sur le cancer (ISREC)
EPF de Lausanne
CH-1015 Lausanne
joerg.huelsken@epfl.ch
Fotogramm / Haselnuss, 2013
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Huelsken Joerg | Immunotherapy against cancer  
stem cells (KFS 3135-02-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
One adverse characteristic of cancer is that tumours es-
cape the control of the immune system. The concept of 
adoptive immunotherapy is focused on re-arming the im-
mune system against cancer cells by using the patient’s 
own T-cells. These cells are redirected against a new tar-
get and amplified in a laboratory setting before they are 
given back to the patient. This involves equipping the 
T-cells with a new kind of molecule (called the CAR con-
struct), which combines the high specificity of an anti-
body together with the strong effector signals of the 
T-cell itself. With this molecule the T-cell can now escape 
suppressive mechanisms in the tumour and can again 
attack the cancer cells. When using this approach it is 
necessary to be as precise as possible to avoid unwanted 
side effects. 
Our research is focused on targeting a specific tumour cell 
population that is mainly responsible for the outgrowth 
and spread of the cancer: cancer stem cells (CSCs). We will 
target these important cancer cells by novel CAR designs 
that allow us to specifically recognize these cells, generate 
a durable immune attack, and thereby prevent cancer pro-
gression and metastasis.
Project coordinator
Dr Karine Lefort
Département de biochimie 
Université de Lausanne 
CH-1066 Epalinges
karine.lefort@unil.ch
Lefort Karine | Notch signalling in lung squamous cell 
carcinoma (KFS 3301-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Lung cancer is the main cause of death by cancer. Squa-
mous cell carcinomas (SCCs) of the lung account for 30 % 
of lung cancer. Compared to lung adenocarcinoma, the 
main histological subtype, lung SCC is less well under-
stood and has far fewer treatment options. The epidemi-
ology of lung SCC is different from that of adenocarci-
noma. A distinguishing feature of these tumours is their 
elevated degree of heterogeneity and differentiation, 
which may explain their resilience to conventional and 
novel targeted therapy. Conventional chemotherapy re-
mains the cornerstone of SCC treatment, and there is an 
urgent need for improvement of treatment of this disease, 
which has a median overall survival of less than 1 year in 
metastatic patients.
Our study will assess the therapeutic potential of induc-
tion of squamous cell differentiation as a way to counter-
act the consequences of pro-oncogenic events linked with 
lung SCC development. To this purpose, we will use hu- 
man normal epithelial bronchial cells as well as lung SCC 
cell lines to test whether activation of the Notch signalling 
pathway is required and sufficient to induce squamous 
differentiation of these cells and causes reversion of lung 
SCC cells to a more differentiated and less malignant phe- 
notype. Finally, we will assess whether the pro-differenti-
ation function of Notch signalling in lung epithelial cells 
is mediating or controlled by a network of squamous dif-
ferentiation-associated genes that are commonly mutated 
in SCCs.
Project coordinator
Dr Karine Lefort
Département de biochimie 
Université de Lausanne 
CH-1066 Epalinges
karine.lefort@unil.ch
Levesque Mitchell | Functional genomics of melanoma 
heterogeneity and invasion (KLS 3151-02-2013)
Duration: 01. 05. 2013 – 30. 04. 2016
By combining studies on human melanoma biopsies from 
the Zurich University Hospital biobank with an in vivo ze-
brafish melanoma invasion assay, we intend to identify 
and characterize the function of a core set of develop-
mental genes that also enable metastasizing cancer cells 
to colonize new tissues during melanoma progression. 
Since metastasis is a highly dynamic process that occurs in 
a three-dimensional physiological space, the ability to 
switch between our in vitro melanoma assays and in vivo 
embryonic invasion assays will allow us to more effec-
tively investigate this process of cell invasion in both de-
velopmental and pathological contexts.
Our work will therefore take two directions. First, to 
identify genes that have a role in both developmental and 
pathogenic cell invasion, we will test in human cancer 
cells the homologs of genes associated with zebrafish 
neural crest invasion. Second, we will use zebrafish larvae 
as an in vivo xenograph invasion assay to test the neces-
sity and sufficiency of these genes to facilitate melanoma 
invasion. 
Project coordinator
Dr. Mitchell Levesque
Dermatologische Klinik
Universitätsspital Zürich
CH-8091 Zürich
mitchellpaul.levesque@usz.ch
Michielin Olivier | Adoptive cell transfer for stage IV 
melanoma using rationally designed TCR  
(KFS 3180-02-2013)
Duration: 01. 05. 2013 – 30. 04. 2015
Adoptive cell transfer immunotherapy against cancer 
relies on the ability of immune system killer T-cells to rec-
ognize and specifically destroy cancer cells. This recogni-
tion is carried out by a receptor called TCR, which binds 
specifically at the surface of cancer cells, starting a cas-
cade of biochemical events that will eventually destroy 
these cells. Adoptive cell transfer immunotherapy consists 
in extracting from the patient killer cells that are 
specific for the disease, expanding them ex vivo, and 
re-injecting them in the patient to create an efficient 
immune response against the tumour. 
The goal of this project is to optimize TCRs binding specif-
ically to melanoma cancer cells using rational protein en-
gineering, to increase their binding affinity for tumour 
cells and thus their killing capabilities. The TCR that has 
been selected for this study belongs to the repertoire 
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targeting the NY-ESO-1 antigen, which is among the most 
specific cancer-testis antigens. NY-ESO-1 is of utmost im-
portance in melanoma immunity. Patients who express 
NY-ESO-1 show a better response to treatment by the 
monoclonal antibody ipilimumab. 
We have developed a new method based on binding free 
energy calculations that enables us to rationally modify 
the sequence of a TCR targeting NY-ESO-1. We have ob-
tained a 150-fold increase in TCR potency for the binding 
to melanoma cancer cells. Engineering in vitro the patient 
T-cells to express these modified TCRs, we have been able 
to dramatically increase the immune response against 
melanoma cells. Based on these in vitro results, we are 
currently starting an in vivo test on a mouse model that 
will pave the way to a human clinical trial planned for 
2016.
Project coordinator
Prof. Dr Olivier Michielin
Service d’oncologie médicale 
Centre hospitalier universitaire vaudois (CHUV)
CH-1011 Lausanne
olivier.michielin@unil.ch
Müller Antonia | Improving graft-versus-tumour  
effects by donor vaccination with WT1-peptide and 
transplantation of tailored haematopoietic grafts  
(KFS 3183-02-2013)
Duration: 01. 05. 2013 – 30. 04. 2016
Blood or marrow transplantation (BMT) is the only cura-
tive therapy for many patients with blood cancers. The 
host’s blood system, including tumour cells, is eradicated 
by radio-/chemotherapy, and donor grafts containing 
blood stem cells and immune cells are infused. Donor im-
mune cells recognize the patient’s tumour cells as foreign, 
which is called ”graft-versus-tumour” reactivity, and are 
thus critical for durable tumour eradication. But they also 
attack healthy host tissues; this is a potentially detrimental 
clinical condition called ”graft-versus-host-disease” that 
kills 15–20 % of all BMT-recipients. Novel therapeutic 
strategies with both enhanced efficacy and better tolera-
bility are urgently warranted.
Here, we propose to improve BMT by combining the cel-
lular therapy with vaccination against the tumour. To 
obtain enhanced anti-tumour immunity, donors will be 
vaccinated against the recipient’s tumour. These tumour-
specific immune cells will be isolated and transplanted, to-
gether with blood stem cells, into tumour-bearing recipi-
ents. Blood stem cells sustain healthy blood production 
while the selected tumour-specific immune cells can ex-
pand in the recipient, attacking tumour cells only, and 
unspecific tissue damage can be avoided – as no other im-
mune cells are transferred. A combined approach that 
generates potent immune populations in the donor that 
after transplantation exclusively target recipient’s tumour 
cells without damaging healthy tissues would be a major 
advancement in the battle against cancer.
Project coordinator
Dr. med. Antonia Müller
Klinik für Hämatologie
Universitätsspital Zürich
CH-8091 Zürich
antoniamaria.mueller@usz.ch
Münz Christian | Collaboration of Epstein Barr virus 
and Kaposi sarcoma-associated herpes virus during 
lymphomagenesis (KFS 3234-08-2013)
Duration: 01. 02. 2014 – 31. 01. 2017
One fifth of all tumours in humans are presumably caused 
by infections. In this regard a subgroup of herpes viruses 
features prominently. Epstein Barr virus (EBV) causes 
among others Burkitt’s lymphoma, which is still the most 
common childhood tumour in Sub-Saharan Africa, and 
Kaposi sarcoma-associated herpes virus (KSHV) is associ-
ated with the most common tumour in patients with 
AIDS, Kaposi sarcoma, and certain lymphomas. 
We recently discovered that double-infection with both 
viruses, which occurs in primary effusion lymphoma in 
patients, allows us to establish persistent KSHV infection 
in a mouse model of the human immune system. This first 
small animal model of chronic KSHV infection shows co-
operation of both viruses not only during infection but 
also for tumourigenesis. This model now allows us to study 
the contribution of KSHV in tumour formation and KSHV-
specific immune responses as well as their protective 
value. These investigations should enable us to develop 
new molecular therapy approaches against this human 
tumour virus, and to evaluate vaccination strategies.
Project coordinator
Prof. Dr. rer. nat. Christian Münz
Institut für Experimentelle Immunologie
Universität Zürich 
CH-8057 Zürich
christian.muenz@uzh.ch
Schäfer Beat W. | Novel in vivo models of rhabdomyo-
sarcoma tumourigenesis (KFS 3238-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Sarcomas are rare paediatric cancers that are very ag-
gressive. Treatment in certain subgroups is only effective 
in less than 50 % of cases, thereby highlighting the need 
to develop novel treatment strategies. To learn more 
about the development of this tumour, it is necessary to 
generate models that faithfully mimic human disease. 
Here, we propose to develop two novel models for the 
paediatric tumour alveolar rhabdomyosarcoma (aRMS). 
The first method is based on recently developed tech-
niques that allow reprogramming normal human cells 
such as fibroblasts into pluripotent stem-like cells. We 
now propose to use these techniques to reprogramme hu-
man aRMS cells from patients and thereby turn the wheel 
of tumour development backwards. Reprogrammed cells 
are allowed to progress through tumourigenesis either in 
vitro as organoid cultures or in vivo after subcutaneous 
injection into mice. This makes possible close monitoring 
of tumourigenesis characterization of individual steps on 
the molecular level. The second model is based on recent 
insights obtained from genetic studies of the human dis-
ease. These analyses have highlighted a few crucial ge-
netic alterations. We will introduce these alterations into 
the mouse genome and expect that these mice will then 
develop tumours that are similar to the human disease. 
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These novel mouse models will aid evaluation of novel 
drugs in future preclinical studies. This is especially im-
portant for rare tumours, since too many new drugs are 
available to test them all directly in patients. 
Project coordinator
Prof. Dr. sc. nat. Beat W. Schäfer
Abteilung Onkologie
Kinderspital Zürich
Universitäts-Kinderkliniken
CH-8032 Zürich
beat.schaefer@kispi.uzh.ch
Swartz Melody | Targeting tumour-associated lym-
phatics for cancer immunotherapy (KFS 3312-08-2013)
Duration: 01. 03. 2014 – 28. 02. 2017
Lymph node metastasis of many cancers, including breast 
and cervical cancer, is the leading cause of cancer mortal-
ity. Lymph nodes that contain metastases are typically 
surgically removed, and tumour-associated lymphatic 
vessels have mainly been considered as routes for tumour 
dissemination.
The lymphatics play an important role in guiding immune 
cell homing and may play an active role in defining the im-
mune status of the tumour microenvironment. Lymphat-
ics are therefore an interesting and novel target, not just 
for the prevention of metastasis but also for therapies 
targeting the “re-regulation” of the local immune cell 
population towards an efficient anti-tumour response. We 
hypothesize that tumours can use lymphatic vessels and 
drainage to lymph nodes to reprogramme the immune 
system, promoting immunological tolerance. 
This research study will explore this new hypothesis in 
mouse models of spontaneous breast and cervical cancers. 
Specifically, we will determine how tumour-associated 
lymphatics and their drainage to the lymph node affect 
host immunity to the tumour and explore strategies to 
reverse this immunological tolerance. We believe that this 
research will introduce a new paradigm to our under-
standing of how tumours modulate the host immune sys-
tem, leading to new therapeutic strategies targeting lym-
phatic vessels and tumour-draining lymph nodes for 
helping to drive efficient anti-tumour immune responses.
Project coordinator
Prof. Dr Melody Swartz
Institut interfacultaire de bioingénierie
EPF de Lausanne
CH-1015 Lausanne 
melody.swartz@epfl.ch
Thome-Miazza Margot | Identification of a ubiquitin 
ligase driving lymphomagenesis (KFS 3265-08-2013)
Duration: 01. 05. 2014 – 30. 04. 2017
The proliferation of lymphocytes is normally tightly con-
trolled. Defects in this process can promote an unlimited 
proliferation of lymphocytes, which results in the devel-
opment of leukaemias or lymphomas. Our objective is to 
explore the molecular mechanisms underlying the control 
of lymphocyte proliferation in a particularly aggressive 
form of diffuse large B-cell lymphoma (DLBCL). Our pre-
vious work revealed that the activity of the protease 
MALT1 plays an important role in this type of malignant 
lymphocyte proliferation, in which MALT1 is hyperactive 
because of its modification by an unknown ubiquitin 
ligase. This suggests that the unknown ubiquitin ligase 
responsible for MALT1 ubiquitination could be a good 
drug target for the treatment of such MALT1-dependent 
cancers. 
The goal of this study therefore is to identify the ubiquitin 
ligase responsible for MALT1 activation by a combination 
of biochemical and genetic approaches, and to further 
characterize the relevance of this enzyme for the growth 
of lymphoma cells. We believe that this may pave the way 
for the development of small molecule inhibitors of the 
ubiquitin ligase responsible for MALT1 ubiquitination, 
which could be a rational strategy to treat aggressive 
DLBCL.
Project coordinator
Prof. Dr. Margot Thome-Miazza
Département de biochimie 
Université de Lausanne 
CH-1066 Epalinges
margot.thomemiazza@unil.ch
Tritschler Isabel | TGF-  family members and propro-
tein convertases: potential therapeutic targets in glio-
blastoma? (KFS 3305-08-2013)
Laufzeit: 01. 02. 2014 – 31. 01. 2016
Glioblastoma is the most aggressive subtype of the glio-
mas, a group of intrinsic brain tumours. Glioma cells re-
lease immunosuppressive molecules such as transforming 
growth factor (TGF)- . Moreover, TGF-  promotes inva-
siveness of glioma cells and regulates their stem cell prop-
erties. Although the family of TGF-  family ligands con-
sists of 33 proteins, preclinical and clinical therapeutic 
approaches have focused on TGF- , whereas the role of 
other members of the TGF-  family has remained under-
explored. 
We aim at identifying the role of the respective TGF-  
family proteins as well as the proprotein convertases (PCs) 
that may be responsible for processing the TGF- -related 
proproteins especially in glioma stem cells. The results of 
this work will be fundamental in determining the value of 
the specific inhibition of distinct ligands of the TGF-  su-
perfamily as well as of the use of the appropriate PC inhib-
itors in patients with gliomas.
Project coordinator
Dr. med. et Dr. rer. nat. Isabel Tritschler
Klinik für Neurologie
Universitätsspital Zürich
CH-8091 Zürich
isabel.tritschler@usz.ch
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van den Broek Maries | The role of immune defense 
and platelets in the development of spontaneous  
metastases (KFS 3233-08-2013)
Duration: 01. 04. 2014 – 31. 03. 2017
Tumour-specific immunity occurs in cancer patients and 
tumour-bearing animals, and significantly contributes to 
control of cancer. Metastasis – the major cause of death 
associated with solid tumours – may form even before the 
primary tumour becomes clinically apparent. Such early 
metastases remain in a dormant state for a considerable 
time, which means that the cancer cells hardly divide. 
Therefore, metastases are insensitive to therapies that 
target dividing cells such as radiotherapy or chemother-
apy, whereas they can still be targeted by T-lymphocytes. 
Our first goal is to investigate how tumour-specific im-
munity can be employed to better control metastatic 
lesions.
Two recent studies in humans found that patients with a 
heart condition who were taking aspirin for a very long 
time because of this had a lower risk of dying of cancer. 
Because aspirin affects platelets and platelets promote 
the formation of metastases, our second goal is to inves-
tigate whether the anti-platelet effect of aspirin is re-
sponsible for the protection from lethal cancer. We think 
that our results will provide novel and essential knowl-
edge on the interaction between metastatic tumours and 
the immune system. We expect that this knowledge will 
contribute to developing better immunotherapies that 
are efficacious in controlling metastatic lesions in men.
Project coordinator
Prof. Dr. Maries van den Broek
Institut für Experimentelle Immunologie
Universität Zürich
CH-8057 Zürich
vandenbroek@immunology.uzh.ch
 
Weller Michael |  CD317 immunotoxin therapy for 
glioblastoma (KLS 3110-02-2013)
Duration: 01. 02. 2014 – 31. 01. 2016
Glioblastoma is the most common malignant primary 
brain tumour. Half of the patients die within 10 to 12 
months after start of treatment, despite improved thera-
peutic options including surgery, radiotherapy and temo-
zolomide chemotherapy. Therefore, innovative strategies 
to fight these brain tumours are urgently needed. In an 
attempt to follow the ideas of Paul Ehrlich’s ”magic bul-
let”, we intend to investigate a new therapeutic molecule 
that consists of an antibody fragment coupled to a toxic 
protein. A designer protein-toxin consisting of a single 
chain Fv (scFv) fragment binding to the tumour cell and 
pseudomonas exotoxin A (ETA’) as a toxic moiety will 
be analysed. This conjugate binds to CD317 (HM1.24), 
which is highly expressed on certain tumours including 
glioblastomas. 
In initial cell culture experiments, the HM1.24-ETA' im-
munoconjugate showed promising results. HM1.24-ETA' 
is humanized and therefore should be well tolerated. Af-
ter binding to CD317, this antibody-based toxin will be 
internalized, and the free toxic moiety of ETA’ kills the tu-
mour cell. In addition, interferon- α/ , a cytokine natu-
rally produced in the body, can induce the expression of 
CD317 on the cell surface of glioblastoma cells. 
We will analyse the effect of this immunoconjugate 
HM1.24-ETA’ on brain tumour cells in cell culture. In a 
next step, the effect of HM1.24-ETA’ will be evaluated 
alone or in combination with interferon-  in a brain tu-
mour model in mice. These studies should provide the ba-
sis for an innovative specific immunotoxin therapy in 
combination with interferon-  for glioblastoma patients.
Project coordinator
Prof. Dr. med. Michael Weller
Klinik für Neurologie 
Universitätsspital Zürich 
CH-8091 Zürich
michael.weller@usz.ch
Further approved research project 2013
Zaugg Kathrin | KLS 2901-02-2012 | CHF 199,800.–
Universitätsklinik für Radio-Onkologie, Inselspital, Universitätsspital Bern
Dose-rate effect of novel radiation technologies: relevance for the clinical use 
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Research and development in tumour surgery:  
The importance of team work
Clinical research
Surgery continues to be one of the most important 
pillars of cancer treatment. Of all treatment options 
available today, surgery with a nearly 100 % response 
rate   is by far the most effective method of removing 
a tumour completely.1 Tumour surgery had its renais-
sance in the 1970s and 1980s, when most of the prin-
ciples and techniques were established that are still 
valid today. In recent years we have learned that 
the basis of successful cancer treatment is, for one, 
understanding the tumour biology, and for another, 
combined-modality treatment.
Advances and problems
Surgical treatment of bone or soft tissue tumours, the 
sarcomas, has a model character for tumour surgery. 
Sarcomas are much less common than carcinomas 
(such as breast, prostate or colorectal cancer) and 
represent only about 1 % of all human cancers. 
Sarcomas can form in connective or supportive tissue 
(bone, cartilage and fat) or in muscle tissue. They are 
rare, and in contrast to carcinomas, they grow in a 
centripetal fashion, and there are satellite cells in the 
reactive zone, which is why the entire sarcoma must 
be removed in the first operation. Sarcomas can be 
treated successfully only through the combination of 
surgery, radiation therapy and chemotherapy.
There were enormous advances in sarcoma surgery 
techniques in past decades.2, 3 Today, it is possible to 
avoid amputation of limbs for a majority of patients. 
Despite this fortunate development, we have to re-
port that in the last 15 years, the advances in surgi-
cal techniques have become increasingly smaller, and 
we are still struggling with the same problems and 
complications, which include infections, prosthetic 
stem loosening, and loss of function. In parallel, the 
survival rates of patients with sarcomas have re-
mained constant. Too many patients with sarcomas 
die because we cannot remove the primary tumour 
completely or because metastases have developed.4 
Prof. Bruno Fuchs, MD, PhD
Director of the Sarcoma Center UZH, Balgrist University Clinic, University of Zurich
Fotogramm / Mehrfachbelichtung eines Lochs, 2011
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Patient benefit as the goal
The main goal of tumour surgery is local removal of 
the primary tumour with as few negative functional 
consequences as possible for the patient. But the de-
velopment of metastases and the spread of cancer 
cells in the body cannot be prevented primarily by 
the scalpel. Despite the treatment options available 
today, approximately 30 % to 40 % of patients with 
sarcomas die. To improve patient survival rates it is 
imperative that we also take the biology of the tu-
mour into account. Through further innovations in 
tumour surgery alone we can at best maintain cur-
rent success rates.
Combined-modality treatment as the recipe  
for success
Before the principles of modern tumour surgery were 
established, soft tissue sarcomas, for example, were 
either removed or radiated. This concept was then 
replaced more and more by a combination of the two 
treatment methods. Radiotherapy has the potential 
to eliminate satellite cells. This in turn allows the sar-
coma surgeon to remove a tumour that lies close to 
a neurovascular bundle without damaging the motor 
function of the body part in question or without hav-
ing to reconstruct the vessels. This functional bene-
fit for the patient can be further improved with radi-
ation treatment prior to surgery, as in this way the 
negative consequences of radiation on the soft tissue 
can be further reduced. Saving limbs and their func-
tion thus came about not through improved surgery 
but through development of a combination of treat-
ments. The key to progress in research and medicine 
therefore lies in interdisciplinary team work.
Necessary paradigm change
We need to think less in terms of areas of expertise 
and instead put a greater focus on patient benefit. Of 
course it is important to study and further develop 
surgical techniques. Examples here are cryotherapy 
(local use of freezing techniques), microwave ther-
apy, pasteurization, photodynamic therapy, and the 
latest radiosurgery techniques like Gamma Knife or 
NanoKnife. For this, we need large numbers of pa-
tients in the framework of international studies. How-
ever, studies of that kind are difficult to conduct, for 
with the exception of the Netherlands, tumour sur-
gery patient data are not systematically registered 
in any European country.
The question is therefore not how sarcoma surgery is 
developing per se but instead in what direction the 
treatment of patients with bone and soft tissue sarco-
mas should develop to reduce side effects while 
maintaining the same effectiveness. We need to work 
in an interdisciplinary way, define a common basis 
and take that basis as our guide. Little is achieved if 
we have highly specialized sub-disciplines but the 
persons involved do not speak the same language or 
if there is insufficient exchange. Research that is not 
aimed at patient benefit has only limited potential to 
bring further advances.5 To the most pressing ques-
tions at present, we have basic and simple answers 
with which we are very familiar. But the problem lies 
in inadequate implementation. 
Interdisciplinary sarcoma boards
Surgeons are often of the opinion that a tumour must 
be surgically removed for evaluation primarily, so that 
thereafter – depending on the pathology results – the 
further therapies can be conducted. Today it is imper-
ative that each sarcoma patient is discussed in an in-
terdisciplinary sarcoma board before any treatment 
at all is undertaken. 6 
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Unplanned operations without prior biopsy
Still today, in more than one-fourth of all patients 
with sarcoma there is unplanned removal of a tu-
mour, where subsequently and surprisingly a sarcoma 
is diagnosed – either due to improvident decisions at 
critical moments, as these tumours are so rare, or be-
cause established surgical principles are violated.7, 8 In 
Switzerland there are still too many patients for 
whom these first operations lead to unnecessary am-
putations or who die as a result of this treatment 
error. Unfortunately, there is some resistance against 
facing up to this internationally known problem. 
Most probably, as the example of the Netherlands 
shows, the problem can be tackled only with higher 
level, political measures. 
Drug therapies 
In cancer medicine we expect that chemotherapy 
mainly affects the tumour cells. Here we monitor in 
particular the side effects, whereas we take the 
main effect as a matter of course. We know that the 
drugs in standard chemotherapy are biodistributed 
in the body through diffusion. It has been shown 
that they almost accumulate in the healthy organs 
everywhere and that uptake is the least in the tu-
mour and in the targeted organ itself.9 In view of 
this, for clinical use of an anticancer drug, why must 
not also the affinity to the tumour and thus the tu-
mour uptake of the drug be demonstrated prior to 
demonstrating that it works locally against cancer 
cells? 6
Clinical studies
Due to the fact that patient survival has plateaued 
over the years, intensive attempts are being made 
to employ new, “targeted” drugs also with patients 
with sarcoma. The mechanism of action of these 
therapies is based on simple mutations or expression 
differences of individual biomarker proteins of tu-
mour cells. Although there are successful examples 
here (such as in the treatment of gastrointestinal 
stromal tumours), we have to accept that they will 
remain exceptions.10 Even scant molecular knowledge 
suffices to understand that in the face of the im-
mense heterogeneity of tumour cells, the problem is 
much more complex than would allow the targeting 
of a simple molecular change to work for the major-
ity of tumours.11 It is again and again astounding how 
a substance can be put into clinical trials with so little 
preclinical validation evidence from laboratory and 
animal trials.12 Apparently, the pressure to obtain 
positive results is great. Today a drug is already con-
sidered successful if it lengthens the time period to 
tumour recurrence by a mere three months, without 
affecting the overall patient survival rate. 
Promoting translational research 
The common denominator of all of these aspects is 
biology. Our understanding of tumour biology has 
increase exponentially in the last 20 years. Unfortu-
nately, this knowledge is not finding its way into 
clinical treatment, because clinicians and biologists 
live in separate worlds and there is too little ex-
change between them.6 We know that the strategy 
for treating sarcoma that we have followed for years 
has not brought any appreciable advances. If we 
want to improve patient survival, we must change 
our thinking. We must bring clinical research and 
basic research closer together, in the sense of trans-
lational research. Biology must be given more prior-
ity in daily clinical practice. Before a clinical study is 
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even launched, we need much more evidence of the 
effectiveness of the substance to be studied.13 At 
the same time, a tumour surgeon lacking an under-
standing of the biology of cancer cells should no 
longer be allowed to remove a tumour. 
Foundations for progress
For collaboration among all disciplines involved in 
sarcoma treatment, we have to create structural and 
clinical prerequisites.14 –17 As already mentioned, part 
of this means that the treatment strategy for each pa-
tient with a sarcoma should be determined by an in-
terdisciplinary sarcoma board 7 made up of all special-
ists, experts and tumour biologists.18, 20, 21 As especially 
in sarcoma treatment a lot of knowledge is based on 
experience and not always on evidence, it is all the 
more important to define common and universally 
accepted treatment guidelines.19, 22 – 25 Data on the di-
agnosis and treatment of every sarcoma patient must 
be registered, and this can be handled best in the 
framework of a national cohort study. Ideally, the co-
hort data set should linked with a sarcoma tissue 
bank that contains tissue from primary tumours and 
possibly metastases as well as blood serum, which 
will make possible further patient-specific analyses in 
addition to the clinical data. 
Last year we founded the Swiss National Sarcoma 
Advisory Board, which aims to implement these ob-
jectives. A common national platform will be estab-
lished to address pressing questions at the national 
and international levels in a targeted and coordinated 
way, so that our understanding of tumour biology 
and the treatment of patients with sarcoma can be 
systematically improved. As mentioned at the start of 
this article, future developments in tumour surgery 
should not be viewed in isolation and in individual 
disciplines but rather must be defined in the context 
of inter.
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Presentation of completed research projects in 2013
Ammann Roland A. | The impact of lowering fever  
limits on the rate of fever in chemotherapy induced 
neutropenia (FN): a prospective single-centre observa-
tional study in children and adolescents with cancer 
(Paediatric FN Definition 2012 Berne)  
(KFS 2933-02-2012)
The most frequent potentially lethal complication of 
chemotherapy in patients with cancer is fever in neutro-
penia (FN, fever and deficiency of white blood cells). 
Today, thanks to emergency hospitalization and empiric 
intravenous broad-band antibiotics, less than 1 % of chil-
dren with FN die. However, bacterial infections are de-
tected in only one-quarter of FN, which implies overtreat-
ment in the remaining three-quarters. One possibility to 
reduce this overtreatment is to diagnose FN less fre-
quently by setting a high fever limit. This limit is used in-
consistently today in paediatric oncology, with a range 
from 37.5° C to 39° C. It is unknown if a higher fever limit 
is efficacious (reduces the number of FN diagnoses) and 
safe (does not increase complications due to delayed diag-
nosis and therapy).
Aim of the study 
To quantify the rate of FN diagnoses when hypothetically 
lowering the fever limit below 39° C (efficacy).
Methods
In Bern, the highest known fever limit of 39° C is used 
clinically. In this prospective observational single-centre 
study, the efficacy of different fever limits can thus be 
studied by simulation without changing diagnosis and 
treatment of FN in reality.
Results
The study was completed as intended. In 39 children and 
adolescents with cancer, 43 FN episodes were diagnosed, 
32 of them at temperatures ≥ 39° C, during 289 months 
chemotherapy exposure time. The fever limit 39° C versus 
lower limits relevantly reduced the number of FN diagno-
ses. For example, with a fever limit of 38° C, 31 additional 
FN would have been diagnosed. In 19 (61 %) of them, the 
hospitalization and antibiotics implied would have been 
useless, because in reality, spontaneous defervescence 
without specific measures was observed. As expected, a 
fever limit of 38° C would have led to an earlier FN diag-
nosis and correspondingly earlier start of antibiotics in 
the majority of FN episodes (median, 1.4 hours).
Conclusions
Only the efficacy, but not the safety, of high temperature 
limits was studied here. This is the reason why this study 
itself will not lead to changes in clinical policies. The de-
sign of an interventional multicentre study, aiming also at 
safety questions, builds upon these results, however.
Project coordinator
Prof. Dr. med. Roland A. Ammann
Abteilung für Hämatologie/Onkologie
Universitätsklinik für Kinderheilkunde
Inselspital, Universitätsspital Bern
CH-3010 Bern
roland.ammann@insel.ch
Bodis Stephan | Pilot study to assess the feasibility 
and toxicity of preoperative external beam radio-
therapy for glioblastoma multiforme  
(KFS 2779-02-2011)
The life expectancy of patients with glioblastoma multi-
forme (GBM) is short despite nearly six weeks of postop-
erative chemoradiation. This study explored the feasibility 
of short course, hypofractionated pre-operative radio-
therapy (25 Gray over five days) followed by neurosurgery 
and adjuvant chemotherapy.
Our aim was to improve patients’ quality of life (QoL) by 
shortening the course of radiotherapy by 5 weeks. We hy-
pothesized comparable treatment efficacy without addi-
tional toxicity as compared to standard multimodality 
therapy. Further, any reduction in the vascularity might 
enhance maximal safe tumour resection. GBMs are chal-
lenging to treat, as the extent of microscopic spread is dif-
ficult to assess. Diffusion tensor imaging (DTI) is an MR-
based technique that can show disruption of water 
diffusion as a surrogate for tumour spread, and applica-
tion of DTI to radiotherapy planning was explored.
We successfully recruited three patients; however, there 
were no subsequent patients who met the eligibility crite-
ria that were necessary for patient safety. The patients 
were able to receive preoperative radiotherapy without 
acute complications, and surgery proceeded as scheduled. 
Patients 2 and 3 developed postoperative infections that 
may or may not have been connected to the biopsy and 
irradiation, given the incidence of postoperative infection 
on the ward at the time. Patients 1 and 3 received chem-
otherapy according to protocol and subsequently received 
stereotactic re-irradiation of recurrent tumours without 
complication. All patients succumbed to their disease 
within the expected time frame for this diagnosis (overall 
survival of 16, 10 and 13 months).
As far as can be evaluated, the primary endpoint to de-
liver preoperative radiotherapy appeared safe and feasi-
ble. Collaboration with a neuropathologist is planned to 
evaluate paired diagnostic biopsy material and irradiated 
resected tumour. We successfully developed a technique 
to utilize diffusion tensor imaging in radiotherapy plan-
ning and presented this at major US, European and Swiss 
radiation oncology meetings (ASTRO, ESTRO and 
SASRO).
Project coordinator
Prof. Dr. med. Stephan Bodis
Institut für Radio-Onkologie
Kantonsspital Aarau 
CH-5000 Aarau
stephan.bodis@ksa.ch
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Buess Martin | Understanding the pathophysiology  
of breast cancer gene expression profiles by in vitro 
analysis of the tumour-stroma interaction  
(OCS 1825-02-2006)
The interaction between malignant tumour cells and ad-
jacent stroma cells plays an important role in the onset 
and the progression of cancer. Specific molecular mecha-
nisms are involved in tumour-stroma interaction. How-
ever, to date there is no satisfactory overview of the 
interactions at the molecular level. Gene expression pro-
filing with DNA microarrays provides a detailed picture of 
the molecules involved in cancer. For most human tu-
mours, gene expression profiles had been generated, and 
tumour subtypes with different clinical outcomes could 
be characterized. Now the challenge is to elicit from this 
large amount of detailed information the pathophysiol-
ogy underlying the gene expression patterns.
In recent years we began to use global gene expression 
analysis to characterize the effects of stromal cells on the 
cancer cells, in particular the interactions between stro-
mal fibroblasts, osteoblasts, endothelial cells and breast 
cancer cells. We established analytical tools, thereby 
demonstrating the variety of tumour-stromal cell interac-
tions. As a hallmark of tumour-endothelial interaction, 
we identified a link between a C44+/CD24- stem cell-like 
gene expression signature and highly aggressive, unfa-
vourable prognostic breast carcinomas. To further char-
acterize the functional effects and their associated mo-
lecular properties, we used an in vitro co-culture model 
of human breast cancer cells and endothelial cells. 
Our data suggest that endothelial cells induce morpho-
logical changes and cell migration in certain breast can-
cer cells. Gene expression analysis generated a list of 
genes that are important for cell migration. This effect is 
mediated by as yet unknown secreted factors. Further, 
we found an IL-6 gene expression pattern induced by 
heterotypic interaction of breast cancer cells with osteo-
blasts in vitro, which was associated with a higher rate of 
bone metastasis in vivo.
With this series of in vitro experiments and correlation 
with data from human tumour tissue banks, we will con-
tinue to identify targets for new therapeutic strategies, 
which aim at the function of tumour endothelial cells, re-
gardless of angiogenesis. In addition, with the detailed 
gene expression analysis, we hope to establish new prog-
nostic and predictive markers for the treatment of breast 
cancer.
Project coordinator
PD Dr. med. et Dr. phil. Martin Buess
Medizinische Onkologie
St. Claraspital
CH-4016 Basel
martin.buess@claraspital.ch
Carbone Giuseppina | Deregulated ETS transcriptional 
network and clinical implications for prostate cancer 
progression (KFS 2573-02-2010)
Prostate cancer is a leading cause of cancer death in West-
ern countries. ETS transcription factors are important ele-
ments in the pathogenesis of prostate cancer, and chro-
mosomal translocations involving ETS genes are very 
common. In this grant application, we proposed to study 
clinical and functional impact of ETS factors alone and in 
combination and to apply ETS-based molecular classifica-
tion of prostate tumours for diagnosis and therapeutic ap-
plications.
To reach this goal, we integrated data from clinical sam-
ples with molecular and functional studies in several ETS 
cell models. Accordingly, we studied the ETS gene family 
in normal prostate and primary prostate cancers and 
found that in addition to the translocated ETS genes, 
other ETS factors are frequently affected in prostate tu-
mours in the absence of gene rearrangements. In particu-
lar, members of the epithelial-specific ETS subfamily 
ESE3/EHF and ESE1/ELF3 were frequently altered in pros-
tate tumours.
We showed that ESE3/EHF acts as a tumour suppressor, 
whereas ESE1/ELF3 has oncogenic properties in prostate 
epithelial cells. Further, our data uncovered important 
links of ETS factors with crucial pathways involved in pro-
gression and resistance to therapy, such as epigenetic, in-
flammation and stemness. Our data also indicated that 
there is an association between specific ETS alterations 
and prostate cancer progression. Overall, our studies re-
sulted in a deeper understanding of the pathogenesis of 
prostate cancer and in clinically relevant findings.
Project coordinator
Dr Giuseppina Carbone
Laboratorio di oncologia sperimentale
Istituto oncologico della Svizzera italiana (IOSI)
CH-6500 Bellinzona
giuseppina.carbone@ior.iosi.ch
Carbone Giuseppina | Identification and clinical  
relevance of microRNA networks regulated by ETS 
transcription factors in prostate cancer  
(KFS 2869-08-2011)
ETS transcription factors have proved to be important fac-
tors in the pathogenesis of prostate cancer. We recently 
reported deregulated expression of several ETS factors in 
prostate tumours and showed that they controlled key 
genes involved in the pathogenesis and progression of 
prostate cancer.
In these studies, we proposed to identify the network of 
microRNAs directly regulated by ETS transcription factors 
in prostate. Accordingly, integrating multiple data from 
prostate cancer patients and functional assays in cell lines, 
we discovered novel microRNAs regulated by ETS factors 
and demonstrated that they play a significant role in pros-
tate cancer progression. The results of these studies led to 
the discovery of novel alterations of microRNAs in pros-
tate tumours that may have important impact on diagno-
sis and management of prostate patients. Therefore, 
these studies led to clinically significant results. Knowl-
edge of this kind is expected in the future to translate to 
significant benefit for patients with prostate cancer.
Project coordinator
Dr Giuseppina Carbone
Laboratorio di oncologia sperimentale
Istituto oncologico della Svizzera italiana (IOSI)
CH-6500 Bellinzona
giuseppina.carbone@ior.iosi.ch
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Foti Michelangelo | Role of dietary free fatty acids,  
microRNA-21, and PTEN in liver cancer  
(KFS 2502-08-2009)
Diabetes and obesity represent important risk factors for 
the development of liver cancer such as hepatocellular 
carcinoma (HCC). Indeed, accumulation of fatty acids in 
the liver (steatosis) occurs with obesity and diabetes and 
represents the first stage of metabolic liver diseases, 
which can progress towards HCC with time. One mecha-
nism by which aberrant accumulation of fat in the liver 
contributes to carcinogenesis is by inducing the expres-
sion of small RNA molecules called microRNAs, which 
play an important role in cancer. In particular, micro-
RNA-21 is upregulated in hepatocytes by fatty acids and 
thereby inhibits the expression of an important tumour 
suppressor called PTEN.
In this project, we investigated the role of dietary fats, 
microRNA-21 and PTEN in the development of pre-can-
cerous stages of the liver and HCC using various rodent 
models of these diseases. In particular, we generated a 
new transgenic mouse lacking the oncogenic micro-
RNA-21 in hepatocytes.
Our results showed first that microRNA-21 is increased, 
and PTEN is decreased, in the liver of human obese sub-
jects having steatosis and other disorders preceding the 
development of HCC. Importantly, mice lacking micro-
RNA-21 in the liver were protected against metabolic 
disorders associated with diet-induced obesity and against 
tumour development in response to chemical carcinogens. 
Genomic and proteomic analyses then allowed us to un-
cover in vitro and in vivo a whole network of oncogenes 
and tumour suppressors that are affected by micro-
RNA-21 and PTEN in the liver and that are potentially 
involved in hepatic carcinogenesis. Further characteriza-
tion of the role of these microRNA-21/PTEN-dependent 
hepatic factors in HCC development is ongoing.
Our research should allow us to better understand the 
molecular basis of liver cancer, in particular in the setting 
of metabolic diseases. Also, the pertinence of future ther-
apeutic interventions restoring normal microRNA-21 and 
PTEN activities in hepatocytes to prevent or to treat liver 
cancer is strongly supported by our results. 
Project coordinator
Prof. Dr Michelangelo Foti
Département de physiologie cellulaire et  
métabolisme
Centre médical universitaire (CMU)
Université de Genève 
CH-1206 Genève
michelangelo.foti@unige.ch
Gruber Günther | BIG 3-07: a randomized phase III 
study of radiation doses and fractionation schedules 
for ductal carcinoma in situ (DCIS) of the breast  
(KFS 2527-02-2010)
Patients with ductal carcinoma in situ (DCIS) of the breast 
are usually treated with breast conserving surgery and ad-
juvant/postoperative whole breast radiotherapy (WB-RT). 
In the BIG 3-07 trial, which is a collaborative trial all over 
the world, two main radiotherapy issues are under inves-
tigation: (1) the duration (shortening) of the WB-RT by 
using higher but fewer fractions, and (2) the increase of 
the total RT dose by giving what is called a “boost”. Be-
sides tumour-related outcomes (e. g. local failure rates), 
we also analysed quality of life (QoL) aspects.
Aim of the trial
To individualize the radiotherapy concept (RT duration; 
increase of the RT dose by a boost) for patients with DCIS 
after breast-conserving surgery in regard to local control 
and QoL.
Methods
Centres could choose to participate in a 2-arm (boost 
question) or 4-arm (boost and fractionation question) 
design. Patients were randomized to: (1) ARM A (25x WB-
RT), or (2) ARM B (16x WB-RT), or (3) ARM C (ARM A + 
8x boost), or (4) ARM D (ARM B + 8x boost). It is planned 
to analyse clinical and biological factors in regard to local 
failure (primary endpoint) as well as QoL aspects.
Results
Patient accrual will be reached successfully in June 2014, 
about two years ahead of schedule! Worldwide a total of 
132 centres have participated in this trial. At the end of 
February 2014, 1 468 of 1,600 patients planned were in-
cluded in the study (Arm A: 384; Arm B: 349; Arm C: 384; 
Arm D: 351). Up to 1 March 2014, eight Swiss centres 
contributed a total of 53 patients to the trial (Brustzen-
trum Zürich-Seefeld; Kantonsspital Graubünden; Univer-
sitätsspital Basel; Kantonsspital Münsterlingen; IOSI; 
Inselspital Bern; Kantonsspital St. Gallen; Klinik Hirslanden).
Potential gain for patients
Together with another ongoing French trial with patients 
with DCIS (2,000 patients planned), which will reach pa-
tient accrual within this year, the BIG 3-07 trail will help 
to individualize the radiotherapy concept in these pa-
tients. It is quite likely that the current study will define a 
new standard of care in the WB-RT of patients with DCIS.
Project coordinator
PD Dr. med. Günther Gruber
Institut für Radiotherapie
Klinik Hirslanden
CH-8032 Zürich
guenther.gruber@hirslanden.ch
Jaggi Rolf | Molecular profiling from archival human 
breast cancer samples (OCS 2132-08-2007)
The oestrogen receptor can be detected in tumour cells 
from about 70 % of post-menopausal patients with dis-
tant, metastasis-free breast cancer. Binding of endoge-
nous oestrogen activates the receptor, which in turn stim-
ulates growth and proliferation of cancer cells. The effect 
can be inhibited or blocked in about 80 % of these pa-
tients by administering tamoxifen (Tam), an antagonist of 
oestrogen in breast cancer cells, or an inhibitor of endog-
enous synthesis of oestrogen such as letrozole (Let). Both 
drugs are similarly effective, with a slight advantage of Let 
over Tam. So far it has not been possible to identify pa-
tients who benefit specifically from one drug versus the 
other. 
We used archival tumour tissue from patients enrolled in 
BIG 1-98, a large clinical trial with more than 8,000 post-
menopausal patients with early, oestrogen receptor-posi-
tive breast cancer. About 2,000 patients were randomly 
selected and treated with Tam for 5 years; another 2,000 
105
were treated with Let for five years. We obtained tumour 
tissue from approximately 300 patients. Half of them were 
treated with Tam and the other half with Let. Tumours 
were randomly selected but such that about half of the 
patients in each group (75 patients) had a relapse (either a 
metastasis or a local recurrence) and the other half (75 pa-
tients) remained relapse-free.
Total RNA was isolated from each tumour and used for our 
analysis. RNA has an important and central function in 
cells as carrier of genetic information that is stored in the 
nucleus of the cells from where it is translocated to the 
cytoplasm, where it is translated into protein. We quanti-
tatively measured 190 RNAs that are of potential interest 
with regard to survival and/or response to Tam or Let 
treatment. A bioinformatics analysis was carried out to 
search for one or several RNAs in primary cancer tissue 
that correlated with critical clinical parameters like out-
come or relapse in patients treated with Tam and/or Let. 
We also studied whether several RNAs could be combined 
in a profile (often termed a signature or score) stably pre-
dicting the efficacy of one or both drugs. Indeed, we iden-
tified a group of nine genes that could be combined in a 
robust profile that we termed the “TamLet score”. The 
score identified tumours that had a significantly better 
outcome when treated with Let rather than with Tam. 
Although TamLet was statistically significant in our study, 
the results need to be validated with material of independ-
ent but similar tumours. Once these additional tests are in 
agreement with our current results, TamLet has the poten-
tial to be used as additional, predictive parameter to in-
form the choice between two treatment options and to 
improve the outcome of some patients with primary, oes-
trogen receptor-positive breast cancer.
Project coordinator
Prof. Dr. phil. nat. Rolf Jaggi
Departement Klinische Forschung
Universität Bern
CH-3010 Bern
rolf.jaggi@dkf.unibe.ch
Kalberer Christian | In vitro expansion of human  
natural killer cells under good manufacturing practice 
conditions for immunotherapy of haematopoietic  
malignancies (KFS 2872-08-2011)
The cytotoxic activity of human natural killer (NK) cells 
against acute myeloid leukaemia (AML) and plasma cell 
myeloma (PCM) is well established. The adoptive transfer 
of NK cells in the early post-transplantation period is a 
rational approach aimed at providing the patient with the 
benefit of competent anti-tumour effector cells. We previ-
ously showed that single NK cell donor lymphocyte infu-
sions (NK-DLI) were safe and could revert graft rejections 
and promote long-lasting remission. The NK-DLI studies 
conducted by our clinic and by others indicated that high 
effector to target cell ratios will be necessary to obtain a 
significant anti-tumour effect in vivo. Our project is con-
cerned with advancing immunotherapeutic NK cell trials to 
provide patients with NK cells with anti-tumour activity.
Towards this goal, we successfully implemented the NK 
cell expansion protocol in the newly available good manu-
facturing practice (GMP) facility of Basel University Hospi-
tal. The pre-clinical protocols were transcribed to standard 
operating procedures and validated under the clean room 
environment to comply with GMP regulations. By the end 
of 2013 we produced NK cells for one patient with AML 
and three patients with PCM. NK cells of healthy haploi-
dentical family donors were purified after leukapheresis by 
T-cell depletion and NK cell selection. Starting from 
2 x 1010 total nucleated cells, 6 x 108 NK cells were ob-
tained with 96.5 % purity and a minimal T-cell contamina-
tion corresponding to a 5.5 log T-cell depletion efficacy. 
Purified NK cells were cultured in GMP medium containing 
growth factors interleukin-2 and interleukin-15 and irradi-
ated feeder cells. Within 19 days NK cell numbers in-
creased 55-fold. The NK cell products were cryopreserved 
as multiple units in escalating doses of up to 1.0 x 108 cells/
kg body weight. The four patients received 20 NK-DLIs in 
total (3–8 doses), which were well tolerated without any 
acute adverse event. Infused NK cells were monitored by 
quantitative real-time PCR of donor DNA. We detected 
donor NK cells up to 20 hours after infusions, indicating 
prolonged survival in recipient’s circulation. 
These results demonstrate the feasibility of large-scale 
GMP expansion and of tolerability of multiple mega-dose 
infusions of human NK cells as immunotherapy after stem 
cell transplantation. The long-term follow-up will show 
whether this new treatment will contribute to an increased 
cure rate of patients with AML and PCM.
Project coordinator
PD Dr. Christian Kalberer
Diagnostische Hämatologie
Universitätsspital Basel
CH-4031 Basel
ckalberer@uhbs.ch
Kristiansen Glen | Identification of a clinically appli-
cable prognostic RNA signature of prostate cancer  
(KFS 2465-08-2009)
In the estimation of biological aggressiveness of prostate 
cancer, clinicopathological parameters do not always 
allow sufficient determination of the individual need for 
active therapy in a given patient. Formerly, almost all 
patients with a newly diagnosed prostate cancer received 
active treatment such as surgery or radiation therapy, but 
it has now been acknowledged that up to 30 % of patients 
are probably overtreated, since they would not have 
succumbed to their cancer even if they were never treated 
for it.
Study aims
We aimed to identify molecular prognostic markers that 
can be clinically applied by conducting a retrospective 
molecular analysis of clinically characterized prostate 
cancer cohorts.
Methods
Following an evidence-based compilation of suitable 
candidate genes, we extracted RNA from archival mate-
rial using a protocol that was developed by the co-appli-
cant, Prof. Rolf Jaggi, for paraffin-embedded tumour 
material. The expression levels of our target genes were 
measured by NanoString hybridization from three differ-
ent cohorts (Zurich, Berlin, Erlangen).
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Results
The bioinformatic evaluation revealed promising results 
for each of the analysed cohorts; however, we also found 
unexpected cohort-specific differences. Only four genes 
were similarly prognostic in all cohorts.
Potential benefit for patients
Our work demonstrates the necessity to verify also mo-
lecular prognostic markers in multiple cohorts, since a 
single demonstration of a prognostic value does not pro-
vide a sufficient basis for a test to be used for prospective 
assessment. The prognostic marker candidates that we 
found are going to be verified in further studies. 
Project coordinator
Prof. Dr. med. Glen Kristiansen
Institut für Pathologie
Universitätsklinikum Bonn
D-53127 Bonn
glen.kristiansen@ukb.uni-bonn.de
Niggli Felix | Constitution of a national study centre 
for the European acute lymphoblastic leukaemia  
trial (AIEOP-BFM ALL 2009) on behalf of the Swiss 
Paediatric Oncology Group (BFM-CH)  
(KLS 2578-02-2010)
Acute lymphoblastic leukaemia (ALL) is the most fre-
quent cancer disease in children. Prognosis has been sig-
nificantly improved over the last decades due to clinical 
treatment studies. Today, a combination of various cyto-
static drugs allows a cure rate in over 80 % of all patients; 
however, treatment burden is considerable. Various clini-
cal and biological factors, such as early treatment re-
sponse, cytogenetic abnormalities in leukaemic cells, and 
minimal residual disease after a treatment period of sev-
eral weeks have a significant influence on prognosis. 
According to these risk factors, treatment intensity will be 
adapted.
Aim of the study
The aim was to establish an international treatment con-
cept for ALL with collaborating partners from Switzerland, 
Germany, Austria, Italy, Czech Republic, Israel and Aus-
tralia. To realize this trial, a national study centre had to 
be built up for standardized diagnostics, data manage-
ment and research facilities. This allows a risk-adapted 
treatment approach in children with ALL to further in-
crease cure rate and to reduce treatment toxicity in sub-
groups. To reach this goal, standard treatment will be 
compared with new, potentially more effective treatment 
elements.
Results
We established a national study centre in Zurich, Switzer-
land, for this multicentre randomized clinical trial in ALL. 
This allows centralized reference diagnostics, laboratory 
analysis for measurement of minimal residual disease dur-
ing the course of leukaemia treatment, as well as a com-
mon data registration and counselling for all newly diag-
nosed leukaemias in Switzerland. 
During the first three years after study opening in Swit-
zerland, 127 patients (65 % boys and 35 % girls) could be 
enrolled in the study; 55 % were between ages 1 to 5 years. 
This means that the vast majority of children in Switzer-
land with newly diagnosed ALL are managewithin a com-
mon treatment strategy. 24 % of the patients had to be 
treated in high risk group due to unfavourable cytoge-
netic features or a delayed treatment response to initial 
chemotherapy. Whether there is a further improvement 
of long-term survival within this study can only be ana-
lysed after a longer follow-up period and a higher num-
ber of patients enrolled in the study.
Summary
With the formation of a national study centre, children 
with ALL in Switzerland will benefit not only from a com-
mon treatment concept but also from a centralized plat-
form for optimal diagnostics, advisory service, research 
facilities and data management. 
Project coordinator
Prof. Dr. med. Felix Niggli
Abteilung Onkologie
Kinderspital Zürich
Universitäts-Kinderkliniken
CH-8032 Zürich
felix.niggli@kispi.uzh.ch
Pabst Thomas | Transcriptional dysregulation of the 
myeloid key transcription factor CEBPA in human acute 
myeloid leukaemia (KLS 2520-02-2010)
Improvement of therapeutic concepts in the treatment of 
patients with acute myeloid leukemia (AML) is an unmet 
medical need. In spite of intensive chemotherapy, up to 
60 % of all patients with AML die of their disease. The 
wide application of autologous or allogeneic transplanta-
tion has not changed much in that perspective.
The concept of differentiation therapy is a promising 
novel approach. This is underlined by the success of the 
differentiation therapy with all-trans-retinoic acid (ATRA), 
exclusively effective in patients with acute promyelocytic 
leukaemia (APL). The myeloid transcription factor CEBPA 
is crucial for the differentiation of neutrophils. It specifi-
cally regulates the maturation at the myeloblastic stage: 
if CEBPA is blocked, myeloid maturation is arrested, and 
myeloblastic cells accumulate in the bone marrow and the 
blood, which exactly mirrors the situation observed in 
patients with AML.
In this project, we were investigating how the CEBPA pro-
tein is regulated in leukaemic cells. In addition, we inves-
tigated how CEBPA is regulated by a small class of novel 
regulatory molecules called microRNAs. In fact, we were 
able to demonstrate the regulation of CEBPA by two 
specific microRNAs. Ultimately, these results should aid in 
development of strategies aiming at restoring CEBPA 
function in leukaemic cells in a therapeutic context.
Project coordinator
Prof. Dr. med. Thomas Pabst
Universitätsklinik für Medizinische Onkologie
Inselspital, Universitätsspital Bern
CH-3010 Bern
thomas.pabst@insel.ch
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Further completed research projects in 2013
Moeckli Raphaël | KFS 2637-08-2010 | CHF 107,200.–
Institut de radiophysique, Centre hospitalier universitaire vaudois (CHUV), Lausanne
Evaluation of second cancer risk models in radiotherapy for average and high dose levels
Müller Beatrice | KFS 2449-08-2009 | CHF 297,900.–
Abteilung für Hämatologie/Onkologie, Universitätsklinik für Kinderheilkunde, Inselspital,  
Universitätsspital Bern, Bern
Transcriptional dysregulation during myeloid transformation in acute myeloid leukaemia (AML)
Ozsahin Hulya | KLS 2656-08-2010 | CHF 155,300.–
Unité d’onco-hématologie, Département de l’enfant et de l’adolescent, Hôpitaux universitaires de  
Genève (HUG), Genève
SIOPEL International Childhood Liver Tumour Strategy Group – a comprehensive research  
programme and a randomized trial for standard risk hepatoblastoma
Roth Arnaud | KFS 2697-08-2010 | CHF 202,700.–
Unité d’oncochirurgie, Hôpitaux universitaires de Genève (HUG), Genève
Molecular heterogeneity and prognostic markers in colon cancer by analysis of gene expression  
and gene mutation data
Clinical research
List of approved research projects in 2013
Total funds allocated: CHF 5,096,600.–
Aebersold Rudolf | KFS 3309-08-2013 | CHF 245,700.–
Institut für Molekulare Systembiologie, ETH Zürich, Zürich
Molecular subclassification of non-small cell lung cancer by quantitative kinome interactome analysis
Bairoch Amos | KFS 3297-08-2013 | CHF 231,200.–
Sciences des protéines humaines, Université de Genève, Genève
Improving clinical interpretation of genetic variations underlying common cancers
Dietrich Pierre-Yves | KFS 3270-08-2013 | CHF 248,000.–
Centre d’oncologie, Hôpitaux universitaires de Genève (HUG), Genève
Development of chimeric antigen receptor T-cells for immunotherapy of glioma
Fix Michael | KFS 3279-08-2013 | CHF 221,600.–
Universitätsklinik für Radio-Onkologie, Inselspital, Universitätsspital Bern, Bern 
Dosimetric evaluation and secondary cancer risk of modulated electron radiotherapy
Gerber Nicolas | KFS 3001-08-2012 | CHF 97,900.–
Abteilung Onkologie, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
SIOP CNS GCT II: prospective trial for the diagnosis and treatment of children, adolescents,  
and young adults with intracranial germ cell tumours
Irminger-Finger Irmgard | KFS 3287-08-2013 | CHF 136,400.–
Département de gynécologie et d’obstétrique, Hôpitaux universitaires de Genève (HUG), Genève
BARD1, a molecular target for prostate cancer screening and therapy
Kalberer Christian | KLS 3190-02-2013 | CHF 224,300.–
Diagnostische Hämatologie, Universitätsspital Basel, Basel
Immunotherapy with mega doses of activated natural killer cells in haematopoietic malignancies and  
follow-up analysis of in vivo cell migration and survival
108
Krenger Werner | KFS 3237-08-2013 | CHF 179,900.–
Departement Biomedizin, Universität Basel, Basel
Role of sphingosine-1-phosphate (S1P) receptor agonism in engraftment, T-cell regeneration and  
anti-tumour immunity in preclinical and clinical haematopoietic stem cell transplantation
Kruithof Egbert | KFS 3163-02-2013 | CHF 111,700.–
Service d’angiologie et d’hémostase, Hôpitaux universitaires de Genève (HUG), Genève
Regulation of procoagulant activities of acute promyelocytic leukaemia cells
Langer Rupert | KFS 3083-02-2013 | CHF 236,000.–
Institut für Pathologie, Universität Bern, Bern
The impact of autophagy on biology and chemoresistance of oesophageal adenocarcinomas
Lugli Alessandro | KFS 3294-08-2013 | CHF 233,700.–
Institut für Pathologie, Universität Bern, Bern
MicroRNAs in the tumour microenvironment of colorectal cancer: novel targets for therapeutic intervention?
Matter Matthias | KFS 3302-08-2013 | CHF 214,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Identification of mechanisms that promote liver cancer
Mazzucchelli Luca | KFS 3266-08-2013 | CHF 214,000.–
Istituto cantonale di patologia (ICP), Locarno
MYC activation in diffuse large B-cell lymphomas
Nadal David | KLS 3189-02-2013 | CHF 235,200.–
Abteilung Infektiologie und Spitalhygiene, Kinderspital Zürich, Universitäts-Kinderkliniken, Zürich
Translational research with the goal to identify, characterize, and target B-ALL-specific and Burkitt’s  
lymphoma-specific T-helper cells
Petrausch Ulf | KFS 3115-02-2013 | CHF 190,600.–
Klinik für Onkologie, Universitätsspital Zürich, Zürich
Phase I study for the adoptive transfer of re-directed FAP-specific T-cells in the pleural effusion of patients  
with malignant pleural mesothelioma
Rechsteiner Markus | KLS 3123-02-2013 | CHF 30,000.–
Institut für Klinische Pathologie, Universitätsspital Zürich, Zürich
Non-invasive identification of VHL mutations in plasma by deep-sequencing with subsequent assessment of 
mutant pVHL functionality in FFPE by FRET-FLIM in ccRCC patients
Reyes Mauricio | KLS 3167-02-2013 | CHF 228,300.–
Institut für Chirurgische Technologien und Biomechanik, Universität Bern, Bern
Medical image analysis for brain tumour studies
Rottenburger Christof | KFS 3170-02-2013 | CHF 217,500.–
Klinik für Radiologie und Nuklearmedizin, Universitätsspital Basel, Basel
177Lu-PP-F11N for receptor-targeted therapy and imaging (theranostics) of metastatic medullary  
thyroid cancer – a pilot and a phase I study
Simon Hans-Uwe | KFS 3099-02-2013 | CHF 264,300.–
Institut für Pharmakologie, Universität Bern, Bern
Characterization of ATG5 as a tumour suppressor in cutaneous melanoma
Tausch Christoph | KFS 3300-08-2013 | CHF 249,900.–
Brust-Zentrum Zürich, Zürich
Randomized controlled trial to evaluate the impact of a surgical sealing patch on lymphatic drainage  
after axillary lymph node dissection for breast cancer
Theocharides Alexandre | KFS 3298-08-2013 | CHF 193,600.–
Klinik für Hämatologie, Universitätsspital Zürich, Zürich
The CD47-SIRP  interaction and the role of ikaros in myeloproliferative neoplasms
Tornillo Luigi | KFS 3169-02-2013 | CHF 220,000.–
Institut für Pathologie, Universitätsspital Basel, Basel
Understanding the molecular mechanisms of differential responses to anti-angiogenic treatment in  
colorectal cancer
von der Weid Nicolas | KLS 3175-02-2013 | CHF 215,600.–
Onkologie/Hämatologie, Universitäts-Kinderspital beider Basel, Basel
Effects of a 1-year partially supervised exercise programme in childhood cancer survivors:  
a randomized controlled trial
von Gunten Stephan | KFS 3248-08-2013 | CHF 222,800.–
Institut für Pharmakologie, Universität Bern, Bern
Siglec-7/-9 ligand receptor interactions in NK cell-mediated tumour immunosurveillance
Zajac Paul | KFS 3149-02-2013 | CHF 234,400.–
Departement Biomedizin, Universitätsspital Basel, Basel
Investigator-initiated phase I immunotherapy trial for patients bearing non-small cell lung cancers  
expressing cancer/testis tumour antigens and treated with a non-replicating vaccinia virus encoding for  
7 antigenic epitopes, CD80 and CD154 co-stimulatory molecules
Fotogramm / Mehrfachbelichtung eines Lochs, 2011
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Approved bursaries in 2013
Total funds allocated: CHF 576,600.–
Dawson Heather | BIL KFS 3252-08-2013 | CHF 42,000.–
Interaction between EMT-like cancer cells (“tumour buds”) and blood/lymphatic vessel invasion in  
the tumour microenvironment of colorectal cancer
Destination: Faculty of Medicine, University of Toronto, Toronto, Canada
Fisher Oliver | BIL KLS 3133-02-2013 | CHF 127,000.–
Prognostic biomarkers and long non-coding RNA in oesophageal adenocarcinoma
Destination: St. Vincent’s Centre for Applied Medical Research, Darlinghurst, Australia
Gonseth Nusslé Semira | BIL KLS 3124-02-2013 | CHF 96,900.–
Association between parental folate intake and specific epigenetic patterns in children with  
acute lymphoblastic leukaemia
Destination: Department of Epidemiology & Biostatistics, University of California, San Francisco, USA
Rozenholc Alexandre | BIL KLS 3148-02-2013 | CHF 147,800.–
Blue dye only vs. blue dye + technetium for sentinel node procedure in endometrial cancer
Destination: Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Canada
Pauli Chantal | BIL KFS 3259-08-2013 | CHF 90,400.–
Genetics and epigenetics of high-grade myxofibrosarcoma: a next generation approach towards a better  
understanding of sarcomas with complex karyotypes
Destination: Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, USA
Schaffar Robin | BIL KFS 3274-08-2013 | CHF 72,500.–
Long-term net survival among women with breast cancer in Geneva
Destination: Department of Non-Communicable Disease Epidemiology, London School of Hygiene and  
Tropical Medicine, London, United Kingdom
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Clinical research
Presentation of approved research projects in 2013
Aebersold Rudolf | Molecular subclassification of  
non-small cell lung cancer by quantitative kinome  
interactome analysis (KFS 3309-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
This research project is centred around the quantification 
of the lung cancer proteome, which includes all proteins 
that can be measured by mass spectrometer. A particu-
larly important subset of the proteome is the protein ki-
nases and their interacting proteins. Protein kinases and 
their interactors form functional enzyme complexes that 
phosphorylate other proteins and as a result change their 
functionality. Kinase complexes play a key role in the ini-
tiation and progression of lung cancer.
The primary objective of this study is the identification 
and quantification of previously unknown disease-rele-
vant kinases and their associated proteins in patients with 
early stages of lung cancer to facilitate a new classification 
of the disease. To study the lung cancer proteome, 43 tis-
sue samples from individual patients were collected. 
Further, fractions of lung tumours and adjacent healthy 
tissues will be lysed under high pressure and proteins will 
be extracted from the tissue. The extracted proteins are 
then enzymatically digested to peptides that are identified 
and quantified by mass spectrometry. The profiles kinase 
complex components of cancerous and normal tissues will 
be compared to dissect the disease-related changes in in-
dividual patients. Moreover, such kinase profiles could 
also predict the risk of recurrence after curative surgery 
and the survival potential of advanced tumour stage pa-
tients, thus significantly improving the treatment of pa-
tients with lung cancer.
Project coordinator
Prof. Dr. Rudolf Aebersold
Institut für Molekulare Systembiologie
ETH Zürich
CH-8093 Zürich
aebersold@imsb.biol.ethz.ch
Bairoch Amos | Improving clinical interpretation of  
genetic variations underlying common cancers  
(KFS 3297-08-2013)
Duration: 01. 02. 2014 – 31. 01. 2016
Modern technologies have made DNA sequencing suffi-
ciently affordable to make it feasible to use the genome 
sequence as a diagnostic tool, at a cost that will soon be 
equivalent to that of any standard medical analysis. The 
rate-limiting step, both in terms of time and expertise, is 
the analysis of these results. This is especially true for pa-
tients with genetic diseases or cancers where it is difficult 
to uncover the mutations that are causative of the disease 
from all the benign variations. This problem is exacer-
bated for cancers, as cancerous tissues harbour numerous 
mutations, among which the mutations that are impor-
tant for correct diagnostic and eventual treatment of the 
cancer are ”hiding”.
The aim of this project is to build a compendium of the 
mutations known or expected to be the cause of three 
clinically important types of cancers: leukaemia, Lynch 
syndrome and hereditary breast and ovarian carcinoma 
(HBOC). The work will be carried out using bioinformat-
ics techniques, bioinformatics being the scientific field 
that helps derive knowledge from computer analysis of bi-
ological data. The project will significantly contribute to 
supporting clinicians in establishing and standardizing 
rules for more precise diagnosis of cancers.
Project coordinator
Prof. Dr Amos Bairoch
Sciences des protéines humaines
Université de Genève
CH-1211 Genève
ab@isb-sib.ch
Dietrich Pierre-Yves | Development of chimeric antigen 
receptor T-cells for immunotherapy of glioma  
(KFS 3270-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2016
Brain cancer (mostly glioma) is a major public health prob-
lem, being the first cause of death by cancer in children 
and the third in young adults. Current treatments are 
poorly effective and patient outcome is dismal. Novel 
treatments are warranted. Here, we want to exploit the 
natural ability of the immune system to detect and kill 
cancer cells to design an innovative treatment strategy. 
We recently identified 10 targets that are exclusively or 
preferentially expressed by glioma cells and not by normal 
cells. The next step is now to guide the killer cells of the 
immune system towards these targets for a selective at-
tack on tumour cells without damaging normal cells of the 
brain. 
In this project, we will combine the natural properties of 
two components of the immune system, T-lymphocytes 
(that can kill tumour cells) and antibodies (that recognize 
cell surface targets). T-lymphocytes will be engineered to 
express an antibody acting here as a homing device to 
specifically guide killer T-lymphocytes to the glioma cell 
surface. These engineered T-lymphocytes are called chi-
meric antigen receptor cells (CARs). This project will 
allow engineering and selecting of the most effective 
CARs, which will then be used in future clinical trials, 
establishing a new treatment modality for patients with 
brain cancer.
Project coordinator
Prof. Dr Pierre-Yves Dietrich
Centre d’oncologie 
Hôpitaux universitaires de Genève (HUG)
CH-1211 Genève 14
pierre-yves.dietrich@hcuge.ch
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Fix Michael | Dosimetric evaluation and secondary 
cancer risk of modulated electron radiotherapy  
(KFS 3279-08-2013)
Duration: 01. 03. 2014 – 28. 02. 2016
Recent technological developments in photon radiother-
apy have led to complex treatment techniques (intensity 
modulated radiotherapy or volumetric modulated arc 
therapy) that result in better tumour targeting while spar-
ing neighbouring healthy tissues. In contrast, electron ra-
diotherapy remains at a very basic level, despite the inter-
esting dosimetric properties associated with electrons: 
Indeed, due to their limited penetration depth in tissue (in 
contrast to photons), electron beams are well suited to 
treat shallow tumours and better spare healthy tissues at 
larger depths. Intensity and energy modulation of elec-
tron beams (known as MERT) could further improve the 
dosimetric quality of plans. MERT is more challenging 
than photon IMRT, as more sophisticated dose calcula-
tions algorithms are required and dedicated electron 
beam collimation systems are usually used. 
Using Monte Carlo calculations, our group developed a 
treatment planning tool to create MERT plans for linear 
accelerators using the same collimation system as for the 
photon beams. This tool will be used to determine which 
sites will benefit most from MERT treatment compared to 
photon radiotherapy. In particular, we will assess the risk 
of late effects such as radiation-induced secondary can-
cers and cardiovascular disease. Finally, the impact of 
hardware- and patient-related uncertainties on the ro-
bustness of MERT plans will be assessed. These results will 
provide a further step towards clinical implementation of 
MERT.
Project coordinator
PD Dr Michael Fix
Universitätsklinik für Radio-Onkologie
Inselspital, Universitätsspital Bern
CH-3010 Bern
michael.fix@insel.ch
Gerber Nicolas | SIOP CNS GCT II: prospective trial  
for the diagnosis and treatment of children, adoles-
cents, and young adults with intracranial germ cell  
tumours (KFS 3001-08-2012)
Duration: 01. 09. 2013 – 30. 08. 2016
Intracranial germ cell tumours are among the most com-
mon brain tumours in childhood and adolescence. 
Through the introduction and optimization of surgical 
treatment, chemotherapy and radiotherapy, the cure rate 
in these patients has increased from 20 % to more than 
80 %. However, not all patients can be cured, and at the 
same time, the treatment can cause significant acute and 
late toxicity. With the current treatment protocols, some 
patients appear to be undertreated, and for other pa-
tients treatment is unnecessarily strong. 
The international study SIOP CNS GCT II is trying to bet-
ter tailor the treatment to the individual needs of the pa-
tient according to the tumour subtype, the extent of 
spread and the response to therapy. For example, in pa-
tients with a relatively favourable prognosis (i. e. germi-
noma), the radiation field is extended to the whole ven-
tricular system (since in the previous study, most relapses 
were observed in the ventricles); however, in patients 
with a good tumour response to the preceding chemo-
therapy, the radiation dose is reduced. For another sub-
group of patients with a worse prognosis, chemotherapy 
is intensified using high-dose chemotherapy.
Although germ cell tumours belong to the most common 
brain tumours in children, adolescents and young adults, 
the absolute number of approximately four new cases a 
year in Switzerland is low. Therefore, the treatment of 
these diseases can only be further optimized in interna-
tional multicentre studies of this kind. All Swiss paediatric 
oncology centres are taking part in this study protocol.
Project coordinator
Dr. med. Nicolas Gerber
Abteilung Onkologie 
Kinderspital Zürich
Universitäts-Kinderkliniken 
CH-8032 Zürich
nicolas.gerber@kispi.uzh.ch
Irminger-Finger Irmgard | BARD1, a molecular target 
for prostate cancer screening and therapy  
(KFS 3287-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Prostate cancer is the most frequently diagnosed cancer in 
most Western countries. A general risk factor is androgen, 
but genetic predisposition, linked to mutations in breast 
cancer genes BRCA1 and BRCA2, becomes evident. Early 
detection is necessary for a favourable diagnosis, but the 
screening for the prostate-specific antigen (PSA) has not 
led to a reduced death rate. Thus, novel biomarkers and 
treatment targets are urgently needed. 
We found that BARD1, known as tumour suppressor in-
teracting with BRCA1 and important for breast cancer, is 
present in modified forms that act as oncogenes in breast 
and many other cancers. We propose to define which of 
the aberrant forms of BARD1 are specifically expressed in 
prostate cancer and how this is correlated with patient di-
agnosis and outcome. We will determine the cellular and 
environmentally regulated (epigenetic) factors that drive 
their expression and how we could interfere. These onco-
genic forms of BARD1 are also immunogenic and trigger 
the production of circulating antibodies. 
We will develop a diagnostic or screening test, based on 
detection of such BARD1 antibodies. We have already 
shown in proof of principle studies that such a test is pos-
sible for breast (Patent WO2012038932) and lung cancer 
(Patent WO2012023112). We are aiming at a blood test 
for prostate cancer screening or for discriminating be-
tween prostate cancer and prostate hyperplasia for pa-
tients with high PSA levels.
Project coordinator
Dr. Irmgard Irminger-Finger
Département de gynécologie et d’obstétrique
Hôpitaux universitaires de Genève (HUG)
CH-1225 Genève
irmgard.irminger@unige.ch
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Kalberer Christian | Immunotherapy with mega doses 
of activated natural killer cells in haematopoietic  
malignancies and follow-up analysis of in vivo cell  
migration and survival (KLS 3190-02-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
Acute myeloid leukaemias (AML) are rapidly-progressing 
blood cell malignancies with poor prognosis. Front-line 
high dose chemotherapy and allogeneic stem cell trans-
plantation (HSCT) offer the best chance of cure, but re-
lapses are frequent and often fatal. Improved outcome of 
haploidentical HSCT has been attributed to the graft-ver-
sus-leukaemia effect of alloreactive natural killer (NK) 
cells. It is now established that NK cells have a unique ca-
pacity to exert potent graft-versus-tumour effects not 
only in AML but also in multiple myeloma (MM). 
The specific aims of this study are: (1) Two clinical studies 
to assess feasibility and safety of infusions of expanded 
haploidentical NK cells in patients with AML and MM af-
ter HSCT. NK cells are processed in the newly built good 
manufacturing practice (GMP) clean room facility of the 
Diagnostic Haematology Laboratory. The NK cell expan-
sion protocol yields cellular products with high numbers 
needed for multiple mega dose NK-DLIs to achieve clini-
cally relevant effector to target ratios in vivo. (2) Charac-
terization of NK cell products to correlate the treatment 
outcome with NK cell dose, timing and properties. We will 
monitor survival of infused NK cells in blood and analyse 
their chemokine receptors expression pattern for a better 
understanding of NK cells’ migration patterns. The goal of 
this study is to advance immunotherapeutic NK cell trials 
by developing clinically-suitable approaches to increase 
the cure rate of patients with AML and MM.
Project coordinator
PD Dr. Christian Kalberer
Diagnostische Hämatologie
Universitätsspital Basel
CH-4031 Basel
ckalberer@uhbs.ch
Krenger Werner | Role of sphingosine-1-phosphate 
(S1P) receptor agonism in engraftment, T-cell regener-
ation, and anti-tumour immunity in preclinical and 
clinical haematopoietic stem cell transplantation  
(KFS 3237-08-2013)
Duration: 01. 03. 2014 – 29.02.2016
The combination of radiotherapy, chemotherapy and allo-
geneic hematopoietic stem cell transplantation (allo-
HSCT) is an important treatment option for blood cancers 
such as leukaemia and lymphoma. One major complica-
tion after allo-HSCT is graft-versus-host-disease (GvHD), 
which occurs in up to 50 % of all patients. GvHD is in-
duced by donor T-cells contained in the transplant, at-
tacking recipient tissues in skin, liver and gastrointestinal 
tract. Currently, there is no effective treatment for GvHD 
apart from immunosuppressive drugs, which also enhance 
the risk for infections. 
Our research targets a successful inhibition of T-cell mi-
gration into target tissue. Sphingosin-1-phosphate recep-
tor (S1PR) is known to be crucial for T-cell trafficking. A 
modified S1PR agonist can interfere with cell trafficking 
and may thus avoid target organ damage. Using mouse 
models of GvHD we aim to investigate the impact of S1P 
receptor agonism on anti-tumour immunity, T-cell regen-
eration and stem cell engraftment. These results will pro-
vide important knowledge about the clinical potential of 
S1P agonist and aid the designing of future clinical trials 
that might introduce S1P agonist to prevent GvHD while 
maintaining anti-tumour immunity.
Project coordinator
PD Dr. phil. II Werner Krenger
Departement Biomedizin
Universität Basel
CH-4058 Basel
werner.krenger@unibas.ch
Kruithof Egbert | Regulation of procoagulant activities 
of acute promyelocytic leukaemia cells  
(KFS 3163-02-2013)
Duration: 01. 10. 2013 – 30. 09. 2014
Acute promyelocytic leukaemia (APL) is associated with 
severe bleeding complications. Production of a pro-throm-
botic factor by the leukaemia cells leads to the formation 
of blood clots. In reaction, endothelial cells, which sur-
round the blood vessels, release an anti-thrombotic factor 
that stimulates thrombus degradation. Together these pro- 
and anti-thrombotic activities are responsible for an ex-
haustion of blood coagulation factors, which increases the 
risk of bleeding. Mortality used to be very high in APL, but 
since the introduction of therapy with retinoic acid, sur-
vival prognosis is relatively good. Nevertheless, severe 
bleeding remains one of the principal complications, even 
with optimal therapy. 
We will use APL cells as a model to better investigate the 
mechanisms that regulate the production of pro-throm-
botic factors of these leukaemia cells. The knowledge that 
we hope to gain may be relevant not only for acute pro-
myelocytic leukaemia but also for other types of leukaemia 
and solid tumours where thrombotic complications are fre-
quent.
Project coordinator
Prof. Dr Egbert Kruithof
Service d’angiologie et d’hémostase
Hôpitaux universitaires de Genève (HUG)
CH-1211 Genève
egbert.kruithof@hcuge.ch
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Langer Rupert | The impact of autophagy on  
biology and chemoresistance of oesophageal adeno-
carcinomas (KFS 3083-02-2013)
Duration: 01. 06. 2013 – 31. 05. 2015
Oesophageal adenocarcinomas (EAC) are highly aggres-
sive tumours showing considerable rates of resistance to 
conventional cytotoxic treatment. EAC represent the 7th 
leading cause of cancer related deaths in the Western 
world, and incidence is increasing. The underlying reasons 
for chemoresistance of a subset of EAC are still not fully 
understood, and there is also a lack of appropriate tools 
for pre-therapeutic response prediction or strategies to 
overcome chemoresistance. 
We aim to determine the role of autophagy (self-diges-
tion), a molecular mechanism that helps to maintain cel-
lular homeostasis, in EAC with a special emphasis on 
chemotherapy response. We are combining cell line ex-
periments with molecular genetic analysis of molecules in 
tissue of EAC. The current therapeutic approach for the 
treatment of advanced EAC offers a valuable model for 
studying therapy effects by comparing molecular signa-
tures of tumours before and after treatment. These anal-
yses are paralleled by laboratory experiments, where cell 
lines are treated likewise. We aim at obtaining novel in-
sights into the impact of this highly interesting cellular 
mechanism in cancer. 
We hope that we will be able to identify autophagy-re-
lated molecules as potentially useful prognostic or predic-
tive biomarkers for the use in clinical practice. The results 
of our study may offer a valuable contribution for the un-
derstanding of cancer biology, chemotherapy resistance 
and response.
Project coordinator
PD Dr. med. Rupert Langer
Institut für Pathologie
Universität Bern
CH-3010 Bern
rupert.langer@pathology.unibe.ch
Lugli Alessandro | MicroRNAs in the tumour micro-
environment of colorectal cancer: novel targets for 
therapeutic intervention? (KFS 3294-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2015
The tumour microenvironment of colorectal cancer (CRC) 
is the frontline of tumour-host interaction. Infiltration by T-
effector lymphocytes is characteristic of an active anti-tu-
moural immune defence by the host. In contrast, presence 
of dissociated tumour cells at the invasive front of CRC 
(“tumour budding”) is a central hallmark of aggressive dis-
ease biology and is related to the process of epithelial-mes-
enchymal transition (EMT). These features represent dia-
metrically opposed sides of an attacker/defender model. 
Recent studies indicate that the composition of the tumour 
microenvironment is a central histomorphological prognos-
tic factor and influences therapy response of CRC patients. 
We hypothesize that the balance of pro- and anti-tumoural 
factors could be significantly influenced through the ex-
pression of short, non-coding, highly conserved RNA-oli-
gonucleotides (microRNA). 
In this study, microRNA expression and the composition of 
the tumour microenvironment is investigated in a well-
characterized cohort of CRC patients using the newly de-
veloped next generation tissue microarray (ngTMA) tech-
nology. The aim of the first part of our study is to identify 
prognostically relevant microRNAs in the tumour microen-
vironment of CRC and to study their impact on EMT and 
tumour immune rejection. In the second part of our inves-
tigation, functional analyses and therapeutic targeting of 
specific microRNAs will be performed using cell biology 
methods and murine models.
Project coordinator
Prof. Dr. med. Alessandro Lugli
Institut für Pathologie
Universität Bern
CH-3010 Bern
alessandro.lugli@pathology.unibe.ch
Matter Matthias | Identification of mechanisms that 
promote liver cancer (KFS 3302-08-2013)
Duration: 01. 05. 2014 – 30. 04. 2017
Hepatocellular carcinoma (HCC) is the third leading cause 
of cancer related deaths and the fifth most common cancer 
in the world, with a fast growing incidence in the United 
States and Europe. Most HCCs develop in the context of a 
chronic liver inflammation, mainly due to chronic infection 
with hepatitis C or B virus or alcoholic and non-alcoholic 
steatohepatitis. Chronic liver inflammation causes tissue 
damage with liver cirrhosis and creates a microenvironment 
that favours the development of HCC.
Currently, little is known about why certain patients with 
cirrhosis develop HCC, whereas others do not. Clearly 
missing in the field of HCC research are longitudinal stud-
ies that analyse the changes occurring in the liver over the 
years up to HCC development in the same patient. In our 
project, we will therefore analyse liver tissue samples from 
patients at two different points in time: one when no HCC 
was present and one when a HCC was present. 
We will perform an array-based whole genome RNA ex-
pression analysis to investigate the changes occurring be-
tween these two liver samples. We will analyse liver tissue 
samples in a control group of cirrhotic tumour-free patients 
who have not developed a HCC in a defined time period. 
Our analysis will help design treatment options for the pre-
vention of HCC and improve our understanding of the 
mechanisms involved in HCC development.
Project coordinator
Dr. med. et Dr. phil nat. Matthias Matter
Institut für Pathologie
Universitätsspital Basel
CH-4031 Basel
matthias.matter@usb.ch
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Mazzucchelli Luca | MYC activation in diffuse large  
B-cell lymphomas (KFS 3266-08-2013)
Duration: 01. 02. 2014 – 31. 01. 2017
Diffuse large B-cell lymphoma (DLBCL) is the most fre-
quent aggressive B-cell lymphoma in adults. Up to 40 % of 
treated patients have refractory disease or relapse. Despite 
several efforts over the recent years, the molecular basis of 
DLBCL remains largely unclear, and few results have at-
tained clinical relevance.
This incomplete success reflects the heterogeneity of 
DLBCL and the poor understanding of its pathogenesis. 
One of the most important pathogenic features in DLBCL 
is activation of the MYC oncogene, which can be caused 
by several mechanisms and leads to aggressive behaviour. 
For this reason, characterization of MYC target genes in 
DLBCL and of their downstream effectors represents a 
crucial step in the understanding and prevention of lym-
phomagenesis.
The aim of the research project is therefore to analyse the 
prognostic impact of the genetic alterations of MYC, as 
well as of its expression levels, in a large series of patients 
with DLBCL, with well characterized follow-up informa-
tion. Further, we intend to study the role of MYC activa-
tion on two recently discovered proteins, PIM1 and STAT3, 
known to play a major role in regulation of MYC expres-
sion. Finally, we will analyse the expression of BRD4 and 
TTP in a series of DLBCL, as these proteins were shown to 
represent two potential therapeutic targets in haemato-
logic neoplasms characterized by MYC activation.
Project coordinator
Prof. Dr. med. Luca Mazzucchelli
Istituto cantonale di patologia (ICP)
CH-6601 Locarno
luca.mazzucchelli@ti.ch
Nadal David | Translational research with the goal  
to identify, characterize, and target B-ALL-specific  
and Burkitt’s lymphoma-specific T-helper cells  
(KLS 3189-02-2013)
Duration: 01. 09. 2014 – 30. 08. 2016
Acute lymphoblastic leukaemia (ALL) represents the lead-
ing cause of cancer related deaths in children and young 
adults. Although modern treatment has reached an excel-
lent rate of success, about 20 % of the patients relapse, 
and side effects remain a problem. Similarly, intensive 
chemotherapy has reached excellent cure rate in children 
with Burkitt’s lymphoma (BL), but patients suffer from se-
vere side effects. There is a need for less toxic and more 
targeted therapies. Cancer cells (B-ALL cells and BL cells) 
grow and expand in the patients’ bone marrow and or-
gans, where they interact with surrounding cells, such as 
T-helper cells. The influence of these T-helper cells on B-
ALL or BL cells is not known so far.
In this project, we will investigate the role of T-helper cells 
in B-ALL and BL disease development. To do so, the lym-
phoma-interacting T-helper cells will be isolated from pa-
tients and cultured together with B-ALL and BL cells from 
the same patient. In this way, we will analyse whether 
these T-helper cells can kill the tumour cells, or whether 
they in contrast help the malignant cells to survive and/or 
expand. Further, we will analyse the mechanisms that are 
involved in the interaction of T-helper cells with B-ALL 
and BL cells. The question as to whether T-helper cells 
promote lymphoma and leukaemia growth is highly rele-
vant for future therapies, which might involve specific re-
moval of disease-promoting T-helper cells. In addition, 
the project may identify molecules involved in this inter-
action. Future cancer therapies may involve blocking such 
molecules.
Project coordinator
Prof. Dr. David Nadal
Abteilung Infektiologie und Spitalhygiene
Kinderspital Zürich
Universitäts-Kinderkliniken
CH-8032 Zürich
david.nadal@kispi.uzh.ch
Petrausch Ulf | Phase I study for the adoptive  
transfer of re-directed FAP-specific T-cells in the  
pleural effusion of patients with malignant pleural 
mesothelioma (KFS 3115-02-2013)
Duration 01. 10. 2013 – 30. 09. 2015
T-cells are effector cells of the immune system and con-
stantly scan the body for malignant transformation of 
cells. If malignant transformation is detected, the trans-
formed cells are destroyed. However, the process of ma-
lignant transformation also includes processes by which 
the malignant cells escape T-cell recognition and tumour 
formation occurs. As part of this clinical phase I study 
protocol, T-cells from patients with malignant pleural 
mesothelioma (MPM) will be isolated and reprogrammed 
to detect the fibroblast activation protein (FAP) on the 
tumour cell surface. Today, MPM is an incurable disease 
for which new therapeutic approaches have to be devel-
oped. 
The target antigen FAP is highly expressed on MPM cells. 
The reprogrammed T-cells from the patients will receive 
by gene transfer a new receptor recognizing FAP. When 
the receptor binds to the FAP molecule on MPM cells, T-
cells will become activated and kill the tumour cells spe-
cifically. To optimize the efficacy of the approach, T-cells 
will be injected into the thoracic cavity to allow for rapid 
contact of the T-cells with the tumour cells. Patients in-
cluded in this trial might not have an immediate thera-
peutic effect, since the first T-cell dose administered will 
be quite low. However, the low dose is necessary, be-
cause this is the first application of FAP-specific T-cells in 
humans. We believe that the trial will generate new 
knowledge in the field of adoptive T-cell transfer.
Project coordinator
PD Dr. med. Ulf Petrausch
Klinik für Onkologie
Universitätsspital Zürich
CH-8091 Zürich
ulf.petrausch@usz.ch
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Rechsteiner Markus | Non-invasive identification of 
VHL mutations in plasma by deep-sequencing with 
subsequent assessment of mutant pVHL functionality 
in FFPE by FRET-FLIM in ccRCC patients  
(KLS 3123-02-2013)
Duration: 01. 07. 2013 – 30. 06. 2014
Renal cell carcinoma (RCC) is the most frequent malig-
nant tumour affecting the adult kidney, and its manifes-
tation is often asymptomatic in its early phase. Charac-
teristic for the majority of ccRCC is the functional loss of 
the von Hippel-Lindau (VHL) tumour suppressor gene. 
Up to now, no non-invasive tool is available to determine 
the mutation status of VHL. Therefore, the first aim of 
this project is to establish a method to isolate tumour 
DNA, which is present in smallest amounts in the blood. 
The VHL mutation status can then be assessed by a new 
technology, called ultra-deep-sequencing.
The common mutations of VHL in ccRCC led to its in-
depth characterization, which revealed its function as a 
multiadapter protein, in particular its interaction with the 
hypoxia-inducible factor α (HIFα). HIFα is involved in i. e. 
the regulation of tumour angiogenesis, which may be in-
hibited by targeted therapy. To select the patient popula-
tion that benefits the most from such a therapy, not only 
the mutation status of VHL is important to know but also 
whether it has lost its functionality. Therefore, we aim in 
this project additionally to establish a FRET assay that can 
measure the binding differences from non-mutated and 
mutated pVHL to HIFα. The ultimate goal of this project is 
to integrate ultra-deep-sequencing and FRET technology 
as identification and monitoring tools of ccRCC in clinical 
diagnostics. 
Project coordinator
Dr. Markus Rechsteiner
Institut für Klinische Pathologie
Universitätsspital Zürich
CH-8091 Zürich
markus.rechsteiner@usz.ch
Reyes Mauricio | Medical image analysis for brain  
tumour studies (KLS 3167-02-2013) 
Duration: 01.08.2013 – 31. 07. 2015
Brain tumours are rare but have a limited survival rate. 
Magnetic resonance imaging (MRI) is the method of 
choice in diagnosis, treatment and follow-up of brain tu-
mours. Currently, tumour size and growth assessment is 
performed visually by experienced radiologists using di-
ameter measurements. Automatic methods for analysing 
brain tumour images volumetrically would facilitate and 
accelerate the clinical workflow. At the same time, this 
can have a positive impact on therapy. Previously, we de-
veloped software tools for automatic segmentation of tu-
mour sub-compartments as well as healthy tissues. 
The aim of this project is to consolidate previous develop-
ments and transform the tools into a clinical application. 
For this, we want to integrate the tools into a clinically-
oriented graphical user interface for thorough evaluation 
and validation in a clinical study that is carried out to-
gether with our clinical partners. Based on the results of 
the study and feedback from the physicians, detailed im- 
provements will be made. This suite of tools has the po-
tential to significantly ease the burden of image analysis 
work currently posed on radiologists and will benefit pa-
tients by providing more accurate and objective interpre-
tation of the disease.
Project coordinator
PD Dr. Mauricio Reyes
Institut für Chirurgische Technologien und  
Biomechanik 
Universität Bern
CH-3014 Bern
mauricio.reyes@istb.unibe.ch
Rottenburger Christof | 177Lu-PP-F11N for receptor- 
targeted therapy and imaging (theranostics) of  
metastatic medullary thyroid cancer: a pilot and  
a phase I study (KFS 3170-02-2013)
Duration: 01. 07. 2014 – 30. 06. 2017
Today, patients with advanced medullary thyroid carci-
noma who do not have the option of curative surgery 
have very limited treatment options, as chemotherapy or 
external beam radiotherapy are not effective enough. 
Novel substances (called multikinase inhibitors) are now 
available for the treatment of medullary thyroid cancer. 
However, they have not improved survival of these pa-
tients. Unfortunately, these multikinase inhibitors can 
have adverse effects that impact quality of life. 
Often the tumour marker calcitonin is increased in these 
patients, indicating residual or recurrent tumour disease. 
Frequently, the residual or recurrent tumour cannot be 
found with conventional imaging such as CT or MRI. Sci-
entific studies have shown that almost all medullary thy-
roid carcinomas express the gastrin receptor at a high 
density on the cell surface. Therefore, peptides that bind 
to the gastrin receptor were designed and labelled with 
radionuclides. These substances have been improved re-
cently and are now available for imaging and therapy 
studies in patients with medullary thyroid carcinomas. 
We are investigating whether these new substances are 
useful for imaging and therapy of advanced medullary 
thyroid cancer. Further, we will determine the maximal 
treatment dose that is safe and effective in patients.
Project coordinator
Dr. med. Christof Rottenburger
Klinik für Radiologie und Nuklearmedizin
Universitätsspital Basel
CH-4031 Basel
christof.rottenburger@usb.ch
Simon Hans-Uwe | Characterization of ATG5 as a  
tumour suppressor in cutaneous melanoma  
(KFS 3099-02-2013)
Duration: 01. 07. 2013 – 30. 06. 2015
Cells require the removal of damaged proteins and orga-
nelles to stay healthy. This renovation process is per-
formed by intracellular digestion of cytosolic material, 
which is called autophagy. There is evidence that insuffi-
cient autophagy contributes to cancer, but the molecular 
mechanisms remain largely unclear. We hypothesize that 
the expression of genes regulating autophagy is dysregu-
lated in cancer. In this project, we are investigating the ex-
pression and function of autophagy-regulating genes in 
melanoma patients.
Project coordinator
Prof. Dr. med. et Dr. phil. Hans-Uwe Simon
Institut für Pharmakologie
Universität Bern
CH-3010 Bern
hus@pki.unibe.ch
Tausch Christoph | Randomized controlled trial  
to evaluate the impact of a surgical sealing patch  
on lymphatic drainage after axillary lymph node  
dissection for breast cancer (KFS 3300-08-2013)
Duration: 01. 10. 2014 – 30. 09. 2016
This study is based on the use of the local haemostyptic 
and sealing surgical patch TachoSil®. A meta-analysis of 11 
randomized controlled trials with 632 patients showed no 
impact of the use of fibrin glues after axillary lymph node 
dissection (ALND) on the risk of seroma or the length of 
hospital stay but revealed a trend toward less drainage 
volume. In all of the studies, the liquid form of fibrin seal-
ant was used. 
TachoSil® is a sterile, ready-to-use, absorbable surgical 
patch – as opposed to the liquid fibrin sealant mentioned 
above, and it consists of an equine collagen sponge coated 
with human fibrinogen and human thrombin. TachoSil® 
was launched in Europe in 2004 as a further development 
of the TachoComb® and TachoComb H® products, which 
have been used in more than 1.7 million patients in over 
20 different countries in a wide range of surgeries since 
their introduction in the early 1990s. TachoSil® is used not 
only for haemostasis but also for closure of other anatom- 
Fotogramm / Zickzack, 2013
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ical structures in many surgical disciplines due to its excel-
lent sealing capacity. The use of TachoSil® has been shown 
to reduce the lymphatic drainage after lymphadenectomy 
in several indications. 
We propose to conduct a multicentre prospective rand-
omized clinical trial in Switzerland to evaluate the impact 
of TachoSil® on axillary drainage after ALND for breast 
cancer. We hypothesize that the use of TachoSil® signifi-
cantly and relevantly reduces the volume and duration of 
axillary drainage after ALND. This is likely to affect patient 
safety and to decrease the length of hospital stay as well 
as hospital costs, and it has the potential to banish the ax-
illary drain from clinical routine in the future. 
Project coordinator
Dr. med. Christoph Tausch
Brust-Zentrum Zürich
CH-8008 Zürich
c.tausch@brust-zentrum.ch
Theocharides Alexandre | The CD47-SIRP  interaction 
and the role of ikaros in myeloproliferative neoplasms  
(KFS 3298-08-2013)
Duration: 01. 10. 2013 – 30. 09. 2016
Myeloproliferative neoplasms (MPN) are a group of 
blood stem cell disorders characterized by increased pro-
duction of blood cells. Therapy-resistance and develop-
ment of acute leukaemia (post-MPN-AML) are two of the 
most important complications in MPN that significantly 
impact survival. Macrophages are cells of the innate im-
mune system that can eliminate cancer cells. This study 
aims at elucidating the role of an interaction between 
macrophages and MPN cells and at developing a therapy 
model for post-MPN-AML. Cancer cells carry proteins on 
their surface that mediate interactions with macrophages 
and prevent them from being eliminated. 
We will assess whether blocking these interactions by a 
novel therapeutic strategy leads to elimination of MPN 
cells by macrophages. To model post-MPN-AML, human 
blood cells will be genetically modified with genes known 
to be involved in leukaemia initiation. Genetically modi-
fied cells will be exposed to a panel of therapeutic com-
pounds in tissue cultures to identify the one with the 
greatest therapeutic potential. The same cells will then be 
transplanted into a mouse model, and mice will be treated 
with the most promising compound selected from the tis- 
sue culture experiments. The proposed model will consti-
tute a highly valuable tool to assess efficacy of novel 
agents and to set the stage for a clinical trial with the 
most promising therapeutic regimen for post-MPN-AML.
Project coordinator 
Dr. med. Alexandre Theocharides
Klinik für Hämatologie
Universitätsspital Zürich 
CH-8091 Zürich
a.theocharides@gmx.ch
Tornillo Luigi | Understanding the molecular mecha-
nisms of differential responses to anti-angiogenic 
treatment in colorectal cancer (KFS 3169-02-2013)
Duration: 05. 01. 2013 – 30. 04. 2016
Despite improvements in surgical and pharmacological 
therapies, the 5-year survival rate for advanced stage 
colorectal cancer (CRC) is about 10 %. Although the re-
cent introduction in treatment of an antibody (bevaci-
zumab, BV) that targets the product of a gene named 
VEGFA doubled the survival expectancy of patients with 
CRC, the results are still rather poor compared to other 
cancers, and the response to BV in the individual patient 
remains unpredictable.
We found that amplification of the VEGFA genes identifies 
a subset of patients with CRC with highly aggressive dis-
ease who probably respond better to BV treatment than 
patients without gene amplification. At present, however, 
we do not know the molecular mechanism underlying our 
data. We therefore aim to unravel the BV mechanisms of 
action, by using an animal model recapitulating the human 
disease, and to investigate how VEGFA gene and its fam-
ily members modulate patients’ response to BV treatment. 
Altogether, our study will help the setting of personalized 
therapeutic strategies by: (1) helping to identify those pa-
tients who most probably will profit from BV treatment; 
(2) avoiding unnecessary side effects and costs for nonre-
sponders; and (3) planning future alternative and/or com-
bination treatments for patients with CRC based on the 
functional results obtained. We believe that patients with 
CRC will greatly benefit from these research activities.
Project coordinator
PD Dr. med. Luigi Tornillo
Institut für Pathologie
Universitässpital Basel
CH-4003 Basel
ltornillo@uhbs.ch
von der Weid Nicolas | Effects of a 1-year partially  
supervised exercise programme in childhood cancer 
survivors: a randomized controlled trial  
(KLS 3175-02-2013)
Duration: 01. 01. 2014 – 31. 12. 2016
Exercise can play a major role in mitigating or even pre-
venting diverse late effects in cancer survivors, such as 
cardiovascular disease, obesity, osteoporosis and reduced 
quality of life. The objective of this study is to assess the 
effect of an exercise programme of one year’s duration on 
cardiovascular health, obesity, osteoporosis, mental health 
and quality of life in childhood cancer survivors. 
We will recruit survivors aged 16 years and older from the 
paediatric oncology clinic at Children’s Hospital Basel and 
randomize them into an intervention and a control group 
after stratification for type of tumour and therapy. The in-
tervention group will be asked to increase their physical 
activity for one year by at least three hours of intense 
physical activity weekly and reduce screen time by 25 %. 
Regular feedback will be given via a step counter, an on-
line activity diary, and by the centre staff. The control 
group participants will keep their activity level constant. 
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All participants will be seen after three, six and 12 months 
to assess health and quality of life parameters. After one 
year, the control group will be given the opportunity to 
receive the same intervention to profit from an active life-
style. 
Should the program prove effective, a complete package 
will become available to all paediatric oncology centres in 
Switzerland to promote exercise in childhood cancer sur-
vivors.
Project coordinator
Prof. Dr. med. Nicolas von der Weid
Onkologie / Hämatologie
Universitäts-Kinderspital beider Basel
CH-4031 Basel
nicolas.vonderweid@ukbb.ch
von Gunten Stephan | Siglec-7/-9 ligand receptor  
interactions in NK cell-mediated tumour immunosur-
veillance (KFS 3248-08-2013)
Duration: 01. 02. 2014 – 31. 01. 2017
Altered surface glycosylation (presence of carbohydrate 
residues) on malignant cells may directly influence im-
mune responses by interaction with receptors on immune 
cells. By this means tumour cells are protected from the 
immune response by natural killer (NK) cells by interact-
ing with inhibitory Siglec-7 and -9 receptors. In this study 
we are investigating the stage-dependent expression of 
carbohydrate ligands for Siglec-7 and -9 in different types 
of cancer. The role in tumour defence of specific Siglec-7- 
or -9-positive NK cell subsets will be investigated. Fur-
ther, we will explore the extent to which overexpression 
of Siglec-7 and -9 ligands protects against NK cell-medi-
ated defence, and whether interference of Siglec ligand 
receptor interactions restores or enhances NK cell-medi-
ated immunosurveillance of NK cell-resistant or -sensitive 
tumours. 
Mechanistic studies will uncover a potential role of 
Siglec-7 and -9 receptors in the formation of the NK cell 
immunological synapse, the site of contact between NK 
cell and the targeted tumour cell. The experiments will 
provide further insights into the role of Siglec receptor li-
gand expression and interactions in different types of 
malignancies and might lead to novel diagnostic or prog-
nostic biomarkers and molecular targets for therapeutic 
intervention in cancer.
Project coordinator
PD Dr. med. et Dr. phil. Stephan von Gunten
Institut für Pharmakologie
Universität Bern
CH-3010 Bern
stephan.vongunten@pki.unibe.ch
Zajac Paul | Investigator-initiated phase I immuno-
therapy trial for patients bearing non-small cell lung  
cancers expressing cancer/testis tumour antigens  
and treated with a non-replicating vaccinia virus  
encoding for 7 antigenic epitopes, CD80 and CD154 
co-stimulatory molecules (KFS 3149-02-2013)
Duration: 01. 05. 2013 – 30. 04. 2015
Recent clinical developments have finally led to recogni-
tion of immunotherapy as a major approach to treatment 
of cancer. In this framework, the objective of our phase I/
II clinical study is to validate a new generation cancer vac-
cine, notably for patients with lung cancer. The vaccine 
consists of an inactivated (non-replicating) viral vector 
expressing seven tumour antigen epitopes stimulating 
specific cytolytic immune responses against tumour cells. 
Moreover, the vaccine expresses two immune stimulatory 
molecules, CD80 and CD40 ligand, which significantly 
improve the quantitative and qualitative activation of cy-
totoxic T-lymphocyte. Targeting the “cancer/testis anti-
gens” allows the generation of immune responses specific 
against tumour cells, and the multiplicity of targeted anti-
gens limits the frequent “tumour escape” that is observed 
in mono-antigen therapies. 
Following surgical tumour resection and post-op standard 
of care, selected patients with cancer will receive a total 
of eight intradermal vaccinations during a period of one 
year. The primary objective of this phase I study is the 
vaccine safety demonstration for the patient. But the sec-
ondary objectives of immunological and clinical efficacy 
will also be carefully followed and analysed.
Project coordinator
PD Dr. phil. Paul Zajac
Departement Biomedizin
Universitätsspital Basel
CH-4031 Basel
pzajac@uhbs.ch
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Web-based psychological support for people  
with cancer
Psychosocial research
For most people, a cancer diagnosis means an exis-
tential life crisis. The disease and the medical treat-
ments bring many physical, emotional, and social 
stresses and strains. When people learn that they 
have cancer, complex emotional/mental processing 
begins that can lead to a temporary stress response 
and, for approximately 30 % of patients, to a mental 
disorder (most frequently adjustment disorders in re-
sponse to the new life event, depression, and anxiety 
disorders).1 Depressive disorders and anxiety disor-
ders have, among other things, a negative effect on 
quality of life, treatment compliance, health behav-
iour, and decision making.2 Many patients with can-
cer deal with the challenges that cancer brings by 
themselves or with support from their social net- 
work. But more than half of all persons with cancer 
demonstrate a need for psychosocial treatment or 
counselling in the course of the disease.3
The overarching goals of psycho-oncological inter-
ventions are facilitation of dealing with the disease 
through the patient developing adequate response 
and coping strategies, increasing the patient’s re-
sources, maintaining or improving quality of life, and 
treating emotional stress responses in patients and 
also in their family members. The effectiveness of 
psycho-oncological interventions in reducing emo-
tional and stress reactions, improving quality of life, 
and coping with side effects has been well researched 
and is supported by the evidence.4
PD Sibil Tschudin, MD
Head physician, Gynaecological Social Medicine and Psychosomatics, Department of Obstetrics  
and Gynaecology, University Hospital Basel
PD Judith Alder, PhD
Owner of Praxisgemeinschaft Schlüsselberg, Basel
Astrid Grossert, MSc 
Doctoral student at Department of Oncology, University Hospital Basel
Fotogramm / Trigon, 2013
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STREAM: A web-based stress management  
programme for patients with a new cancer  
diagnosis
The aim of this new Internet-based stress manage-
ment programme is to help patients newly diagnosed 
with cancer to cope with their stress. Previous stud-
ies showed that stress reduction techniques from be-
havioural therapy are very effective in reducing stress 
and improving adjustment to the disease. A first on-
line stress management intervention was found to 
improve participants’ coping with their cancer.7 The 
STREAM (Stress aktiv mindern) project, funded by 
the Swiss Cancer Research foundation and the Swiss 
National Science Foundation, is testing the feasibil-
ity, practicability, and effectiveness of a web-based 
intervention. All that is required of patients is that 
they have basic skills in using the Internet and com-
puters and good knowledge of German. The STREAM 
project is examining what groups (age, gender, and 
type of cancer) make use of this kind of psycho- 
oncological care and for how long and to what ex-
tent. To test the effectiveness of the programme, the 
participants are being surveyed on stress and their 
quality of life. 
The stress management intervention is based on ele-
ments of cognitive behavioural therapy and on mind-
fulness- and acceptance-oriented techniques. It was 
developed by psychologists at University Hospital 
Basel and Bern University Hospital with the assis-
tance of oncologists. The programme contains eight 
chapters on understanding stress and the effects of 
stress at the cognitive, emotional, and physical levels. 
With the help of interactive elements, participants 
are meant to learn and practice coping strategies and 
mobilize resources. Each chapter begins with an in-
formation section followed by a self-observation 
part and a part with practice exercises. Patients work 
through the programme contents on their own and 
in a specified order. Regular contacts with the psy-
chologists on the study team take place weekly by 
The National Cancer Programme for Switzerland 
2011–2015 (NCP II) and, based on that, the “National 
Strategy Against Cancer 2014–2017” (NSC) aim in 
particular to create better connections between ex-
isting psycho-oncological services and oncological 
health care and to make the treatment/counselling 
options available to everyone. In addition, the ser-
vices are to be low-threshold as well as time- and 
cost efficient. 
To meet these goals, the question arises as to whether 
psycho-oncological care, which takes place in direct 
contact with the patients, can be usefully comple-
mented by web-based counselling and treatment op-
tions. Studies in other countries have found that web-
based options that contain interactive elements (for 
example, with symptom monitoring or in the form of 
practice exercises) as well as regular feedback from 
and contacts with a psycho-oncology specialist are 
more effective than purely self-help programmes.5, 6 
Online research in the field of psycho-oncology has 
only just begun in Switzerland. In the following, we 
present three ongoing research projects, each with a 
different focus, in which web-based counselling and 
treatment options are being developed for different 
patient groups and their usefulness and potential for 
psycho-oncological care in Switzerland investigated. 
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e-mail. After completing the programme, the partici-
pants are free to continue to use the contents. 
All of the exercise materials such as audio files and 
instructions to the exercises are available on the web-
site at www.stress-aktiv-mindern.ch. The online por-
tal is divided into a public area with general infor- 
mation on the stress management programme and 
contact and sign-up information. The password- 
protected area is only accessible by study partici-
pants. For further information on the programme and 
the research study, e-mail stream@usb.ch. 
FAMOCA: Web-based psycho-oncological  
support for families with parental cancer
A cancer diagnosis of a parent is a great challenge for 
the whole family, and it can change family stability, 
relationships within the family, and quality of life. 
About 25 % to 30 % of partners and children of a 
parent with cancer develop clinically relevant levels 
of psychological symptoms. Up to now, there have 
been only few preventive interventions and treat-
ment approaches that include the whole family, be-
cause it is often difficult to bring all family members 
together at one place and time. Here, the Internet 
offers a new and cost-effective possibility, as it can 
be used by several persons independently of time 
and location. 
Funded by the Swiss Cancer Research foundation, 
the FAMOCA (Family online counselling for families 
with parental cancer) project is being conducted by 
University Hospital Basel, Child and Adolescent Psy-
chiatry Baselland, and the University of Basel. The 
project is investigating what help a web-based coun-
selling programme for families affected by parental 
cancer can offer for dealing with the disease and is 
evaluating the programme’s effectiveness. The web-
site www.famoca.ch has separate areas for parents, 
young people aged 12 to 18 years, and children aged 
3 to 11. Thanks to this division, information and sug-
gestions for promoting family communication and 
for developing and practising coping strategies can 
be provided at the individual, couple, and family 
level age-specifically. The aim is to improve the fam-
ily members’ adjustment to the disease. The pro-
gramme contains four chapters, which are provided 
at monthly intervals. Children can work on the con-
tents by themselves or in the company of a parent. 
Various elements are available also in audio format.
The online portal has a public area providing general 
information on the programme and contact and sign-
up information. The password-protected can be ac-
cessed only by families that are participating in the 
study. For further information on the programme 
and the research study, e-mail info@famoca.ch. 
Online decision-aid tool for young women  
with cancer 
Successful cancer treatment can lead to a temporary 
or lasting reduction of fertility, which can have seri-
ous consequences for the later quality of life of young 
women with cancer. Today, various fertility preserva-
tion options are available in part established methods 
like embryo (fertilized egg) freezing, in part still largely 
experimental methods like removal and freezing of 
ovarian tissue. If they want to choose one of these 
options, young women have to make their decision 
within the short period of time between cancer diag-
nosis and the start of treatment, which is stressful in 
an already stressful time. This situation is a challenge 
for both patients and their families and the health 
care team. Several studies have shown that for young 
women with cancer later fertility is very important, 
but they have insufficient knowledge of the fertility 
preservation options. And later on, some patients do 
not even remember having ever been informed about 
these options. 
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To optimize counselling in such situations, a group of 
researchers in Australia developed a decision aid in 
the form of a brochure. The researchers found that 
thanks to the information and the worksheets, the 
patients participating in the study felt that they had 
less decisional conflict, were better informed, and re-
gretted their decision one year later less frequently 
than women who been advised in the customary way.8 
These results show that a standardized instrument 
that complements the usual advising has a positive 
effect on the decision-making process. Computer 
and Internet are young patients’ preferred communi-
cation medium. Based on these results, a research 
team at the Department of Obstetrics and Gynaecol-
ogy at University Hospital Basel developed a web-
based decision-aid tool concerning fertility preserva-
tion options. 
The research project, which won the Swiss Bridge 
Award 2013, encompasses both the development 
and the evaluation of the decision-aid tool. The eval-
uation is being conducted in collaboration with other 
centres for reproductive medicine in Switzerland that 
perform fertility-preserving procedures. The study, 
titled “Decisional conflict of young cancer patients 
with regard to fertility preservation – effects of an 
online decision-aid tool”, seeks answers to the fol-
lowing questions: Can the decision-making process 
be supported and made easier? Can patients’ knowl-
edge of fertility preservation options be improved? 
Can decisional conflict be significantly reduced? Will 
the web-based decision-aid tool result in less fre-
quent regret about the decision made? 
One group of participants will receive the advising 
that is standard practice today and will be compared 
to a group of patients that in addition to the usual 
advising will be able to use the online tool. To meas-
ure the amount of decisional conflict and how much 
the decision may be regretted, validated question-
naires are available. If the web-based tool proves to 
be valuable, the plan is to make it available in the 
future to all young women with cancer diagnoses 
whose treatment could result in infertility.
The three projects described here illustrate how 
web-based support instruments could complement 
psycho-oncological treatment offerings in Switzer-
land. How much benefit they provide to patients will 
be seen in the next few years. Whether this type of 
support should be further pursued will depend on 
that.
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Psychosocial research
Completed research project in 2013
Burton-Jeangros Claudine | KFS 2816-08-2011 | CHF 80,800.–
Département de sociologie, Université de Genève, Genève
Women’s views on cervical cancer screening. A qualitative study of barriers to screening and  
HPV self-sampling acceptability
Psychosocial research
Presentation of completed research project in 2013
Burton-Jeangros Claudine | Women’s views on cervical 
cancer screening: a qualitative study of barriers to 
screening and HPV self-sampling acceptability  
(KFS 2816-08-2011)
Social science studies have identified several obstacles to 
cervical cancer screening, including barriers related to 
information, and emotional and practical barriers. It is ex-
pected that HPV self-sampling procedures could reduce 
some of these barriers.
Aim
This study aims at describing women’s views on cervical 
cancer screening, assessing the different obstacles that re-
strict participation in screening and evaluating the benefits 
and disadvantages of HPV self-sampling.
Method
We conducted 24 focus groups with a total of 125 partici-
pants, aged between 24 and 67, in the French-speaking 
part of Switzerland in 2012.
Results
Participants confirmed that various difficulties concerning 
getting screened arise; rather than one single factor ex-
plaining non-attendance, a constellation of barriers may 
deter women from attending screening. These factors re-
late to different aspects of the Pap smear procedure, in-
cluding gaps in information, reluctance or difficulty to see 
a gynaecologist, and uneasiness associated with the pelvic 
examination. Gaps in knowledge were not specific to par-
ticular subgroups of the participants and were observed 
for Swiss and migrant women, women with a professional 
education and women having attended university, and 
young and older participants. Barriers are also related to 
the social life of these women: Some life stages are more 
(pregnancy) or less (absence of sexual activity) conducive 
to seeing a gynaecologist for prevention reasons. Partici-
pants saw some advantages in HPV self-sampling, but 
they also expressed concerns regarding their ability to per-
form the test in an adequate manner.
Recommendations
In the Swiss opportunistic system, some important gaps in 
information related to cervical cancer screening exist. 
Therefore, it is particularly important to improve the infor-
mation level in the whole population. Furthermore, the 
study highlighted the importance of the context in which 
screening takes place and makes gynaecologists aware of 
the difficulties expressed by women, which could contrib-
ute towards improving screening participation.
Project coordinator 
Prof. Dr Claudine Burton-Jeangros
Département de sociologie 
Université de Genève
CH-1211 Genève 4
claudine.jeangros@unige.ch
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List of approved research projects in 2013
Total funds allocated: CHF 985,700.–
Baumgartner Edgar | KFS 3112-02-2013 | CHF 150,000.–
Hochschule für Soziale Arbeit, Fachhochschule Nordwestschweiz, Olten
The effect of social counselling services on quality of life and coping with burden of parents  
of a child with cancer: a randomized intervention study at the University Paediatric Clinic Zurich
Eicher Manuela | KFS 3269-08-2013 | CHF 34,400.–
Recherche & développement, Haute école de santé Fribourg, Fribourg
Testing the feasibility of an integrated care model in ambulatory oncology furthering resilience  
in patients with gastrointestinal and lung cancer: a phase II trial (GI & LUNG RESIL-Trial)
Rüesch Peter | KFS 3258-08-2013 | CHF 148,700.–
Fachstelle Gesundheitswissenschaften, Departement Gesundheit, Zürcher Hochschule für Angewandte  
Wissenschaften (ZHAW), Winterthur
Prostate cancer e-health tutorial (PROCET)
Senn Beate | KFS 3160-02-2013 | CHF 164,000.–
Institut für Angewandte Pflegewissenschaft, Hochschule für Angewandte Wissenschaften, St. Gallen
The impact of the self-management intervention “WOMAN-PRO II programme” on patients with  
vulvar neoplasia to minimize post-surgical symptom prevalence: a mixed-methods project
Urech Corinne | KFS 3260-08-2013 | CHF 252,300.–
Gynäkologische Sozialmedizin und Psychosomatik, Frauenklinik, Universitätsspital Basel, Basel
Web-based stress management for newly diagnosed cancer patients (STREAM-1): a randomized,  
wait-list controlled intervention study
Zwahlen Diana | KLS 3186-02-2013 | CHF 236,300.–
Abteilung Psychosomatik, Universitätsspital Basel, Basel
Understanding why cancer patients accept or turn down psycho-oncological support. A prospective  
observational study including patients’ and clinicians’ perspective on communication about distress
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Presentation of approved research projects in 2013
Baumgartner Edgar | The effect of social counselling 
services on quality of life and coping with burden  
of parents of a child with cancer: a randomized inter-
vention study at the University Paediatric Clinic  
Zurich (KFS 3112-02-2013)
Duration: 01. 12. 2013 – 30. 11. 2016
Childhood cancer often leads to acute psychosocial bur-
den for the child and the whole family. After the shock of 
the diagnosis and the subsequent necessity for the entire 
family system to learn to deal emotionally with diagnosis 
and prognosis, there is often a difficult phase of adapta-
tion to restrictions in life conduct due to the treatment re-
gime. This is where social counselling offers professional 
support: it makes possible active life conduct and coping 
with everyday life with the goal to improve or at least 
stabilize the quality of life of families. However, little is 
known about the effect of this kind of clinical social work 
practice. 
This randomized intervention study at the University 
Paediatric Clinic Zurich aims to investigate whether social 
counselling can support the life conduct of families and 
deal with problematic dynamics successfully and effec-
tively. Further, different methods of social diagnosis will 
be applied to explore the need for support services. The 
investigation of the effects of these different methods will 
provide a basis for targeted allocation of limited counsel-
ling resources.
Project coordinator 
Prof. Dr. Edgar Baumgartner
Hochschule für Soziale Arbeit
Fachhochschule Nordwestschweiz 
CH-4600 Olten
edgar.baumgartner@fhnw.ch
Eicher Manuela | Testing the feasibility of an inte-
grated care model in ambulatory oncology furthering 
resilience in patients with gastrointestinal and lung 
cancer: a phase II trial (GI & LUNG RESIL-Trial)  
(KFS 3269-08-2013)
Duration: 15. 11. 2013 – 14. 09. 2015
Besides the importance of cancer survival, health profes-
sionals involved in cancer care increasingly recognize the 
value of considering how well people live with and after 
cancer. Psychosocial care that mainly aims at relieving 
emotional distress and promoting well-being is a central 
element in improving the quality of patients’ lives. Many 
people with gastrointestinal and lung cancer who could 
benefit from psychosocial care do not receive it. This 
might negatively impact their return to an active life. To 
improve the psychosocial care of patients with gastroin-
testinal and lung cancer, we developed an integrated care 
model furthering resilience and thereby improving sup-
portive care.
The aim of this study is to test if this intervention provided 
by nurses and oncologists is feasible within the real life 
context of an ambulatory oncology clinic, and to find out 
what the ideal intensity of such an intervention is. Patients 
willing to participate in the study will be randomly allo-
cated into two groups. In both groups patients will be in-
vited to fill out questionnaires on resilience, their per-
ceived unmet supportive care needs, their general mood, 
perceived quality of life and coping effort. Information on 
individual resilience level and unmet needs will be synthe-
sized electronically and directly fed back to the oncolo-
gists and nurses in charge of the patient. They will receive 
tailored propositions on how to support patients to meet 
their needs in a resilience-furthering way. In one group, 
patients will in addition be supported by two individual 
nurse consultations provided face-to-face and three con-
sultations provided by telephone. This study will give us 
new information on how to improve access to psychoso-
cial care for gastrointestinal and lung cancer patients and 
thereby improve quality of care.
Project coordinator 
Dr. rer. med. Manuela Eicher
Recherche & développement 
Haute école de santé Fribourg
CH-1700 Fribourg
manuela.eicher@hefr.ch
Rüesch Peter | Prostate cancer e-health tutorial  
(PROCET) (KFS 3258-08-2013)
Duration: 01. 04. 2014 – 31. 03. 2017
Prostate cancer is the most common cancer in men, with 
around 5700 cases and 1300 deaths per year in Switzer-
land. Men with early-stage prostate cancer are faced with 
difficult decisions. They are confronted with different 
treatment alternatives, each with its own benefits and 
risks. Therefore, comprehensive information provision is 
very important to facilitate patients’ participation in the 
decision-making process (shared decision-making).
The aim of this project is to develop an e-health tutorial 
concerning prostate cancer. The e-health tutorial will be 
developed in a participatory process of technology devel-
opment. It will then be tested at several urological clinics 
in the German-speaking part of Switzerland. The tutorial 
should meet the diverse information needs of patients 
confronted with early-stage prostate cancer in a compre-
hensive way by addressing individual information needs. 
Moreover, it should facilitate the interaction between 
patients and physicians and reduce decisional conflict 
with regard to treatment decisions. In addition, general 
suggestions for setting up an online tool for other cancer-
specific and/or health-related issues will be deduced from 
the findings of this project.
Project coordinator
Prof. Dr. Peter Rüesch
Fachstelle Gesundheitswissenschaften
Departement Gesundheit
Zürcher Hochschule für Angewandte  
Wissenschaften (ZHAW)
CH-8401 Winterthur
rech@zhaw.ch
Senn Beate | The impact of the self-management inter-
vention “WOMAN-PRO II programme” on patients 
with vulvar neoplasia to minimize post-surgical symp-
tom prevalence: a mixed-methods project  
(KFS 3160-02-2013)
Duration: 01. 09. 2013 – 31. 08. 2016
In pre-cancer/cancer of the external female genital 
(vulva), surgical interventions cause multiple symptoms 
that have an impact on women’s quality of life and con-
tribute to high health care costs. Patients’ symptoms can 
be reduced by providing adequate treatment. This study 
aims to compare the impact of standardized care with the 
WOMAN-PRO II counselling programme regarding the 
number of post-surgical symptoms in women with vulvar 
pre-cancer/cancer.
To this purpose, 90 surgically treated patients with vulvar 
pre-cancer/cancer will be recruited in six hospitals in 
Switzerland, Austria and Australia. Women will be rand-
omized to standardized care and the WOMAN-PRO II 
programme. The standardized care group will receive the 
usual care and a set of informational leaflets during rou-
tine medical treatment. The WOMAN-PRO II programme 
group will receive standardized care, tailored information, 
motivational interviewing, and strategies to support pa-
tient self-management by specially trained gynaecology-
oncology nurse specialists during six counselling sessions. 
Symptom prevalence and secondary outcomes will be 
collected by means of questionnaires. Additionally, inter-
views will be conducted with patients and gynaecology-
oncology nurse specialists.
Project coordinator
Prof. Dr. phil. Beate Senn
Institut für Angewandte Pflegewissenschaft
Hochschule für Angewandte Wissenschaften
CH-9001 St. Gallen
beate.senn@fhsg.ch
Fotogramm / Wurmloch, 2013
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Urech Corinne | Web-based stress management  
for newly diagnosed cancer patients (STREAM-1):  
a randomized, wait-list controlled intervention 
study (KFS 3260-08-2013)
Duration: 01. 01. 2014 – 31. 12. 2016
About half of patients with cancer suffer from severe 
stress symptoms, and around one-third of the patients 
fulfil the criteria for a clinically relevant psychological dis-
order. It has been demonstrated that psycho-oncological 
interventions achieve a reduction in levels of anxiety, dis-
tress and depression, as well as an increase in quality of 
life. Still, psycho-oncological support is rarely utilized by 
male patients and is insufficiently accessible for many 
patients (i. e. lack of supply in the respective area, cost 
issues). Web-based psychotherapeutic interventions are a 
growing field of interest in research, as they can be used 
independently of time and location and therefore may 
improve adequate provision of support. However, web-
based interventions for cancer patients are still scarce. 
This research project will develop a comprehensive stress 
management programme accessible for a vast number of 
cancer patients. The study aims primarily to evaluate the 
feasibility of the programme (technical and organizational 
feasibility, accessibility). In addition, the preliminary effi-
cacy of the programme will be analysed (by means of 
changes in levels of stress, anxiety, depression and quality 
of life). The start of the study or the start of the eight-
week programme is 1 June 2014.
Project coordinator
Dr. phil. Corinne Urech
Gynäkologische Sozialmedizin und Psychosomatik
Frauenklinik
Universitätsspital Basel
CH-4031 Basel
corinne.urech@usb.ch
Zwahlen Diana | Understanding why cancer patients 
accept or turn down psycho-oncological support:  
a prospective observational study including patients’ 
and clinicians’ perspective on communication about 
distress (KLS 3186-02-2013)
Duration: 01. 10. 2013 – 30. 09. 2016
One of the objectives of current developments in psycho-
oncological care is to introduce routine screening ques-
tionnaires for psychosocial distress in order to accurately 
identify patients in need of psycho-oncological treatment 
and to ensure that patients have access to supportive care 
services. The practice has been shown to be effective. 
However, only a moderate proportion of the distressed 
patients also accept referrals, and desire for psycho-onco-
logical support is broadly independent of the severity of 
distress.
In this study we want to better understand: (1) potential 
predictors of utilization of psycho-oncological service, (2) 
the reasons given by the patient for (non-)utilization of 
psycho-oncological support service, and (3) how commu-
nication about psychosocial distress and psycho-oncolog-
ical services on the basis of a short screening question-
naire is perceived by patients and clinicians. This is a 
prospective observational study. Patients are assessed by 
telephone interview and with a questionnaire shortly 
after the first clinical encounter and four months later. 
Clinicians answer one single questionnaire after the first 
encounter.
The results may help to adapt routine practices to elimi-
nate barriers to adequate health care and thereby better 
meet the needs of patients. This investigation will also 
provide insight into patients’ and oncologists’ perceptions 
of discussing psychosocial distress and referral to psycho-
oncological support on the basis of a screening question-
naire.
Project coordinator
Dr. phil. Diana Zwahlen
Abteilung Psychosomatik 
Universitätsspital Basel
CH-4031 Basel
diana.zwahlen@usb.ch
Fotogramm / Doppelt und umgekehrt, 2012
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Cancer survivors: a fast growing segment  
of the population
Epidemiological research
The number of people newly diagnosed with cancer 
has increased over the last 30 years in Switzerland 
and worldwide. This is the result of higher life expec-
tancies, the growth and the ageing of the population, 
intensified early detection, and increased public 
awareness of the disease.1 Cancer is mainly a disease 
of the elderly, as two-thirds of cancer cases are diag-
nosed after age 60. In the same time period, cancer 
mortality has declined due to earlier diagnosis and 
more effective treatments, and survival rates have 
improved.2, 3 The conjunction of these factors has led 
to a large and rapidly growing number of people di-
agnosed with cancer during their lifetime.
In Switzerland there are approximately 37,000 new 
cases of cancer and 16,000 cancer deaths each year.4 
The most frequently diagnosed cancers are breast, 
prostate, colorectal, lung, skin, and cancer in the 
haematopoietic system. Cancer is a broad umbrella 
term covering a multitude of different, complex dis-
eases that differ greatly with regard to their develop-
ment, course, and treatment. 
Cancer survivors: a heterogeneous group
In the English-speaking world, persons living with a 
cancer diagnosis are called cancer survivors. The 
number of these persons is called “complete preva-
lence”, which is a measure of the prevalence of can-
cer in the entire population. Cancer survivors are 
a heterogeneous group with differing care needs: 
Whereas some survivors are disease free and only 
need to be encouraged to have a healthy lifestyle, 
others struggle with the disease, side effects of treat-
ment, or other consequences sometimes for decades. 
Silvia M. Ess, MD, MPH
Head physician, St. Gallen-Appenzell Cancer Registry
Christian Herrmann, Dipl.-Math.
Scientific associate, St. Gallen-Appenzell Cancer Registry
Fotogramm / Tillia, 2013
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Consideration of the special needs of cancer  
survivors 
Cancer survivors have greater needs for health care 
and an elevated risk for new primary cancers than 
the general population does.5 For this reason, there 
is a growing need for additional specialized health 
personnel 6 and a need for increased training in sur-
vivorship care to support delivery of multidimen-
sional primary care for long-term survivors.7 For some 
years now, there has been increasing concern among 
experts that the services required to meet the phys-
ical, social, and emotional needs of cancer survivors 
will have not been adequately developed.8 
To adequately develop the strategies and services 
required to improve the health and care of cancer 
survivors, reliable data on numbers and time trends 
are essential. In Switzerland no information was avail-
able until recently. The study that we present in the 
following 9 not only provides data on the number of 
cancer survivors living in Switzerland today but also 
delivers information on their characteristics, devel-
opment over time up to now, and trends in the next 
10 years. 
Cancer survivors in Switzerland
Data collection by cancer registries for a number of 
years is sufficient for producing epidemiological data 
on new cancer diagnoses annually. However, to cal-
culate the number of cancer survivors, cancer regis-
tration for a period of 50 years or more is required. 
Since there is no such data in Switzerland, for our 
study we used a well-known mathematical model 
that is based on the connection between incidence, 
survival, and mortality, estimates missing values using 
times series, and checks the results by comparison 
with observed data.
Almost 4 % of the population affected
The results of our study show that the number of 
cancer survivors has increased sharply since 1990. 
This group has grown even faster than the rest of the 
population, and this development has accelerated 
strongly in recent years. There are about 300,000 
persons, or 3.7 % of the population, with a history of 
cancer living in Switzerland today. This is double the 
number of cancer survivors of 20 years ago. Accord-
ing to our projection, this number will probably in-
crease by 30 % in the coming 10 years. 
Our study also reveals that the group of long-term 
cancer survivors (20 years or more) shows the great-
est increase, rising 140 % (Figure 1). This is testimony 
to advances in the treatment of cancer. Due to higher 
general life expectancy in the population and further 
improvements in treatments, this group is going to 
grow even larger in the next 10 years. But treatments 
can cause late toxicities in long-term survivors, such 
as cardiotoxicity after cytotoxic drugs, cognitive def-
icits, and osteoporosis. Moreover, persons in this 
group are at higher risk for other primary cancers, 
and they frequently report poorer health generally 
and greater limitations of activities of daily living 
than persons without a history of cancer.10, 11
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The effects of demography, screening, and  
treatment
The exponential increase in the number of cancer 
survivors in Switzerland in the last 20 years is mainly 
attributable to the increased cancer incidence, in-
creased life expectancy, and growing segment of the 
aged population.
Types of cancers that can be detected through 
screening, such as prostate and breast cancer, have 
contributed greatly to the increase in the incidence 
rates. The widespread use of prostate specific anti-
gen (PSA) screening has led in Switzerland and world-
wide 12 to three- to four-fold increases in incidence 
Cancer survivors diagnosed 1 to 5 years ago consti-
tute the largest group, making up 30 % of all cancer 
survivors. Many of them are still in treatment or are 
being closely monitored, and most need close man-
agement of care by health professionals. In this large, 
heterogeneous group there are persons with ad-
vanced stage cancer, persons who were treated suc-
cessfully but are suffering side effects of cancer 
treatments (such as bowel complications after treat-
ment for colorectal tumours, incontinence, and erec-
tile dysfunction after prostatectomy, or lymphoe-
dema after breast cancer treatment), and many 
persons who are symptom free.
Figure 1
Estimated number of cancer survivors in Switzerland in the period 1990–2010  
(all invasive cancer, not including non-melanoma types of skin cancer)
Number of cancer survivors Increase 1990 – 2010: + 107 %
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rates for prostate cancer. Moreover, the average age 
at diagnosis has decreased, which has further con-
tributed to an increase in the survival rate and the 
prevalence of prostate cancer survivors. The rate for 
new breast cancer cases has doubled in the last 20 
years. However, expert opinions are divided concern-
ing the extent to which early detection and other 
factors like hormone replacement therapy have con-
tributed to this increase. 13, 14
In the last 20 years there have also been considera-
ble advances in the treatment of many types of can-
cer. This is especially apparent in the increases in the 
number of survivors with haematological malignan-
cies and lung cancer by 94 % and 67 %, respectively 
(Figure 2).
A phenomenon of the Western world
Similar results concerning trend and proportion of the 
population with a history of cancer have been found 
in other European countries. In the Nordic countries 
(Denmark, Finland, Iceland, Norway, and Sweden) 
3.4 % to 4.1 % of the population is estimated to be 
cancer survivors by the end of 2010.15 In the United 
Kingdom it is estimated that in 2010 about 3.1 % of 
the population had a history of cancer,16 and in Italy 
the projections for 2010 estimate that 4 % of women 
and 3 % of men were cancer survivors.17 Internation-
ally, researchers and stakeholders have only recently 
begun to focus on this group.6, 18, 19 Also in Switzer-
land, cancer survivors have received insufficient 
attention up to now.
Figure 2
Trend of prevalence of cancer survivors by type of cancer in Switzerland with highest incidence 
expressed as the per cent of the 1990 value.
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A challenge for all
Chances of curing cancer are continuing to increase, 
and patients – including patients with advanced 
stage cancer – are living longer. In view of our find-
ings, there is an urgent need to inform persons with 
cancer and health specialists about the long-term 
effects of cancer and the consequences of treatment 
as well as to identify psychosocial needs and re-
sources, so as to better contribute towards preven-
tion, maintenance of health, and increased quality 
of life. Particularly for people below the age of 65, 
who make up about one-third of cancer survivors, 
psychological and/or social support and return to 
work are essential aspects.
To improve the health and care of cancer survivors, 
new concepts are needed. For one, we need con-
certed action on the part of everyone involved – re-
searchers, health professionals, patients with cancer, 
associations and foundations, politicians and the 
authorities – to deliver optimal care and support to 
cancer survivors. For another, the relevant scientific 
data must be collected. The Eastern Switzerland 
Cancer League, for instance, is conducting a project 
with the aim to capture needs of cancer survivors 
that have been insufficiently characterized up to 
now. In the longer term, the cancer registries and 
cancer epidemiologists need to include the estima-
tion of the number of cancer survivors and long-term 
prevalence in the catalogue of regularly published 
cancer statistics.
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Privacy preserving probabilistic record linkage (P3RL) for cancer epidemiology research
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Bordoni Andrea | Indicators of quality of cancer care  
in Southern Switzerland (KFS 2668-08-2010)
Assessing the quality of cancer care (QoCC) has become 
increasingly important to providers, regulators and pur-
chasers of care. As a consequence of yearly renewed in-
ternational guidelines for cancer treatment, the need to 
evaluate the real conditions of care in the community ap-
pears important. Population-based cancer registry data 
are therefore essential to describe and reflect real world 
and routine care as well as to provide regular feedback to 
healthcare workers and decision makers about the man-
agement of a disease in the daily practice and those treat-
ments that are routinely prescribed and/or effective in all 
patient groups.
Aim of the study
This study aimed to develop evidence-based quality indi-
cators (QIs) for different cancer types (i. e. colorectal, 
prostate, ovarian and endometrial cancers) to be applied 
in a population-based setting, with the collaboration of 
working groups (WG) of local health care providers and 
an external independent academic advisory board.
Methods
Using the validated Delphi methodology, including litera-
ture review of the evidence and integration of local and 
international expert opinions, a list of QI was defined to 
assess QoCC. By means of the Ticino Cancer Registry, in-
formation on different cancer types was collected.
Results
The QoCC population-based project, involving both pub-
lic and private hospitals and clinics in the Canton of 
Ticino, is currently ongoing. So far, a peer-review publica-
tion on QI definition has been accepted by BMJ Open, 
and different newsletters have been produced for the 
WG, with the aim to define standards of care for each QI 
in terms of minimum and target requirements. Two publi-
cations reporting results on colorectal and prostate can-
cers are in preparation.
Conclusion and importance for patients
The systematic analysis of QIs allows assessment of im-
mediate changes and improvements in the diagnostic-
therapeutic process, which could be translated into a 
short-term benefit for patients, without waiting for sur-
vival analysis that typically needs some years to be pro-
duced because of the patients’ follow-up. This system of 
evaluation and auto-evaluation could favour surveillance 
and monitoring of the comprehensive level of oncological 
care in Southern Switzerland, clinical performance homo-
geneity, possible weakness of the clinical network, and 
finally corrective interventions to be adopted to improve 
QoCC.
Project coordinator
Dr. med. Andrea Bordoni
Registro cantonale dei tumori
Istituto cantonale di patologia (ICP)
CH-6601 Locarno
andrea.bordoni@ti.ch
Ess Silvia M. | The burden of metastatic breast cancer 
in Eastern Switzerland: a population-based study  
(KFS 2864-08-2011)
Breast cancer is the most frequently diagnosed malig-
nancy among women. Although cancer mortality has 
been decreasing since 1990, metastatic breast cancer 
continues to be the most frequent cause of cancer-related 
death and premature death (before the age 70) among 
women. Data on the number of affected women, survival 
among them and factors influencing survival of meta-
static breast cancer in Switzerland are scarce.
Objectives
The aim of this study was to quantify the burden of met-
astatic breast cancer in Eastern Switzerland and to study 
which patient and tumour characteristics are associated 
with better survival. 
Patients and methods
From the database of the cancer registries of St. Gallen-
Appenzell and Grisons-Glarus we identified 7,607 women 
living in the region with a diagnosis of invasive breast can-
cer made during or before the start of the study period, 
which included the years 2003 through 2009. Through 
chart review and questionnaires filled out by treating phy-
sicians we identified women developing metastatic breast 
cancer after a diagnosis of early breast cancer and women 
diagnosed with de novo stage IV disease.
Results
We identified 857 patients diagnosed with recurrent sys-
temic or stage IV breast cancer in the years 2003–2009. 
In 65 % of women metastatic disease developed after 6 
months to over 20 years of disease-free survival. These 
cases had been initially diagnosed with localized (stage I 
and II) disease (60 %) or locally advanced (stage IIIa-IIIc) 
disease (40 %). Median age at diagnosis of metastatic 
disease was 66 years (range 29 to 98 years). Median sur-
vival was 24 months. However 15 % (n = 138) lived five 
years or more. Endocrine sensitivity of the tumour, ab-
sence of visceral metastases, age below 70 years, and 
localized disease were associated with better survival. 
Differences between rural and urban areas were observed 
only in patients aged 70 years or older.
Conclusions
The development of new drugs and new strategies in the 
management of metastatic breast cancer has led to con-
siderable improvement in survival within and outside clin-
ical trials. More research is needed to better understand 
patient-related factors related to poor survival and factors 
improving survival and quality of life in this patient group.
Project coordinator
Dr. med. Silvia M. Ess, MPH
Krebsregister St. Gallen-Appenzell
Krebsliga Ostschweiz
CH-9000 St. Gallen
silvia.ess@kssg.ch
Martin Brian | Impact of physical activity on cancer 
mortality in Switzerland: results of a 30-year follow-up 
(KLS 2820-08-2011)
The World Health Organisation WHO describes physical 
inactivity as one of the four main risk factors for non-
communicable diseases, together with tobacco use, harm-
ful use of alcohol and unhealthy diets. However, there are 
only very few estimates concerning the potential of phys-
ical activity for cancer prevention in Switzerland. Even in 
the international scientific literature, little can be found 
about the effects of different domains (domestic, occupa-
tional, transport-related and leisure-time) of physical 
activity behaviour.
Study aim 
In a longitudinal study design, the effects of different do-
mains of physical activity behaviour on cancer mortality 
and on overall mortality in the Swiss population were to 
be quantified.
Methods
Using an anonymous record linkage procedure, it was 
possible to connect data from two large cross-sectional 
health surveys (MONICA and National Research Project 
1A), carried out between 1977 and 1993, to mortality 
data from the Swiss National Cohort. In the 17,663 female 
(51.1 %) and male study subjects in the age range of 16 to 
92 years, 3,878 cases of deaths were observed during up 
to 32 years of follow-up, including 1,351 cancer deaths.
Results
Individuals with a high leisure-time activity level at base-
line (regular vigorous physical activity) had a 31 % reduced 
risk of dying of cancer in the next decades. Those with a 
moderate leisure-time activity level (frequent walking or 
cycling; other frequent activities such as gardening) had 
a risk reduction of 8 %, although not at a statistically 
significant level. Regarding all-cause mortality, high and 
moderate levels of leisure-time activity were associated 
with statistically significant risk reductions of 27 % and 
12 %, respectively, compared to those with low activity 
levels. There were no protective effects for active trans-
port (walking and cycling) and for work-related physical 
activities.
Recommendations
The present analyses add evidence of the importance of 
physical activity, especially during leisure-time, for the 
prevention of cancer and premature deaths in general 
also in Switzerland. Improved methodological approaches 
in future studies may allow better quantification of the 
potential of active transport and work-related physical 
activity.
Project coordinator
PD Dr. med. Brian Martin
Arbeitsbereich Bewegung und Gesundheit
Institut für Sozial- und Präventivmedizin
Universität Zürich
CH-8001 Zürich
brian.martin@uzh.ch
Fotogramm / Tillia, 2013
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Mullis Primus-E. | Risk of cancer and long-term  
mortality in children treated with growth hormone: 
Swiss participation in the EU FP7 project “Safety and 
Appropriateness of Growth Hormone Treatment in  
Europe” (SAGhE) (KLS 2948-02-2012)
Growth Hormone (GH) promotes body growth. If GH 
production is impaired, GH can be substituted with daily 
injections. A large proportion of patients treated with GH 
in Switzerland are patients with childhood cancer. How-
ever, well-conducted long-term studies on safety of GH 
replacement therapy are lacking. This project assesses 
long-term safety after childhood treatment with GH, as a 
part of the European SAGhE study.
Study aim 
The project aims to study long-term efficacy (final height) 
and quality of life (QoL) in adulthood after GH treatment 
in childhood and to investigate long-term risk of cancer 
and mortality.
Methods
We collected medical data from patient files in the hospi-
tals. Information about QoL and current health status was 
assessed by means of questionnaires. We compared our 
population to cancer registries and mortality statistics of 
the Swiss Federal Statistical Office to obtain information 
about cancer incidence and mortality.
Results
We identified 754 persons treated with GH in Switzerland 
during childhood who were older than 18 years by 1 March 
2011. Of 639 persons contacted, 383 (60 %) returned a 
questionnaire. QoL depended mainly on the underlying in-
dication for GH treatment. Persons with idiopathic growth 
hormone deficiency or with associated diseases or syn-
dromes had a QoL comparable to peers. Childhood cancer 
survivors with GH treatment were at high risk for reduced 
QoL. It shows that this group needs long-term follow-up. 
Fourteen patients died and six patients were diagnosed 
with cancer after GH treatment started. With the low 
number of cases found in Switzerland, we can only draw 
conclusions with pooled data from all SAGhE countries. 
The anonymized data has been delivered to the SAGhE 
project leader. Publications are expected in 2014.
Potential benefits for patients
The results will aid adaptation of the recommendations 
for treatment with GH in children to guarantee long-term 
safety for current and future patients. For former patients, 
preventive medical check-ups can be planned.
Project coordinator
Prof. Dr. med. Primus-E. Mullis
Abteilung für Pädiatrische Endokrinologie,  
Diabetologie und Stoffwechsel 
Universitätsklinik für Kinderheilkunde
Inselspital, Universitätsspital Bern
CH-3010 Bern
primus.mullis@insel.ch
Spörri-Fahrni Adrian | Privacy preserving probabilistic 
record linkage (P3RL) for cancer epidemiology research 
(KFS 2763-02-2011)
Aim of the study
This study aimed to develop a new method for record link-
age with securely encrypted person-identifying character-
istics, and to test and evaluate the methods using simu-
lated and real cancer registry data.
Methods
Probabilistic record linkage allows the linking of datasets in 
spite of small differences in the linkage variables, e. g. due 
to typos or errors in data management. Until recently, it 
was not possible to link datasets with encrypted variables 
allowing for minor differences. Small variations made it im-
possible to combine records that probably belonged to the 
same person. Privacy preserving probabilistic record link-
age methods (P3RL) has person-identifying information, 
like names, date of birth, or place of residence on Bloom 
filters. These securely encrypted bit arrays allow calcula-
tion of similarities. This facilitates the linkage of datasets 
even with minor divergences.
Results
In the P3RL project, methods for the secure linkage of per-
son records using Bloom filters were developed, software 
tools programmed, and the usability as well as the quality 
of the links tested and evaluated. A first study using simu-
lated data revealed that the quality of the linkage with en-
crypted versus unencrypted names, date of birth and place 
of residence was almost identical (precision-recall curve). 
For a second study with real Swiss cancer data, P3RL 
methods were applied for the linkage. In previous years, 
this linkage was feasible with plain person characteristics. 
In this study, the results of the older record linkage with 
plain variables served as the gold standard. The linkage 
using P3RL methods was almost as efficient, and 99.4 % 
of the former records could be linked with the encrypted 
linkage variables.
Outlook
Record linkage is a method for combining existing data 
and is a potentially important source of valuable cancer 
epidemiological information – for example, information 
shedding light on the effectiveness of certain cancer 
screening methods or information for evaluating the long-
term effects of cancer treatments. The ability to link can-
cer-related data sources using important discriminating 
information such as patient name without breach of con-
fidentiality – privacy preserving probabilistic record link-
age (P3RL) – has the potential to transform cancer epide-
miology research by making available vast amounts of 
cancer-related data anonymously and thus heretofore not 
previously accessible.
Project coordinator
Dr. Adrian Spörri-Fahrni
Institut für Sozial- und Präventivmedizin (ISPM) 
Universität Bern
CH-3012 Bern
spoerri@ispm.unibe.ch
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List of approved research projects in 2013
Total funds allocated: CHF 989,700.–
Guessous Idris | KLS 3144-02-2013 | CHF 69,900.–
Département de médecine communautaire, de premier recours et des urgences, Hôpitaux universitaires  
de Genève (HUG), Genève
Socio-demographic and socio-economic inequalities in cancer screening, Switzerland 1992 – 2012:  
trend analyses based on the Swiss Health Survey
Levi Fabio | KFS 3255-08-2013 | CHF 241,000.–
Unité d’épidémiologie du cancer, Institut universitaire de médecine social et préventive Lausanne,  
Centre hospitalier universitaire vaudois (CHUV), Lausanne
Cancer mortality in Europe: monitoring trends and predictions
Low Nicola | KFS 3264-08-2013 | CHF 233,400.–
Institut für Sozial- und Präventivmedizin (ISPM), Universität Bern, Bern
Human papillomavirus-associated cervical neoplasia in Switzerland at the start of a national vaccination  
programme: cross-sectional study
Schneider Uwe | KFS 3249-08-2013 | CHF 176,000.–
Forschungsgruppe Medizinische Physik, Universität Zürich und Institut für Radiotherapie, Hirslanden Klinik, Zürich
The impact of image-guided radiotherapy on second cancer incidence
Schoeni-Affolter Franziska | KFS 3165-02-2013 | CHF 125,000.–
Centre de coordination et de données, Etude Suisse de Cohorte VIH, Lausanne
An update of cancer risk in persons infected with HIV in Switzerland
Stöckli Sandro | KLS 3153-02-2013 | CHF 144,400.–
Hals-Nasen-Ohrenklinik, Kantonsspital St. Gallen, St. Gallen
Impact of human papillomavirus (HPV) infection on outcome in surgically treated patients with oropharyngeal 
squamous cell carcinoma (OPSCC)
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Guessous Idris | Socio-demographic and socio- 
economic inequalities in cancer screening, Switzerland 
1992–2012: trend analyses based on the Swiss  
Health Survey (KLS 3144-02-2013)
Duration: 02. 09. 2013 – 01. 09. 2014
Cancer morbidity and mortality are associated with socio-
demographic and socio-economic status, such as educa-
tion and income. In Switzerland, cancer screening repre- 
sents a cost for individuals, depending on their socio- 
economic status and on their annual health care use. For 
many years, it has been hypothesized that universal health 
insurance coverage, high levels of living standards, wealth 
and well-being in Switzerland would lead to limited ine-
qualities in health and healthcare access.
However, the recent economic downturn in Switzerland 
has accentuated health access disparities in the general 
population, as shown by the fact that a substantial pro-
portion of the Swiss adult population is forgoing health-
care for economic reasons. With the delivery of the fifth 
waves of the Swiss Health Study – a nationally represent-
ative cross-sectional survey – we have the possibility to 
examine cancer screening inequalities in Switzerland and 
their evolution over the past two decades, from 1992 to 
2012.
Project coordinator
Dr Idris Guessous
Département de médecine communautaire,  
de premier recours et des urgences
Hôpitaux universitaires de Genève (HUG)
CH-1211 Genève
idris.guessous@hcuge.ch
Levi Fabio | Cancer mortality in Europe: monitoring 
trends and predictions (KFS 3255-08-2013)
Duration: 01. 10. 2013 – 30. 09. 2016
Our aim is to maintain and improve the integrated system 
of monitoring of cancer mortality in Europe and other 
areas of the world. Within the project’s main aim, in 
2013–2016 we plan to exploit cancer mortality data from 
recent years in order to promptly identify and interpret 
early signals of evolution, and to further develop and test 
modelling techniques for interpreting past trends, and for 
predicting short term trends, which are of key interest for 
cancer management on a public health scale.
The main expected results include: (1) systematic analy-
sis of cancer mortality in Europe for 2005–2009 and sub-
sequent years when data is available; (2) age-period- 
cohort analysis of cancer mortality in Europe for the pe-
riod 1970–2009, i. e. for the cohorts born between 1885 
and 1970; (3) annual prediction of cancer mortality in the 
EU in the current year; (4) systematic analysis of cancer 
mortality in (Latin) America from 2000 in comparison 
with Europe; (5) monitoring of the tobacco-related 
cancer epidemic in Europe, with specific focus on oesoph-
ageal and laryngeal cancer; (6) developing methods for 
evaluating the impact of cancer screening on mortality; 
(7) analysis of cancer burden and trends in older Europe-
ans; (8) in depth analyses for specific cancer sites, includ-
ing pleura, skin/melanoma, ovary, testis, prostate, be-
nign prostatic hyperplasia, Hodgkin and non-Hodgkin’s 
lymphomas and sarcomas.
Project coordinator
Prof. Dr med. Fabio Levi
Unité d’épidémiologie du cancer
Institut universitaire de médecine sociale et  
préventive Lausanne
Centre hospitalier universitaire vaudois (CHUV)
CH-1010 Lausanne
fabio.levi@chuv.ch
Low Nicola | Human papillomavirus-associated  
cervical neoplasia in Switzerland at the start of a  
national vaccination programme: cross-sectional 
study (KFS 3264-08-2013)
Duration: 05. 01. 2014 – 04. 01. 2016
Almost all cases of cervical cancer are caused by a viral 
infection (human papillomavirus, HPV). HPV is transmit-
ted through sexual intercourse; in most cases cancer will 
appear many years after infection. There are now vaccines 
that protect against the two most common cancer-causing 
HPV types (16/18). Since 2008, Switzerland has had can-
tonal programmes to offer HPV vaccination to girls aged 
11–14 years. It is essential to monitor the effectiveness of 
vaccination in preventing cancer. Trends in pre-cancerous 
stages can be used to indicate how effective HPV vaccina-
tion will be in preventing future cases of cervical cancer. 
This project aims to: (1) describe the distribution of HPV 
types in cervical pre-cancer and cancer before it has been 
affected by the HPV vaccination programmes, and (2) ex-
amine factors that might affect the reliability of a system 
for monitoring outcomes of the vaccination programmes. 
The project will take place in seven locations in German-, 
French- and Italian-speaking regions of Switzerland. We 
will identify women diagnosed with cervical pre-cancer or 
cancer from laboratory records. We will study biopsy spec-
imens that were used to make the diagnosis and test them 
for HPV type. 
We plan to determine HPV type in 200 specimens from the 
recent past (2013) and 700 from 2014–2015. We will ask 
women diagnosed from 2014 onwards for permission to 
collect additional information about factors that might be 
associated with cervical pre-cancer and cancer. We will 
compare basic characteristics of women who do or do not 
give consent for additional data collection. We will then 
compare the characteristics of women with cervical pre-
cancer and cancer with a random sample of women in 
the general Swiss population. The benefit of the project is 
that it will provide the information needed to monitor the 
future effectiveness and fairness of HPV vaccination in 
Switzerland.
Project coordinator
Prof. Dr. med. Nicola Low
Institut für Sozial- und Präventivmedizin (ISPM)
Universität Bern
CH-3012 Bern
low@ispm.unibe.ch
Schneider Uwe | The impact of image-guided  
radiotherapy on second cancer incidence  
(KFS 3249-08-2013)
Duration: 03. 03. 2014 – 02. 03. 2017
Great advances are currently being made in the delivery of 
external beam radiotherapy with photons through the de-
velopment of intensity-modulated radiotherapy. These 
treatment approaches are very precise, both in dose and 
in the geometrical application of the dose to the patient. 
For this purpose, such treatment strategies require exten-
sive imaging of the patient, which is usually referred to as 
image-guided radiotherapy. The additional dose to the 
patient from such imaging modalities could cause late 
effects: namely, radiation induced cancer. 
It is the aim of this project to perform and analyse dose 
measurements of therapeutic scatter dose for various 
treatment techniques and to develop methods for model-
ling radiation-induced cancer to estimate the magnitude 
of this effect for the patient. In addition, the gain of mod-
ern treatment techniques will be quantified in terms of 
normal tissue complication and tumour control. The re-
sults of the cancer risk estimates and the benefits from the 
complication and tumour control calculations will be com-
pared for typical clinical treatments. The consequences 
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based on this analysis will be evaluated in the context of 
practical considerations regarding the work flow in radia-
tion oncology for clinical patients.
Project coordinator
Prof. Dr. Uwe Schneider
Forschungsgruppe Medizinische Physik
Universität Zürich und 
Institut für Radiotherapie 
Hirslanden Klinik
CH-8032 Zürich
uwe.schneider@uzh.ch
Schoeni-Affolter Franziska | An update of cancer risk  
in persons infected with HIV in Switzerland  
(KFS 3165-02-2013)
Duration: 01. 04. 2014 – 30. 09. 2015
SSince the introduction of successful antiretroviral treat-
ment, HIV infection has become a treatable chronic dis-
ease. Many HIV-infected patients are now living into their 
50s, 60s and beyond. Cancer has become a leading cause 
of morbidity and mortality in our aging population includ-
ing HIV-infected persons: some studies indicate a higher 
risk for HIV-infected persons than for the general popula-
tion. 
With this project we aim at studying this increasing can-
cer burden in the HIV-positive population in Switzerland. 
We will examine trends in incidence, survival and mortal-
ity of several cancers. General immunodeficiency, life-
long antiretroviral treatment, effects of age and other risk 
factors will be analysed. Understanding risk factors lead-
ing to cancer will allow preventing the worst case through 
better prevention and targeted screening. 
Detailed cancer information from the population-based 
network of cancer registries will be linked to the an-
onymized longitudinal clinical data and treatment infor-
mation of patients in the Swiss HIV Cohort Study (SHCS). 
This will allow ascertainment of cancer in the SHCS, com-
parison of cancer incidence to the general Swiss popula-
tion and analysis of risk factors.
Project coordinator
Dr. med. Franziska Schoeni-Affolter
Centre de coordination et de données 
Etude Suisse de Cohorte VIH
CH-1011 Lausanne
franziska.schoni-affolter@chuv.ch
Stöckli Sandro | Impact of human papillomavirus 
(HPV) infection on outcome in surgically treated  
patients with oropharyngeal squamous cell carcinoma 
(OPSCC) (KLS 3153-02-2013)
Duration: 01. 01. 2013 – 31. 12. 2014
HPV-related oropharyngeal cancer is associated with sig-
nificantly improved survival, but it is not clear whether 
this is due to a better response to chemoradiation or if sur-
gical treatment leads to equivalent results. Therefore, we 
do not know whether HPV-positive tumours should be 
treated with radiotherapy or could be treated with less 
toxic treatment regimens, such as lower radiation dose or 
abandonment of adjuvant treatment in case of surgical 
resection.
In this project we will evaluate survival in surgically treated 
HPV-positive and HPV-negative patients and set up a 
Swiss data and tissue bank. We will conduct a retrospec-
tive chart analysis and investigation of formalin-fixed, 
paraffin-embedded tissue samples of patients with oro-
pharyngeal cancer treated surgically in Swiss head and 
neck centres between 2002 and 2010. Futhermore, we 
will evaluate the impact of different clinical and histolog-
ical factors and HPV status on outcome in relation to 
treatment.
HPV-positivity is not integrated in the decision regarding 
treatment modality. Little is known about the prognostic 
significance of HPV-positivity in surgically treated pa-
tients. Patients with favourable HPV positive OPSCC 
might benefit from less intensive and less toxic adjuvant 
treatment after surgery.
Project coordinator
Prof. Dr. med. Sandro Stöckli
Hals-Nasen-Ohrenklinik
Kantonsspital St. Gallen
CH-9007 St. Gallen
sandro.stoeckli@kssg.ch
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We need your support!
To better understand the causes of cancer,  
prevent its development, detect it earlier, and  
treat the disease more effectively, continued  
strong investment in research is needed. With  
our work, we support researchers in their intensive 
efforts to improve the understanding of cancer  
and contribute to the development of improved 
treatment methods and optimal care of persons  
with cancer and their families. 
Help us in our fight against cancer. 
Thank you very much!
Donations account PK 30-3090-1
Swiss Cancer Research foundation, Bern
www.krebsforschung.ch
Printed on non-chlorine-bleached paper.
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